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period from 1970 to 1994, as well as information on 
the progress of cancer registration in Germany. A 
separate chapter devoted to cancer in children already 
featured in the first edition as it has in all subsequent 
editions.
Data from the registries in Hamburg, the Saar-
land, Muenster and the National Cancer Registry of 
the former GDR was included in the evaluations for 
the first edition. Only the data from the Saarland can-
cer registry could cover the entire period while those 
from the former GDR cancer registry, at that time, 
ended in 1989. For the first time for Germany there 
was systematically processed and reliable informa-
tion, albeit on the basis of still very limited data at this 
point. With increasing coverage and level of com-
pleteness of data coming from the epidemiological 
cancer registries within the German states, the data-
base for »Cancer in Germany« has improved con-
siderably across the various editions. »Cancer in Ger-
many« also became more extensive and informative 
with regard to the reporting itself.
In this context, the spectrum of cancers reported 
on in the 10th edition has increased to 27 from the 16 
covered originally. In addition to the above, data from 
all federal states is meanwhile being incorporated in 
the reporting. The successive inclusion of results on 
stage distribution, survival rates, 5-year prevalence 
and – last but not least – the type of presentation, all 
contribute significantly to the information content 
now publically available on »Cancer in Germany«. 
This means that the booklet, which had already been 
well accepted in professional circles, has become 
even more appreciated.
Until the 4th edition in 2006, the booklet was 
published by the Working Group of Population-based 
Cancer Registries in Germany (ABKD). Thereafter, 
publication was assumed by the organisation set up 
to succeed the ABKD, namely GEKID – the Associa-
tion of Population-based Cancer Registries in Ger-
many. Since the 6th edition (2008), »Cancer in Ger-
many« has featured as a standard publication in the 
Federal Health Reporting series by the Robert Koch 
Institute. Joint publishers are the Centre for Cancer 
Registry Data (ZfKD) at the Robert Koch Institute and 
GEKID.
From its very beginning, »Cancer in Germany« 
has become an integral source of reporting cancer 
incidence in Germany. But even more – either in 
printed form or as a digitally available version, the 
booklet can be rightly seen as the core publication on 
this subject. It underlines the important role of can-
cer registries in combating cancer. In our role as 
 »obstetricians« for »Cancer in Germany« we gladly 
accepted the request to share our pleasure on the 
success of the booklet in this preface to this 10th 
With about half a million new cases per year, cancer 
is among the most common diseases in Germany 
and it is also the second most common cause of 
death. Half of these cases are accounted for by the 
four most common forms of cancer – breast, pros-
tate, bowel and lung cancer. This and other basic data 
that is needed to successfully combat cancer – such 
as trends, prevalence and regional distribution statis-
tics are all comprehensively presented in the »Cancer 
in Germany« booklet, now available in this 10th edi-
tion. It is the latest update of a publication, which 
over almost 20 years of its existence has followed the 
development, establishment and advances made in 
epidemiological cancer registration in Germany.
How did this series come about? Coming into 
force in 1995, the Federal Cancer Registry Act estab-
lished a legal basis obligating the Federal States of 
Germany to set up epidemiological (i. e. popula-
tion-based) cancer registries if not already in exist-
ence. Before this, alongside the national German 
Cancer Registry for Children in Mainz there were 
only population-based cancer registries in Hamburg, 
the Saarland, the administrative district of Muenster 
(NRW) and in the eastern federal states (former 
GDR). In the process of implementing the new can-
cer registries it soon became evident that given the 
resultant different state-specific provisions, it seemed 
both sensible and necessary to bundle the activities 
of cancer registration in Germany. This led to the 
founding of the Working Group of Population-based 
Cancer Registries in Germany (ABKD) in 1996, an 
association of existing epidemiological cancer regis-
tries and those being established at that time. The 
primary objective of the ABKD was to achieve exten-
sive methodological consistency and standardisation 
in order to guarantee comparability of data (Cancer 
in Germany, 1st Edition 1997, page 6). The Federal 
Ministry of Health provided sustained support for 
this work and integrated the ABKD in the then 
»Agenda for Cancer Control«.
In this context, the need for systematic process-
ing of the cancer registry data to make it accessible to 
as many people as possible was quickly recognised. 
This heralded the arrival of »Cancer in Germany«. 
Inspired by the »Facts and Figures« booklet pub-
lished by the »Europe against Cancer« programme, 
which was based on data from European cancer reg-
istries, the first edition appeared in 1997, funded by 
the German Federal Ministry of Health. It was pub-
lished by the »Working Group of Population-based 
Cancer Registries in Germany« (ABKD) in collabora-
tion with the then ›Federal Cancer Reporting Unit‹ at 
the Robert Koch Institute. In 60 pages, the brochure 
contained information on incidence and mortality 
rates regarding 16 selected types of cancer for the 
Preface
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»coming of age« in impressive fashion looking at the 
continuous renewal of content and presentation. We 
are convinced that it is an important contributor to 
our better understanding of cancer and therefore to 
the control of this disease.
   
 edition. At the same time »Cancer in Germany« has 
also »come of age«, so to speak, with all editions now 
spanning 18 years between 1997 and 2015. We would 
like to take the opportunity to congratulate GEKID 
and ZfKD on the fact that it is possible to follow this 
»Cancer in Germany«, 1st Edition 1997
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Population-based cancer registries conduct surviv-
al-time analyses of all cancer patients in their regis-
tration region. Population-based survival rates are an 
important parameter for assessing the effectiveness 
of diagnosis, therapy and aftercare of cancers. In re-
cent years, German registry data has been used for 
international comparisons of survival rates, for exam-
ple within Europe.
Because of the demographic development in Ger-
many, it is expected that there will be more than a 
20 % increase in new cases of cancer between 2010 
and 2030.
The prediction of the future number of new cancer 
cases is an important aspect of requirement planning 
within the health service. The population-based can-
cer registries provide the baseline data needed for 
this.
The data from population-based cancer registries is 
also used for scientific research into the causes of 
cancer or for health services research. Such studies 
(case-control studies, cohort studies, etc.) investigate 
issues such as:
▶ What are the causes of childhood leukaemia?
▶ Do women who take hormone-replacement ther-
apy for menopausal problems have a higher risk 
of developing breast cancer?
▶ Does lung cancer develop more frequently in peo-
ple in certain occupational groups?
▶ Are diagnosis, therapy and aftercare being carried 
out according to the latest standards?
Population-based cancer registries make it possible 
for all cases of the disease that have occurred in a 
defined population to be taken into account in re-
search projects. If as many patients as possible par-
ticipate in the project, it can be broadly guaranteed 
that the findings of such studies can be extrapolated 
to the general population. Population-based case-con-
trol studies and cohort studies consequently use data 
from population-based cancer registries for research 
into the causes and risks of cancer.
Further or specific issues may also be analysed using 
the registry data. Examples include:
Population-based (epidemiological) cancer registries 
are institutions for the collection, storage, process-
ing, analysis and interpretation of data on the inci-
dence and prevalence of cancers within defined reg-
istration areas (e. g. one German federal state). The 
data from the cancer registries also forms an indis-
pensable basis for further studies into the causes of 
carcinogenesis, the assessment of early detection 
measures and population-based care of tumour pa-
tients.
Findings from population-based cancer regis-
tries include:
In Germany, 480,000 people are diagnosed with can-
cer each year.
The incidence of cancers (i. e. how frequently they 
occur annually in a certain population group) can be 
described using the data from population-based can-
cer registries. The incidence is calculated according 
to cancer type, patient age and gender, as well as oth-
er characteristics. Reliable information regarding 
incidence is indispensable for depicting the extent 
and type of the burden that cancer places on a popu-
lation.
For some years there have been just as many new 
cases of lung cancer among women under the age of 
forty as among men of the same age.
Only by using data from the population-based cancer 
registries can the development of incidence over time 
(trends) can be observed. The registries have a key 
function for health reporting in this context.
Regional differences in the incidence of malignant 
melanoma of the skin can be observed in Europe and 
in Germany.
Population-based cancer registries can analyse the 
regional distribution of various types of cancer. It is 
also within their remit to investigate any cancer clus-
ters observed. Further clarification of these clusters 
with regard to possible causes usually involves target-
ed analytical studies.
In recent years, the survival prospects following diag-
nosis with cancer have largely converged in both the 
western and eastern federal states.
1 Epidemiological cancer registration in Germany 
1.1 Aims and tasks of population-based cancer registries
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other countries have been published already and 
show that the objectives from European guidelines 
haven’t been achieved.
In 2008, the statutory health insurers intro-
duced screening for skin cancer, the effects of which 
on the incidence of skin cancer and related mortality 
can also be investigated using the data from the can-
cer registries.
A longer-term task of the population-based can-
cer registries is also to examine the effectiveness of 
the vaccination program for girls between 9 and 14 
years of age against human papillomaviruses (HPV) 
with the aim of significantly reducing the number of 
new cases of cervical cancer.
In order to fulfil the stated objectives and tasks 
of the cancer registries it does not suffice to operate 
population-based cancer registries in selected re-
gions of Germany. To achieve this it is necessary to 
operate cancer registries in all federal states nation-
wide. This has been achieved in the meantime with 
commencement of registration in Baden-Wuerttem-
berg in 2009. The Federal Cancer Registry Data Act, 
which came into force in the same year, further 
 improved the scope for collection and evaluation of 
anonymised cancer registry data at the national level 
via the newly established German Centre for Cancer 
Registry Data at the Robert Koch Institute.
In order to be able to pool information about an 
individualʼs cancer condition from different sources, 
data is collected in such a way that multiple reports 
on the same person are identifiable. For research pur-
poses it has to be possible to re-establish the link be-
tween the data and the individual. However in order 
to safeguard patientsʼ privacy and their right to con-
trol what happens to their data, all population-based 
registries are required under state legislation to adopt 
extensive precautions to protect and secure personal 
data.
Undistorted evaluation of the data is only possi-
ble if more than 90 % of all new cancer cases are 
registered. The cooperation of all physicians and den-
tists involved in diagnosis, treatment and aftercare is 
therefore crucial to the significance of data from a 
population-based cancer registry. Patients are also 
requested to take an active part in cancer registration. 
Ask your doctor to report your case to the appropriate 
cancer registry! This way you too can contribute to 
improved evaluation of cancer-related developments, 
cancer research and also help to improve cancer de-
tection, treatment and aftercare.
▶ Detailed analyses regarding survival prospects 
following diagnosis of cancer
▶ Examination of oncological care and long-term 
quality of life of cancer patients
▶ Occurrence of second tumours after a different 
primary cancer
▶ Evaluation of screening measures as for example 
mammography-screening or bowel cancer 
screening, especially coloscopy
▶ Studies of the connection between social strata 
and cancer incidence and mortality
▶ Cooperation with the cancer centers, e. g. in the 
assessment of the long-term survival of treated 
patients
▶ Study on the effectiveness of colonoscopy screen-
ing
A detailed list can be found at: www.gekid.de.
In the years to come, the evaluation of the organised 
screening programs introduced in Germany will 
present a particular challenge for the popula-
tion-based cancer registries. Using the data provided 
by the registries, it will be possible to assess whether 
screening has had the desired effect of reducing the 
number of advanced cancers within the population. 
By linking the registry data with the respective 
screening program it should also be possible to 
demonstrate reduction in mortality among partici-
pants in such measures.
The National Cancer Plan emphasised the cen-
tral role of cancer registration in assessing the effects 
of organised programs for the early detection of can-
cer. A number of implementational recommenda-
tions were adopted in the plan, which may ensure 
improved coordination in the future between the 
early recognition programs and the information col-
lected in the cancer registries. These recommenda-
tions have been integrated in national laws (Cancer 
Screening and Cancer Registration Act).
One initial focus in this regard has been the as-
sessment of mammography screening, which had 
been introduced nationwide by 2009. The popula-
tion-based cancer registries have already provided 
detailed basic data for the first evaluation reports 
on mammography screening (www.mammo-pro-
gramm.de), and this is being used for quality assur-
ance and an initial assessment of the program. A new 
task scheduled here is the identification of interval 
carcinomas (incidence of breast cancer following 
negative screening examination). First results from 
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States will fulfil these requirements by the end of 
2017.
Additional German cancer registries have ap-
plied for their epidemiological cancer data to be 
 included in the current edition of the publication 
»Cancer Incidence in Five Continents« (Volume X) 
published by the International Agency for Research 
on Cancer (IARC) at the WHO in Lyon, France. Only 
those cancer registries that meet internationally es-
tablished, strict quality criteria are included here. For 
the latest reporting period 2003–2007, eight German 
States have been included. It is foreseeable, however, 
that for the next reporting period (2008–2012) more 
cancer registry will achieve the required data quality 
and will therefore be included in this WHO central 
publication series.
Data from German cancer register are already 
available today alongside data from other European 
countries on ENCR website (European Network for 
Cancer Registries) which can be found at http://eco.
iarc.fr. Here, the German data can be easily compared 
with the information from other European registries.
GEKID, the membership of which also includes 
research scientists in the field of cancer epidemiology 
as well as all of the population-based cancer regis-
tries, has, in the past two years, continued to concern 
itself intensively with improved usage of the cancer 
registry data. One important result of this work is the 
updating of GEKID’s Interactive Cancer Atlas to re-
flect current cancer incidence and mortality in the 
federal states. In addition to data regarding incidence 
and mortality the atlas now includes details of surviv-
al following cancer at regional level. The Atlas can be 
accessed via the GEKID homepage at www.gekid.de 
and offers interactive regional comparisons for 23 
cancer sites in cartographic form.
Above and beyond purely presenting cancer reg-
istry data, the population-based cancer registries and 
GEKID have participated in planning and imple-
menting epidemiological cancer research projects. 
Pivotal in this regard was the funding of a programme 
»Cancer Epidemiology« by the German Cancer Aid. 
Together with the German Cancer Research Center 
(DKFZ) in Heidelberg it was possible to conduct ex-
haustive research into survival following cancer and 
to publish these findings internationally. Further-
more several significant international publications 
have emerged from other research projects, some of 
them addressing the linkage of research datasets with 
cancer registry data. You can find information on 
 further research projects or current publications on 
the GEKID website and in the annex to this report.
These examples illustrate that the focus of epide-
miological cancer registration in Germany is current-
ly shifting away from the pure collection of data and 
more toward the active scientific use of the data. This 
development is of essential importance, because 
1.2  Current development of cancer  
registration in Germany
Since 2009, all new cases of cancer are being system-
atically registered across the whole of Germany on 
the basis of regional legislation. As a consequence, 
the current situation for population-based cancer reg-
istration is to be viewed as very positive. For the year 
2012 it is estimated that eleven federal States have 
reached a completeness of at least 90 %. This means 
that reliable data on new cases of cancer is available 
today for a population of nearly 55 million people. 
Across Germany about 95 % of the estimated number 
of new cases of the disease for 2012 have actually 
been recorded in the registries – ten years prior to 
this the figure was still under 60 %, Internationally, 
barely any other country of comparable population 
size has achieved such a high rate of registration to 
date.
Numerous individual initiatives in the federal 
states to improve cancer registration have contribut-
ed to this great result. Population-based cancer regis-
tration has also continued to receive support from the 
Federal Government with the Federal Cancer Regis-
try Data Act of 2009 and the establishment of the 
German Centre for Cancer Registry Data (ZfKD) 
within the Robert Koch Institute. Since the end of 
2011, all regional cancer registries have been provid-
ing the ZfKD with de-personalised data on an annual 
basis in a standardised format. This collective data 
forms the basis of the analyses carried out by the 
ZfKD which are presented in this, the 10th edition of 
»Cancer in Germany«.
Another milestone in the development of cancer 
registration in Germany was the adoption of the Can-
cer Screening and Registration Act (KFRG) in 2013, 
where significant recommendations from the Na-
tional Cancer Plan have been implemented. The Act 
obligates all Federal States to set up a system of ad-
vanced clinical cancer registry in addition to the al-
ready established population-based cancer registry – 
a system where detailed data regarding therapy and 
disease process will be recorded. The last two years 
have seen the beginnings of the cancer registry trans-
formation supported by the Association of Popula-
tion-based Cancer Registries in Germany (GEKID) 
and the Association of German Tumour Centres 
(ADT). In regions where there are still no clinical 
cancer registries, usually the population-based cancer 
registries are being expanded into clinical-epidemio-
logical registries. Where clinical registries already 
exist, they are being adapted to meet the require-
ments of the KFRG. New regional cancer registry 
legislation has been adopted in many federal states, 
some already working according to specifications 
contained in the KFRG. It is assumed that all Federal 
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without in-depth scientific analysis, the knowledge 
gained from painstakingly collected data would be 
limited. After all, all of the anonymised data records 
gathered from all of the registries may now be ac-
cessed and used on application via the ZfKD by exter-
nal researchers, an option which has been taken up 
to an increasing extent over the past two years. The 
many contributions by the cancer registries and the 
ZfKD have also become an important element of 
 Federal Health Reporting.
A completely new era is dawning now with the 
introduction of the clinical cancer registries. The data 
from the cancer registries will be useful for compre-
hensive quality assurance and healthcare research. 
Thus, the importance of the cancer registry for the 
oncological research and healthcare and therefore 
also for the benefit for cancer patients will further 
increase. Generally speaking, the current develop-
ments in cancer registration in Germany are to be 
seen as positive and to have considerable future po-
tential. In an international context, the build-up of 
nationwide clinical cancer registration means that 
Germany will join the top flight in this field.
1.3  Current priorities of the Centre for 
Cancer Registry Data (ZfKD)
Almost six years after the founding of the Centre for 
Cancer Registry Data (ZfKD), its start-up phase can 
be seen as a largely completed. An interactive data-
base has been established at www.krebsdaten.de as 
well the application process for external use of ano-
nymised data from individual cases. So far, 16 appli-
cations have been made, of which almost all were 
granted without restriction. The past two years have 
seen the first publications resulting from these pro-
jects.
The tasks of the ZfKD arising from the Federal 
Cancer Registry Data Act (BKRG) (see annex 5.1), in-
clude conducting its own analyses and producing 
scientific publications. In addition to numerous con-
ference contributions a special issue focused on pop-
ulation-based cancer registration was published at 
the beginning of 2014 in the German Federal Health 
Gazette (»Bundesgesundheitsblatt«), which included 
contributions from authors within the cancer regis-
tries, the ZfKD, the German Cancer Research Center 
and university institutions. In its capacity as part of a 
public-health institute, the ZfKD focuses particularly 
on those types of cancer which may in principle be 
influenced through early detection or prevention 
measures, with regard incidence or mortality. For in-
ternationally published papers estimates of the num-
ber of cancers attributable to the consumption of to-
bacco and alcohol in Germany were calculated. The 
proportion of new cases of cancer associated with 
smoking or consumption of alcohol across all cancer 
sites amounted to 16 % and 3 % respectively. This 
means that a total of about one-fifth of all cancers in 
Germany is caused just by these two risk factors, 
which can be influenced by various measures. Fur-
ther publications on the impact of obesity, and certain 
chronic infections (particularly human papillomavi-
rus, HPV) are in preparation. Indirectly, clear region-
al or international differences or rising trends may 
also indicate factors that could be influenced. Gener-
ally, the task of the ZfKD in this regard is to indicate 
where more research is needed. In this context, in 
another English-language publication, in-depth anal-
yses on the incidence of vulvar carcinoma were pre-
sented, a tumour that has clearly been increasing re-
cently in Germany (cf. annex 5.6).
In addition, the ZfKD addresses research topics, 
which require a large data base. These relate, for ex-
ample, to rare tumours, the risk of secondary cancers 
or the specific analysis of clinically important sub-
groups of certain types of cancer or oncologic diseases 
that are not classified as ›malignant‹ under the cur-
rent international classification of diseases (ICD), for 
example non-invasive bladder cancers and myelodys-
plastic syndromes (MDS). Another concern of the 
ZfKD is to make its data and results available for oth-
er researchers. In this sense, the ZfKD sees itself as a 
service facility for a broad number of scientific disci-
plines. The growing number of enquiries is proof that 
this service has come to be increasingly used and ap-
preciated.
Ultimately, the work of the ZfKD should benefit 
both the population-based registries and the clinical 
cancer registries currently being established. This in-
cludes the joint effort to find a standardised method 
of data collection as well as achieving uniformity in 
plausibility checks with regard to international re-
quirements and classifications or their updates. The 
transition table between ICD-O-3 and ICD-10 devel-
oped by the ZfKD together with registry representa-
tives for types of leukaemia and lymphomas has, in 
the meantime, become part of the testing and conver-
sion software for cancer registry data (IARCcrgTools) 
after clearance with the results of a British working 
group.
Even though the ZfKD has not been delegated 
any direct tasks within the nationwide build up of 
clinical cancer registration in the next few years, there 
will be at least one direct reference to this topic in the 
future: the results of the estimation of data complete-
ness for each registry, according to the method devel-
oped by the ZfKD, have been determined a core crite-
rion for the funding of the registries by the German 
health insurance companies, which means that the 
ZfKD will have a special responsibility in this regard. 
Because of this, the methods which had already been 
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modified some years ago, are being subjected to care-
ful re-examination and in particular the validity of the 
underlying assumptions are being re-checked as far 
as possible.
2016 will see the first issue of another series of 
ZfKD reports to be published every five years using 
additional data sources to provide comprehensive in-
formation about cancer in Germany. In addition to 
detailed analyses regarding the epidemiology of can-
cer, these will also deal with aspects of prevention, 
early detection, care and the consequences of cancer, 
as well as containing information on the current sta-
tus of the implementation of the National Cancer 
Plan. The ZfKD website (www.krebsdaten.de) pro-
vides information on additional current projects and 
activities.
2 Methodological Aspects
2.1  Estimating the degree of capture in  
the epidemiological cancer registries 
(Estimation of Completeness)
The usefulness of population-based data with regard 
to cancer largely depends on the level of completeness 
with which new cancer cases are registered. Therefore 
the Centre for Cancer Registry Data (ZfKD) annually 
checks the completeness of the data from the popula-
tion-based cancer registries in Germany, since 2010 
for all federal states. The estimation is made with the 
help of an internationally accepted indicator of com-
pleteness, namely the ratio of mortality to incidence. 
This ratio (M/I Index) can largely be assumed to be 
regionally constant for the respective cancer diagno-
sis, provided there are no fundamental differences in 
diagnosis and therapy and therefore also in the sur-
vival prospects of cancer patients in Germany. With 
the help of the M/I-Index in a particular reference 
region where registration is known to be comprehen-
sive and by using regional mortality figures, the inci-
dence in the respective region examined can be esti-
mated and compared with the actual recorded data. 
Cases identified through death certificate only (DCO) 
are not taken into account here. The completeness of 
the reference region register is also estimated by 
means of comparison with the expected values.
The following inclusion criteria were established 
for the reference region in 2010.
▶ Comprehensive cancer registration for a period of 
at least ten years
▶ Completeness of more than 90 % for cancer over-
all over the past ten years (using the previous RKI 
estimation method) and more than 80 % for all 
individual years
▶ Proportion of DCO-cases of less than 15 % for can-
cer overall over the past ten years or at least from 
the sixth year since the beginning of registration
These criteria were met by the registries in Saarland, 
Hamburg, Bremen, Schleswig-Holstein, Lower Sax-
ony, Bavaria, Brandenburg, Mecklenburg-Western 
Pomerania, Saxony, Thuringia and the administrative 
district of Münster (North Rhine-Westphalia). It is 
expected that this pool will grow to include further 
registries in the next few years.
According to the principle described in the above, 
expected values are calculated for six age groups for 
men and women respectively and for 16 diagnosis 
groups. In order to compensate for random fluctua-
tions the observed and expected values were smoothed 
using log-linear models.
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If mortality in the region being studied is too low 
(less than five cases of death per year on average) the 
modelled (smoothed) incidence in the reference re-
gion is used instead of the quotients derived from 
incidence and mortality for the appropriate age group 
in order to calculate the expected number of new cas-
es. The estimated degree of completeness for each 
diagnosis group is the result of the ratio of observed 
and expected case figures accumulated across all age 
groups. The completeness for cancer overall is again 
estimated by summing the observed and expected 
values for all diagnosis groups.
The procedure described has limitations, espe-
cially if the mortality for one type of cancer is low in 
absolute terms or relative to incidence (testicular can-
cer, malignant melanoma, thyroid cancer), or if the 
real ratio of mortality to incidence differs between the 
regions. This may, for example, be the case if early 
detection measures are utilised to varying degrees in 
the federal states or if they are introduced at different 
points in time, as was the case with mammogra-
phy-screening.
According to the current estimation, 12 federal 
states are already achieving an estimated complete-
ness of at least 90 % for 2012, with seven of the states 
even achieving over 95 % in relation to the aforemen-
tioned reference registries. In the last ten years, the 
degree of capture has consequently increased consid-
erably (Illustration 2.1.1). Any deficits that still exist 
can in part be explained by the fact that the forwarding 
of data regarding patients treated outside their state 
of residence is not yet satisfactorily regulated in all 
areas. Especially the requirements of the clinical can-
cer registries should lead to further improvements in 
the next few years.
Figure 2.1.1
Development of the estimated completeness of the population-based cancer registries in Germany 2000 to 2002 and 2010, 
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1953 East-Berlin, 1995 Berlin (re-united)
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 1986 Münster administrative district, 2005 all North Rhine-Westphalia
3
 2003 Darmstadt administrative district, 2007 all Hesse
14 Cancer in Germany
2.2  Estimating national incidence  
for Germany
The estimation of incidence rates for Germany are 
based on the results of completeness estimation as 
explained in 2.1. The estimated nationwide figures for 
new cases for the individual diagnoses and years arise 
from the summation of the results from the registries 
with a degree of capture over a certain threshold level 
and the expected value from the completeness estima-
tion for those regions that were not (yet) deemed to be 
comprehensive for the respective year.
For all diagnoses except from thyroid cancer and 
the malignant melanoma, registries with a degree of 
capture of at least 90 % are considered as complete. 
Due to strong fluctuations in the ratio of mortality to 
incidence the threshold level for thyroid cancer and 
for the malignant melanoma were set to 70 % and 
80 %, respectively.
The DCO (Death Certificate Only) cases were in-
cluded for the comprehensive registries from the 
sixth year of nationwide registration. For the first five 
years and for the non-comprehensive registers the 
DCO-rates from the five reference registries were 
 taken into the calculation (according to site, age and 
gender). Because of the varying stages of develop-
ment, North Rhine-Westphalia was divided into three 
regions for the time being (the administrative district 
of Münster, Düsseldorf/Cologne and Arnsberg/Det-
mold).
Because the entire dataset is analysed anew for 
every estimation of incidence, this may result in 
changes (usually slight) in the incidence rates from 
estimation to estimation, which partly can be caused 
by delayed notification of incident cases and partly by 
the methodology of the estimation itself.
For the last estimation, the group of reference 
registries was expanded with respect to the long-last-
ing high quality of many epidemiological registries in 
Germany. This expansion lead to a changes in the 
estimated incidence. Consequently the current esti-
mations for 2010 for ›all cancer sites‹ are about 2 % 
higher than two years ago which approximately corre-
sponds to the number of late registrations in the reg-
istries. Depending on the localisation, the deviation 
may vary. The estimation for the melanoma for the 
year 2010 are 6.6 % higher for men than two years 
before and 8.1 % higher for women. The estimation 
for malignant neoplasms of soft tissue for men for the 
year 2010 are about 6 % lower than two years before. 
Changes in encoding and documentation of leu-
kaemias has resulted in higher incidence rates for 
women (12 % higher than 2 years before) and for men 
(10 % higher).
This report presents estimated trends over time 
since 1999. Since the population-based cancer regis-
tries in the densely populated federal states did not 
commence data capture until between 2002 and 
2009, the estimations for recent years are based on a 
significantly broader data basis than those for the pe-
riod before 2002 for instance. Although the same 
methodology was used in each case, estimates for re-
cent years can generally be viewed as more reliable. 
Assuming that the levels of completeness within the 
diagnosis groups do not differ significantly, estima-
tions were conducted for the first time for rarer types 
of cancer according to the same principle. The results 
are shown in Chapter 3.29 and in even more detail on 
the website at www.krebsdaten.de.
An estimation of the incidence of non-melanoma 
skin cancers (C44) is not possible using the method 
described, amongst other things due to the low mor-
tality. Experience shows that the acquisition of data 
pertaining to these diseases in population-based can-
cer registries is difficult since treatment is often on a 
purely out-patient basis. Consequently, even in an 
international context there is very little reliable data. 
However, in recent years some registries in Germany 
have made successful efforts to also include regis-
tered dermatologists in the registration process. This 
first-time estimation of nationwide incidence figures 
is thus based on the data of those registries where the 
age-standardised incidence rate in the past two years 
deviated by less than 25 % from the federal state with 
the highest recorded incidence (Schleswig-Holstein, 
Lower Saxony, North Rhine-Westphalia, Hesse, 
 Mecklenburg-Western Pomerania and the Rhineland 
Palatinate). The calculation was performed by project-
ing the pooled, age-specific incidence rates in these 
states onto the entire German population. However, 
a great degree of uncertainty still surrounds the inci-
dence estimates for non-melanoma skin cancers and 
these do not yet allow any reliable statements to be 
made regarding trends over time, which is why they 
are not presented in their own chapter. With regard to 
the presentation of the incidence of cancer in general 
(chapter 3.1) non-melanoma skin cancers have not, as 
in previous years, been included for reasons of com-
parability.
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2.3  Indicators and graphical  
presentations
The following section provides explanations of the 
measured values used in the results chapters and in 
the graphical presentations.
Age-specific rates
The age-specific rate is determined by dividing the 
number of cases of cancer and deaths in a certain age 
group by the corresponding number of men or wom-
en in this age group within the population. The graph-
ical presentation of these rates shows the relationship 
between age and incidence by gender. The age-specif-
ic incidence rates are expressed as the annual number 
of new cases per 100,000 inhabitants for the respec-
tive age group and year.
Age-standardised rates
As the presentation of the age-specific incidence for 
men and women in this report shows, the cancer in-
cidence rate usually increases considerably with age, 
so that before comparing incidence or mortality in 
different states and regions, or within the same pop-
ulation at different times, differences in the age struc-
ture of the compared populations must first be re-
moved with the help of age-standardisation. This is 
achieved through weighting and subsequent sum-
ming of the observed age-specific rates. An age- 
 standardised rate indicates the incidence of a type of 
illness or cause of death in a total of 100,000 people 
in a pre-defined age structure (standard population). 
In this report the old European Standard Population 
has been used.
Cancer incidence and mortality risks
Age-specific incidence rates and mortality rates may 
be interpreted as measures for the age- and gen-
der-specific risks of developing and dying from a spe-
cific malignant tumour within a year. In addition, age 
and sex specific risks of developing or dying from a 
specific form of cancer within the next ten years or at 
some point in the future were calculated. The results 
are presented both as a percentage and as one in N 
individuals of the same age and sex. So-called »com-
peting risks« were also taken into consideration, e. g. 
the probability of a 75-year-old man to die from some 
other disease within the next ten years. Similarly, the 
»lifetime risk« was calculated, i. e. the risk of develop-
ing a tumour at some point during an entire lifespan. 
However, only the respective current rates (incidence 
and mortality rates and general life expectancy) are 
used in the calculations. No prediction is therefore 
made regarding the future development of these val-
ues. Furthermore, these results are to be viewed as 
average values for the entire German population and 
individual risks may differ considerably due to the 
presence or absence of specific risk factors. The Dev-
Can programme developed by the US National Can-
cer Institute was used to perform the calculations.
International comparison
In order to be able to classify the estimated cancer 
incidence and cancer mortality in Germany in an in-
ternational context, current age-standardised inci-
dence and mortality rates in the countries bordering 
on Germany as well as the United Kingdom, Finland, 
and the USA (see Annex for sources). Where figures 
were available by the editorial dead-line, these results 
refer to the mean value for 2010 and 2011, otherwise 
the latest available data or estimations were used for 
the comparison. For some types of cancer (e. g. blad-
der cancer, renal cancer) the grouping of diagnoses in 
accordance with ICD-10 differs somewhat in individ-
ual countries from that used in Germany, which 
slightly limits comparability in some cases (see appro-
priate footnote).
For countries that haven’t been included in the 
last, 10th edition of the report »Cancer Incidence in 
five continents« by the International Agency for Re-
search on Cancer (IARC) – namely France, Poland 
and Switzerland – estimations have been taken from 
the website of the European Cancer Observatory by 
the IARC for 2012 (http://eco.iarc.fr/eucan/).
Median age at diagnosis
The median age at which a specific cancer develops 
according to cancer site and gender was calculated for 
all cases diagnosed in 2010 and 2011. The inclusion of 
DCO cases, for which the age at death is used instead 
of age at diagnosis, inevitably leads to a slight overes-
timation of this value.
Mortality
Cancer mortality is based on number of deaths in any 
one year due to cancer according to the official cause-
of-death statistics. The deaths are attributed to the 
underlying cause of death and grouped in terms of 
age and sex. The mortality rate is expressed as the 
relationship of the annual number of deaths to the 
size of the population. The rates are relative to 
100,000 people. In this report, the absolute number 
of deaths, as well as crude and the age-standardised 
mortality rates from 1999 to 2012 (European Stand-
ard) are presented. More up-to-date figures are already 
available from the German Federal Statistical Office 
(www.gbe-bund.de) and at www.krebsdaten.de.
Prediction of incidence for 2016
The incidence rates were predicted for 2016 by deter-
mining linear trends in estimated age-, gender- and 
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site-specific logarithmic incidence rates for Germany 
over the past ten years, and continuing these trends 
through to 2016 drawing on the current demographic 
projections from the German Federal Statistical Of-
fice. In variation from the above, constant incidence 
rates were assumed in the case of prostate cancer and 
for the malignant melanoma for all age groups and 
for female breast cancer for the 50 to 69 year age 
group (target group for mammography screening).
Regional comparison
The mean age-standardised incidence rates for 2009 
and 2010 (European Standard) from the federal states 
are expressed in comparison with the corresponding 
estimates for Germany. Any estimated capture rates 
of less than 90 % for 2010 are indicated by highlight-
ing the incidence bar. Age-standardised mortality ac-
cording to site and sex for all federal states is shown 
in comparison to nationwide mortality in Germany 
for the same period, using figures from the German 
Federal Statistical Office (www.gbe-bund.de).
Crude rates
A crude rate of incidence or mortality for a specific 
cancer site and population is calculated by dividing 
the total number of all new cases of cancer reported 
(incidence) or the number of deaths due to cancer 
(mortality) in a pre-determined time period by the 
total number of all women and/or men in the relevant 
population (in this case the residential population of 
Germany). The result is expressed as the number of 
new diagnoses or deaths per 100,000 residents per 
year. In contrast to the age-standardised rates, crude 
rates are highly dependent on the age-structure of a 
population.
Survival rates
The results of survival analyses in this report describe 
the average survival prospects of patients over the age 
of 15 years at the time of diagnosis given a specific 
cancer type. Absolute and relative survival rates from 
one to ten years have been calculated for this purpose. 
Absolute survival rates represent the proportion of 
patients who are still alive at a certain time after their 
diagnosis. For example, an absolute 5-year survival 
rate of 80 % means that 80 people out of 100 diag-
nosed with a specific type of cancer have survived the 
first five years after their diagnosis.
Relative survival rates show cancer-related mor-
tality in terms of the ratio of absolute survival of the 
cancer patients to the expected survival in the general 
population of the same age and gender. For example, 
a relative 5-year survival rate of 100 % means that 
within 5 years of cancer diagnosis, just as many per-
sons affected have died as would have been expected 
even without diagnosis. The relative survival rate is 
always higher than the corresponding absolute rate. 
It has been calculated using the so called »Ederer II 
method« using the federal German mortality tables 
from the Federal Statistical Office.
Like in the last edition of »Cancer in Germany«, 
the basis for the calculation of survival rate includes 
data from Hamburg, Lower Saxony, Bremen, the 
Rhineland-Palatinate, Saarland as well as Mecklen-
burg-Western Pomerania, Saxony, Thuringia (Joint 
Cancer Registry) and from the administrative district 
of Münster (North Rhine-Westphalia). This selection 
guarantees continuous estimations with high data 
quality.
In order to make the most up-to-date estimates of 
survival prospects possible, the so-called »period 
method« was used. This takes into account the surviv-
al of people with cancer who have been alive during a 
specific period (in this case 2011–2012).
The range quoted for five year survival represents 
the lowest and highest values in the individual re-
gions included, though for these purposes only re-
gions with a standard error of less than 7 % for the 
estimated survival were taken into account in the 
analysis. If this criterion was not met by at least seven 
regions, no range details have been presented. Pre-
sumably, the presented range only to a small extent 
reflects ›real‹ differences in the quality of care. Differ-
ences in data quality or in the proportion of DCO 
 cases may play a role, as well as random fluctuations, 
especially for smaller federal states. Methodological 
differences between registries may also influence 
 results, in particular efforts to conduct trace-back 
 research on DCO cases, which is not performed in 
all federal states.
Overall, it can be assumed that the estimated sur-
vival rates quoted for Germany are slightly over-esti-
mated, at least for those types of cancer with worse 
prognoses, but this is probably the case for most of the 
international results published too.
The calculation of survival 10 years after diagno-
sis is based on considerably lower numbers than the 
calculation of survival 5 years after diagnosis. For that 
reason, the registry-specific 10-year-survival is more 
uncertain than the 5-year-survival. Therefore, values 
in the range of relative 10-year-survival can be slightly 
above those for 5-year-survival.
Distribution of stages of tumours
The extent of a solid malignant tumour at the point of 
diagnosis in the years 2011 to 2012 was evaluated us-
ing the TNM-classification. Given the data situation, 
only the distribution of T stages (tumour size) are 
presented here. Included was data encoded according 
to the 7th Edition of the TNM-classification, valid 
since the beginning of 2010. For the respective sites, 
those registries were included in the evaluation where 
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the proportion of missing values (including DCO 
 cases) was less than 50 %. For sites where fewer than 
four federal states were able to fulfil this criterion, the 
stages have not been presented.
5-year prevalence
The 5-year prevalence refers to the number of people 
living at a given time (here 31 December 2012) who 
had been newly diagnosed with cancer within the pre-
vious five years, i. e. between 2008 and 2012. The 
prevalence is calculated using the Pisani method from 
the estimated incidence rates for Germany and the 
absolute survival rates calculated using the Ka-
plan-Meier method (according to age, sex, site, and 
calendar year) for the regions listed under ›survival 
rates‹ (see above).
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3 Results
3.0 Overview of incident cancer cases and cancer deaths
Table 3.0.1
Estimated numbers of incident cancer cases in Germany 2012
No. of incident cases Incidence rate1
Cancer site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 – C14 9,290 3,650 17.9 6.0
Oesophagus C15 5,030 1,510 9.0 2.2
Stomach C16 9,180 6,460 15.6 8.2
Colon and rectum C18 – C21 33,740 28,490 57.1 36.8
Liver C22 6,020 2,560 10.2 3.4
Gallbladder and biliary tract C23, C24 2,170 2,780 3.6 3.4
Pancreas C25 8,250 8,480 14.0 10.6
Larynx C32 3,110 490 5.7 0.9
Lung C33, C34 34,490 18,030 59.1 27.7
Malignant melanoma of the skin C43 10,400 10,420 19.2 19.2
Mesothelioma C45 1,260 300 2.0 0.4
Soft tissue not incl. Mesothelioma C46 – C49 1,800 1,710 3.5 2.9
Breast C50 620 69,550 1.1 117.4
Vulva C51 3,190 4.5
Cervix C53 4,640 9.3
Uterus C54, C55 10,930 16.6
Ovaries C56 7,380 11.4
Prostate C61 63,710 106.7
Testis C62 4,020 10.2
Kidney C64 9,500 5,530 16.9 8.0
Bladder C67 11,270 4,140 18.4 5.0
Central nervous system C70 – C72 3,960 3,220 7.9 5.6
Thyroid gland C73 1,820 4,390 3.8 9.3
Hodgkin's lymphoma C81 1,240 990 2.9 2.3
Non-Hodgkin lymphomas C82 – C88 8,580 7,570 15.4 11.0
Multiple myeloma C90 3,490 2,850 5.8 3.7
Leukaemias C91 – C95 7,180 5,460 13.3 8.2
Other cancer sites 11,960 11,190 21.0 15.1
Total cancer2 C00 – C97 w/o C44 252,060 225,890 440.2 348.9
1 age-standardised (European standard)  2 not including non-melanoma skin cancer (C44)
Figure 3.0.1
Most frequent tumour sites as a percentage of all new cancer cases in Germany 2012  
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Table 3.0.2
Number of deaths from cancer in Germany 2012
Source: Official cause of death statistics, Federal Statistical Office, Wiesbaden
No. of deaths Mortality rate1
Cancer site ICD-10 Men Women Men Women
Oral cavity and pharynx C00 – C14 4,090 1,303 7.7 1.9
Oesophagus C15 4,072 1,188 7.2 1.6
Stomach C16 5,770 4,208 9.5 4.9
Colom and rectum C18 – C21 13,772 12,200 22.4 13.3
Liver C22 5,117 2,553 8.4 3.0
Gallbladder and biliary tract C23, C24 1,415 2,122 2.3 2.4
Pancreas C25 7,936 8,184 13.1 9.6
Larynx C32 1,265 178 2.2 0.3
Lung C33, C34 29,713 14,752 49.8 21.3
Malignant melanoma of the skin C43 1,627 1,248 2.8 1.7
Mesothelioma C45 1,085 275 1.7 0.3
Soft tissue not incl. Mesothelioma C46 – C49 747 794 1.3 1.1
Breast C50 150 17,748 0.3 23.9
Vulva C51 827 0.9
Cervix C53 1,617 2.6
Uterus C54, C55 2,515 3.0
Ovaries C56 5,646 7.5
Prostate C61 12,957 20.1
Testis C62 179 0.4
Kidney C64 3,125 2,131 5.1 2.4
Bladder C67 3,791 1,826 6.0 1.9
Central nervous system C70 – C72 3,293 2,591 6.1 4.0
Thyroid gland C73 330 419 0.6 0.5
Hodgkin's lymphoma C81 219 158 0.4 0.2
Non-Hodgkin lymphomas C82 – C88 3,407 2,955 5.5 3.3
Multiple myeloma C90 1,956 1,870 3.1 2.1
Leukaemias C91 – C95 4,155 3,445 6.8 4.0
Other cancer sites 9,546 8,453 15.9 9.7
Total cancer2 C00 – C97 w/o C44 119,717 101,206 198.6 127.4
1 age-standardised (European standard)  2 not including non-melanoma skin cancer (C44)
Figure 3.0.2
Most frequent tumour sites when cancer was the cause of death in Germany 2012
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Epidemiology
›All cancer sites‹ refers here to all malignant neo-
plasms including lymphomas and leukaemias. 
A ›Malignant Neoplasm‹ is defined by the ›Inter-
national Statistical Classification of Disease and Re-
lated Health Problems‹ (ICD-10, Chapter C). This 
classification is prone to temporal trends and does not 
always reflect the clinical course of the disease: there 
are non-invasive papillary tumours of the urinary 
bladder and certain neoplasms of the hematopoietic 
system (for example myelodysplastic syndrome) that 
constitute more harms and complaints to the con-
cerned than some malignant neoplasms of the thy-
roid gland. In line with normal international practice, 
non-melanoma skin cancers (white skin cancer) are 
not included in the above. Estimates regarding the 
frequency of this widespread yet seldom life-threaten-
ing disease can be found in chapter 3.29.
Cancer can occur in all kinds of organs in the 
body and can originate from different types of cell. 
The origin of most types of cancers are the internal or 
external body surfaces. Approximately 70 % are ade-
nocarcinomas originating in glandular tissue. Around 
a further 15 % are squamous-cell carcinomas, malig-
nant tumours of the transitional epithelium (urothe-
lium carcinoma) and small-cell carcinoma, which 
occur for example in the lung. Alongside leukaemias 
and lymphomas, malignant tumours also have their 
origins, for example, in the support cells of the ner-
vous system (glia cells) or under pigment-producing 
cells (melanomas). Rarer forms of cancer include 
those originating in connective tissue, such as meso-
thelioma and various sarcomas.
According to our estimates a total of approxi-
mately 478,000 new cases of cancer were diagnosed 
in Germany in 2012. Of these, approximately 252,100 
were in men and 225,900 in women.
Just over half of all cases relate to the mammary 
gland (70,200), the prostate (63,700), the bowel 
(62,200) or the lungs (52,500) (Tab. 3.0.1).
Between 2002 and 2012 the number of new can-
cer cases increased among men by around 13 % and in 
women by 10 %. The decisive factor influencing this 
was the changing demographic structure of the pop-
ulation (increase in the proportion of older people), 
which was more pronounced among men than wom-
en. The development in age-standardised incidence 
rates indicates that without these changes there would 
have been decreasing incidence figures among men 
(by 4 %) and an increase of around 5 % in women. The 
latter can be explained to a significant extent by a de-
creasing trend of lung cancer in men versus an in-
crease in women (cf. Chapter 3.10).
The age-standardised mortality rates have de-
creased by 13 % in men and by 9 % in women. Because 
of the demographic change, the absolute number of 
cancer deaths increases instead by 10 % in males and 
2 % in females. The proportion of deaths attributed to 
cancer as underlying cause of death remained con-
stant since the end of the 1990s (22 % in women and 
3.1 All cancer sites
Table 3.1.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C97 without C44
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 259,090 229,720 252,060 225,890 266,800 231,900
Crude incidence rate1 661.3 559.0 641.3 549.3 666.2 559.8
Standardised incidence rate1,2 460.0 356.2 440.2 348.9 437.8 345.2
Median age at diagnosis 70 69 70 69
Deaths 119,368 101,546 119,717 101,206
Crude mortality rate1 304.6 247.1 304.6 246.1
Standardised mortality rate1,2 202.7 129.7 198.6 127.4
5-year prevalence 813,100 789,100 810,300 790,500
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 52 (47 – 55) 59 (55 – 63) 40 (34 – 42) 48 (44 – 50)
Relative survival rate (2011 – 2012)3 62 (56 – 65) 67 (62 – 70) 57 (51 – 61) 62 (58 – 65)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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28 % in men) indicating that the achievements of the 
war against cancer contributed to the increase of life 
expectancy of about two or three years.
Currently every second man (51 %) and 43 % of all 
women can be expected to develop cancer in the 
course of their life. Every fourth man and every fifth 
woman dies of cancer. The relationship between can-
cer incidence and age varies between men and wom-
en. Women under the age of 55 years reveal higher 
incidence rates than men of the same age. In the high-
er age groups this relationship reverses. In the over 
65 year age group the incidence rates among men are 
almost twice as high as those among women.
The relative 5-year survival rates compare the 
higher mortality of cancer patients to that of the gen-
eral population of the same age (100 % indicating 
 similarity). They range from favourable values above 
90 % for malignant melanoma of the skin, testicular 
cancer, and prostate cancer, through to survival rates 
of less than 20 % for lung, liver and pancreatic cancer 
and mesothelioma (Figure 3.1.0). During the last thir-
ty years the prognosis for cancer patients in Germany 
overall has improved considerably. Current estima-
tions using the period method show 5-year relative 
survival rates of 62 % for men and 67 % for women in 
patients diagnosed in 2011 and 2012. The improved 
overall cancer survival rates are due in part to shifts in 
the localisation spectrum, for example the decline in 
cases of stomach cancer and lung cancer among men 
(for which the prognoses are poor) and a larger pro-
portion of colorectal, breast, and prostate cancer with 
relatively better prognoses. The most obvious im-
provements in the survival rates of adult cancer pa-
tients over the last 25 years have been achieved in 
malignant tumours of the mammary gland, the bow-
el and the prostate.
Risk factors and early detection
The aetiology of many cancers is not known, and in 
other cases, known risk factors cannot be influenced. 
Prevention strategies are therefore only available for 
a few tumour types. However, these include types of 
cancer which affect large numbers of people. The 
World Health Organization estimates that more than 
30 % of all cancer cases could be avoided with preven-
tive measures.
Among avoidable risk factors, tobacco consump-
tion is the most important. According to estimates by 
the Centre for Cancer Registry Data, a total of around 
15 % of all cancer cases in Germany in 2008 were to 
be attributed to smoking. Also the roles of excess 
weight and lack of exercise have long been known 
from observational epidemiological investigations. 
Possible underlying biological mechanisms are be-
coming clearer due to the most recent research into 
the metabolic syndrome. This chronic »metabolic 
imbalance« is linked with hypertension, high blood 
cholesterol and hyperglycaemia. Inflammatory pro-
cesses in adipose tissue are also suspected of being 
involved in the development of cancer.
Among individual nutrition-related factors, alco-
hol consumption plays an important role. Low quan-
tities of fruit, vegetables, and dietary fiber, often com-
bined with a high intake of red meat, have been 
identified as risk factors for a number of frequently 
occurring types of cancer. However it has not always 
been possible in observational studies to separate the 
influence of specific foodstuffs and their constituents 
from that of the energy balance.
Also among the avoidable risk factors for devel-
oping cancer is the ultraviolet fraction of sunlight (UV 
radiation). Many people, particularly in Germany, 
overestimate the influence of hazardous substances 
and impurities in foodstuffs, as well as environmental 
factors or toxic exposure at the workplace. However, 
in certain individual cases these factors can also play 
a substantial role in the development of cancer, even 
here. Examples here are radon, the regionally occur-
ring noble gas, which is thought to be responsible for 
up to ten percent of lung cancer cases in Germany, or 
earlier occupational exposure to asbestos, which be-
cause of the long latency period is still causing meso-
thelioma of the pleura or peritoneum even today. Even 
medical procedures may impact on the cancer risk in 
individual cases. Potential risks include diagnostic 
procedures and therapies involving exposure to ra-
diation, cytostatic agents used in chemotherapy, 
and hormone replacement therapy for menopausal 
women, which has been identified as a risk factor for 
breast cancer.
Chronic infections are now known to be risk fac-
tors for some widespread forms of cancer. Vaccina-
tions or the treatment of causal factors can contribute 
to the reduction of cancer risk. This has been estab-
lished for vaccinations against hepatitis viruses as a 
risk factor for liver cancer, and it is hoped that vacci-
nation against human papilloma viruses will have a 
similar effect reducing the incidence rate for cervical 
carcinoma.
In addition to avoidable risk factors, genetic caus-
es may also increase the risk of developing cancer. To 
date, however, only very few of these genetic mu-
tations have been clearly identified. The respective 
relevant risk factors for specific types of cancer are 
presented in more detail in the individual sections.
The early detection programmes supported by 
the statutory health insurance companies in Germany 
screen for cancer of the skin and bowel, as well as 
breast and cervical cancer in women, and prostate 
cancer for men. These early detection measures are 
presented in the individual sections.
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Figure 3.1.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C00 – C97 without C44,  
Germany 1999 – 2012
Figure 3.1.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C00 – C97 without C44,  
Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.1.2
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Table 3.1.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C97 without C44, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 1.2 % (1 in 86) 50.7 % (1 in 2) 0.3 % (1 in 390) 26.2 % (1 in 4)
45 years 3.4 % (1 in 29) 50.6 % (1 in 2) 1.2 % (1 in 85) 26.3 % (1 in 4)
55 years 10.3 % (1 in 10) 50.2 % (1 in 2) 3.8 % (1 in 26) 26.1 % (1 in 4)
65 years 20.6 % (1 in 5) 47.5 % (1 in 2) 7.9 % (1 in 13) 24.7 % (1 in 4)
75 years 27.4 % (1 in 4) 39.9 % (1 in 3) 12.9 % (1 in 8) 21.3 % (1 in 5)
Lifetime risk 50.5 % (1 in 2) 26.0 % (1 in 4)
Women aged in the next ten years ever in the next ten years ever
35 years 2.2 % (1 in 46) 42.7 % (1 in 2) 0.3 % (1 in 310) 20.4 % (1 in 5)
45 years 4.8 % (1 in 21) 41.5 % (1 in 2) 1.1 % (1 in 93) 20.2 % (1 in 5)
55 years 8.5 % (1 in 12) 39.0 % (1 in 3) 2.6 % (1 in 38) 19.5 % (1 in 5)
65 years 12.9 % (1 in 8) 34.2 % (1 in 3) 4.9 % (1 in 20) 17.8 % (1 in 6)
75 years 16.3 % (1 in 6) 26.5 % (1 in 4) 8.0 % (1 in 13) 14.6 % (1 in 7)
Lifetime risk 43.1 % (1 in 2) 20.3 % (1 in 5)
Figure 3.1.4a
Absolute survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C00 – C97 without C44,  
Germany 2011 – 2012 
Figure 3.1.4b
Relative survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C00 – C97 without C44,  


















Distribution of T-stages at first diagnosis by sex
Not included because tumour stages are site-specific.
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Figure 3.1.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C00 – C97 without C44, 2011 – 2012
per 100,000 (European standard)
Figure 3.1.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C00 – C97 without C44, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  data incl. D09.0–1, D30.1–9, D35.2–4, D41.1–9, D32–D33, D42–D43, D44.3–5, D46–D47 but excl. C44 and C46.0
²  data for incidence incl. D00–D09
³  data for mortality incl. C44  
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Epidemiology
Cancer of the oral cavity and the pharynx is made up 
of a heterogeneous group of malignant neoplasms. In 
addition to 90 % squamous-cell carcinomas, some-
what more than 5 % of cases are adenocarcinomas, for 
example of the salivary glands.
The most favourable 5-year-survival rates are as-
sociated with cancer of the lips and salivary glands, 
whereas comparatively unfavourable survival pros-
pects exist for cancers of the floor of the mouth, the 
tongue and the lower part of the throat (hypopharynx). 
Women had the more favourable 5-year survival at 
61 % compared to men with 48 %. Contributing to-
ward this among women is a lower proportion of can-
cers of the floor of the mouth, tongue and hypophar-
ynx that are encouraged mainly by the consumption 
of alcohol and tobacco. One in every three tumours in 
women is diagnosed in the early stages (T1), but only 
one in every four cases in men.
The fact that men in general develop cancer more 
frequently and on average four years earlier than 
women (men aged 62, women at the age of 66) is 
probably connected with tobacco and alcohol con-
sumption. The incidence and mortality rates for can-
cers of the oral cavity and throat have not significantly 
changed since the year 2000. For men, the mortality 
rate has fallen a little, while among women the inci-
dence has increased slightly. Significant regional dif-
ferences are to be reported, especially among men: 
For example, the death rates in Mecklenburg-Western 
Pomerania are currently about twice as high as those 
in Schleswig-Holstein or in southern Germany.
Risk factors
The most important triggers for cancer of the oral 
cavity and pharynx are tobacco and alcohol consump-
tion. The combination of both factors is particularly 
harmful. Another risk factor of major importance is 
an infection with human papilloma virus (HPV), es-
pecially if high risk human papilloma viruses are in-
volved. It is assumed that 40 % of all malignancies of 
the pharynx can be attributed to these viruses. Their 
contribution to the onset of cancer of oral cavity is 
less. Further possible risk factors can be a one-sided, 
vitamin deficient diet with excessive meat consump-
tion. Inadequate oral hygiene and mechanical irrita-
tions, for example due to poorly fitting dentures, are 
also possible risk factors. Exposure to sunlight can 
contribute to carcinoma of the lips. Contact with saw-
dust or some chemicals – mostly in an occupational 
context – can increase the risk of developing tumours, 
especially in the nasopharynx. Epstein-Barr viruses 
are regarded as a further viral risk factor, in particular 
for nasopharyngeal carcinoma. People with type 2 di-
abetes, a marked immunodeficiency or rare pre-exist-
ing conditions may also have an increased risk. There 
are also clear indications that a genetic predisposition 
plays a role in the development of carcinoma in the 
head and neck areas.
Table 3.2.1
Overview of key epidemiological parameters for Germany, ICD-10 C00 – C14
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 10,000 3,900 9,290 3,650 10,000 4,200
Crude incidence rate1 25.52 9.48 23.64 8.87 25.0 10.1
Standardised incidence rate1,2 19.5 6.5 17.9 6.0 18.1 6.5
Median age at diagnosis 62 65 62 66
Deaths 4,064 1,322 4,090 1,303
Crude mortality rate1 10.37 3.22 10.41 3.17
Standardised mortality rate1,2 7.7 2.0 7.7 1.9
5-year prevalence 29,000 12,400 28,700 12,400
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 43 (41 – 46) 55 (48 – 60) 29 (27 – 32) 40 (32 – 45)
Relative survival rate (2011–2012)3 48 (46 – 50) 61 (53 – 67) 36 (34 – 38) 50 (41 – 55)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.2 Oral cavity and pharynx
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Figure 3.2.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C00 – C14, Germany 1999 – 2012
Figure 3.2.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C00 – C14, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.2.2
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Table 3.2.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C00 – C14, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,500) 1.7 % (1 in 59) <0.1 % (1 in 6,000) 0.8 % (1 in 130)
45 years 0.3 % (1 in 350) 1.7 % (1 in 61) 0.1 % (1 in 960) 0.8 % (1 in 130)
55 years 0.6 % (1 in 170) 1.4 % (1 in 70) 0.3 % (1 in 390) 0.7 % (1 in 150)
65 years 0.5 % (1 in 180) 0.9 % (1 in 110) 0.3 % (1 in 380) 0.5 % (1 in 210)
75 years 0.4 % (1 in 280) 0.5 % (1 in 210) 0.2 % (1 in 550) 0.3 % (1 in 360)
Lifetime risk 1.7 % (1 in 59) 0.8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 4,800) 0.7 % (1 in 150) <0.1 % (1 in 27,000) 0.3 % (1 in 390)
45 years 0.1 % (1 in 1,100) 0.7 % (1 in 150) <0.1 % (1 in 4,800) 0.3 % (1 in 400)
55 years 0.2 % (1 in 560) 0.6 % (1 in 170) 0.1 % (1 in 1,800) 0.2 % (1 in 420)
65 years 0.2 % (1 in 510) 0.4 % (1 in 230) 0.1 % (1 in 1,400) 0.2 % (1 in 520)
75 years 0.2 % (1 in 630) 0.3 % (1 in 380) 0.1 % (1 in 1,300) 0.1 % (1 in 730)
Lifetime risk 0.7 % (1 in 150) 0.3 % (1 in 390)
Figure 3.2.4a
Absolute survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C00 – C14, Germany 2011 – 2012
Figure 3.2.4b
Relative survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C00 – C14, Germany 2011 – 2012
Figure 3.2.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports)  
ICD-10 C00 – C14, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
27% 29% 20% 24%
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Figure 3.2.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C00 – C14, 2011 – 2012
per 100,000 (European standard)
Figure 3.2.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C00 – C14, 2011 – 2012 or latest available year (details and sources, see appendix)
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1 data without C07, C08, C11
2 data without C10.1
30 Cancer in Germany Oesophagus
Epidemiology
In Germany, cancers of the oesophagus cause about 
3 % of all cancer deaths among men and approximate-
ly 1 % among women, though their share of all cancer 
cases is lower. In Germany, men are diagnosed with 
cancer of the oesophagus around four to five times 
more frequently than women and at an average age of 
67, typically four years earlier.
Squamous-cell carcinomas account for 50 % to 
60 % of all cases of cancer of the oesophagus. In re-
cent years, the proportion of adenocarcinomas, which 
are almost exclusively found in the lower third of the 
oesophagus, has risen to more than one third of cases.
The age-standardised incidence and mortality 
rates have continued to increase in women since the 
turn of the millennium and have remained virtually 
unchanged in men. Only women aged between 60 
and 70 years of age show increases.
Despite improvements in recent years, the oe-
sophageal carcinoma ranks among those cancers with 
rather unfavourable survival prospects. The relative 
5-year survival rates are currently 22 % for men and 
24 % for women. In line with the unfavourable surviv-
al rates only around one in every seven tumours is 
diagnosed whilst still at an early stage (T1).
Risk factors
The most important risk factors for the development 
of the more frequent squamous-cell carcinoma in the 
oesophagus include alcohol and tobacco consump-
tion. In combination, the two factors reinforce one 
another. Studies have also shown that those affected, 
often eat little fruit and vegetables.
Adenocarcinomas, which are somewhat less fre-
quent, often originate in combination with a gas-
tro-oesophageal reflux disease (long-term flow of 
 gastric juices back into the oesophagus, chronic 
heartburn). This leads to changes to the mucous 
 lining of the lower part of the oesophagus, causing 
a Barrettʼs oesophagus, which is regarded as a pre-
cursor to cancer. Also in the case of adenocarcinoma, 
a consumption below the average of fruit and vege-
tables increases the risk of developing the disease.
Recently, adenocarcinomas of the oesophagus 
have been associated with smoking, being overweight 
and possibly also with type 2 diabetes. Family clusters 
of cases are known, and genetic predisposition is in-
volved as investigations show. The possible influence 
of the human papilloma viruses is a topic of contro-
versial debate.
Table 3.3.1
Overview of key epidemiological parameters for Germany, ICD-10 C15
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 4,950 1,410 5,030 1,510 5,600 1,600
Crude incidence rate1 12.6 3.4 12.8 3.7 13.9 3.9
Standardised incidence rate1,2 9.1 2.0 9.0 2.2 9.3 2.2
Median age at diagnosis 67 71 67 71
Deaths 3,966 1,172 4,072 1,188
Crude mortality rate1 10.1 2.9 10.4 2.9
Standardised mortality rate1,2 7.1 1.6 7.2 1.6
5-year prevalence 8,600 2,300 8,800 2,400
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 19 (9 – 25) 21 (10 – 27) 14 (6 – 18) 16 (6 – 26)
Relative survival rate (2011 – 2012)3 22 (11 – 28) 24 (12 – 31) 18 (9 – 25) 22 (9 – 35)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
3.3 Oesophagus
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Figure 3.3.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C15, Germany 1999 – 2012
Figure 3.3.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C15, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.3.2
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Table 3.3.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C15, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 6,700) 1.0 % (1 in 100) <0.1 % (1 in 10,200) 0.8 % (1 in 120)
45 years 0.1 % (1 in 1,000) 1.0 % (1 in 100) 0.1 % (1 in 1,500) 0.8 % (1 in 120)
55 years 0.3 % (1 in 380) 0.9 % (1 in 110) 0.2 % (1 in 500) 0.8 % (1 in 130)
65 years 0.4 % (1 in 270) 0.7 % (1 in 140) 0.3 % (1 in 340) 0.6 % (1 in 160)
75 years 0.3 % (1 in 310) 0.4 % (1 in 230) 0.3 % (1 in 330) 0.4 % (1 in 230)
Lifetime risk 1.0 % (1 in 100) 0.8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 24,700) 0.3 % (1 in 340) <0.1 % (1 in 40,700) 0.2 % (1 in 420)
45 years <0.1 % (1 in 4,400) 0.3 % (1 in 340) <0.1 % (1 in 7,800) 0.2 % (1 in 420)
55 years 0.1 % (1 in 1,700) 0.3 % (1 in 360) <0.1 % (1 in 2,300) 0.2 % (1 in 440)
65 years 0.1 % (1 in 1,100) 0.2 % (1 in 430) 0.1 % (1 in 1,500) 0.2 % (1 in 510)
75 years 0.1 % (1 in 1,100) 0.2 % (1 in 630) 0.1 % (1 in 1,300) 0.1 % (1 in 680)
Lifetime risk 0.3 % (1 in 340) 0.2 % (1 in 420)
Figure 3.3.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C15, Germany 2011 – 2012
Figure 3.3.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C15, Germany 2011 – 2012
Figure 3.3.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C15, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
14% 12% 57% 17%
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Figure 3.3.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C15, 2011 – 2012
per 100,000 (European standard)
Figure 3.3.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C15, 2011 – 2012 or latest available year (details and sources, see appendix)
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34 Cancer in Germany Stomach
Epidemiology
Histologically, various forms of adenocarcinomas pre-
dominate in the stomach and some are only to be 
found there, such as signet ring cell carcinoma (15 %) 
and certain neuro-endocrine carcinoma. Particularly 
noteworthy are the (mucosa-associated) MALT lym-
phomas originating in the stomach mucosa that 
are increasingly counted among the low-grade non- 
Hodgkin lymphoma. In addition to carcinomas, mesen-
chymal and mixed tumours occur only rarely.
Men on average are diagnosed with stomach can-
cer at the age of 72, women not until the age of 75 – 
both later than for cancer in general. Seventy-five-
year-old men and women are at greatest risk of falling 
ill with stomach cancer within the following ten years. 
Still more than 1 % of the population die from stom-
ach cancer.
For decades in Germany – as in other industri-
alised nations – there has been a steady decline in the 
incidence and mortality rates for stomach cancer. 
This trend has continued even after the turn of the 
Millennium in all age ranges.
The relative 5-year-survival rates are around 30 % 
for both men and women. Although the 5-year-surviv-
al prospects for stomach cancer have recently im-
proved, they still tend to be unfavourable in compari-
son to other forms of cancer. Only in just over half of 
all cases is the tumour stage noted on diagnosis. 
These statistics reveal that about two-thirds of these 
cancers are discovered at a late stage (T3 or T4).
Risk factors
A bacterial infection of the stomach with Helicobacter 
pylori is the most important risk factor for stomach 
cancer, as this can probably strengthen the effects of 
other risks. Smoking and excessive alcohol consump-
tion also increase the risk of stomach cancer. The re-
lationships between dietary factors and the risk of 
stomach cancer are complex. In general, a diet with a 
low fruit and vegetable content and high animal prod-
uct content is associated with a higher risk. There are 
indications that chronic heartburn or gastro-oeso-
phageal reflux increases the risk for certain forms 
of tumour at the transition from the stomach to the 
oesophagus. Being overweight can also promote these 
carcinomas. Low socio-economic status and past 
stomach surgery continue to be associated with an 
increased frequency of stomach cancer.
First-degree relatives of patients have a risk two 
to three times higher than the general population. It 
is not always clear whether this is due to a shared 
lifestyle, to the transmission of Helicobacter pylori 
within the family, or to hereditary gene mutations. In 
the case of young patients, it can be useful for relatives 
to receive genetic advice. The same applies for mem-
bers of families with rare hereditary colorectal cancer 
(HNPCC, Lynch syndrome).
Pernicious anaemia and several other pre-exist-
ing diseases constitute risk factors that affect only 
comparatively few people. Among the mostly benign 
stomach polyps, only the rare adenoma is regarded as 
a precursor to cancer.
3.4 Stomach
Table 3.4.1
Overview of key epidemiological parameters for Germany, ICD-10 C16
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 9,800 6,640 9,180 6,460 9,200 6,400
Crude incidence rate1 25.0 16.2 23.4 15.7 23.1 15.4
Standardised incidence rate1,2 17.0 8.6 15.6 8.3 14.4 7.9
Median age at diagnosis 71 75 72 75
Deaths 5,691 4,399 5,770 4,208
Crude mortality rate1 14.5 10.7 14.7 10.2
Standardised mortality rate1,2 9.7 5.2 9.5 4.9
5-year prevalence 20,100 14,200 19,800 13,900
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 26 (24 – 29) 28 (24 – 32) 19 (16 – 23) 20 (17 – 26)
Relative survival rate (2011 – 2012)3 32 (30 – 34) 33 (28 – 39) 29 (25 – 34) 31 (25 – 45)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.4.1b
Absolute numbers of incident cases and deaths, by sex, 
ICD-10 C16, Germany 1999 – 2012
Figure 3.4.1a
Age-standardised incidence and mortality rates, by sex,  
ICD-10 C16, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.4.2











































36 Cancer in Germany Stomach
Table 3.4.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C16, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 2,600) 1.9 % (1 in 52) <0.1 % (1 in 4,800) 1.3 % (1 in 78)
45 years 0.1 % (1 in 770) 1.9 % (1 in 52) 0.1 % (1 in 1,500) 1.3 % (1 in 78)
55 years 0.3 % (1 in 300) 1.9 % (1 in 54) 0.2 % (1 in 600) 1.3 % (1 in 79)
65 years 0.6 % (1 in 180) 1.7 % (1 in 59) 0.3 % (1 in 300) 1.2 % (1 in 82)
75 years 0.9 % (1 in 110) 1.4 % (1 in 70) 0.7 % (1 in 150) 1.1 % (1 in 90)
Lifetime risk 1.9 % (1 in 52) 1.3 % (1 in 79)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 3,200) 1.3 % (1 in 78) <0.1 % (1 in 6,900) 0.9 % (1 in 120)
45 years 0.1 % (1 in 1,400) 1.3 % (1 in 79) <0.1 % (1 in 2,700) 0.9 % (1 in 120)
55 years 0.2 % (1 in 640) 1.2 % (1 in 82) 0.1 % (1 in 1,200) 0.8 % (1 in 120)
65 years 0.3 % (1 in 320) 1.1 % (1 in 89) 0.2 % (1 in 580) 0.8 % (1 in 130)
75 years 0.5 % (1 in 190) 0.9 % (1 in 110) 0.4 % (1 in 280) 0.7 % (1 in 140)
Lifetime risk 1.3 % (1 in 77) 0.9 % (1 in 120)
Figure 3.4.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C16, Germany 2011 – 2012
Figure 3.4.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C16, Germany 2011 – 2012
Figure 3.4.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C16, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
19% 13% 45% 23%
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Figure 3.4.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,  
ICD-10 C16, 2011 – 2012
per 100,000 (European standard)
Figure 3.4.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C16, 2011 – 2012 or latest available year (details and sources, see appendix)
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38 Cancer in Germany Colon and rectum
Risk factors and early detection
A number of factors increase the risk of colorectal 
cancer. Smoking and being overweight are the prin-
cipal risk factors, followed by insufficient exercise 
and a diet low in fibre. People who regularly consume 
alcohol or eat a lot of red meat or processed meats 
made from red meat are more prone to develop col-
orectal cancer. First-degree relatives of colorectal can-
cer patients are themselves affected with an above- 
average frequency. There is a very high risk of 
 developing colorectal cancer early in life in the case 
of rare inherited diseases such as familial adeno-
matous polyposis (FAP) or Lynch syndrome (heredi-
tary non-polyposis colorectal cancer, HNPCC).
Chronic inflammatory bowel diseases also 
slightly increase the risk of developing this cancer.
As part of the early detection directive, people 
between 50 and 54 years of age with statutory health 
insurance can have an annual test for blood in the 
stool. From the age of 55 years they are entitled to a 
colonoscopy examination, in the course of which 
 colon polyps, which may develop into malignant 
 tumours, can also be removed. If there are no patho-
logical findings, they are entitled to a further 
 colonoscopy ten years later. As an alternative to colo-
noscopy, insured persons can have the above-men-
tioned stool test every two years, with entitlement to 
a follow-up colonoscopy where clarification is re-
quired. Special provisions are made for people with 
an increased risk.
Epidemiology
About every eighth case of cancer of females and 
males in Germany affects colon or rectum. In 2012 
about 33,740 men and 28,500 women were diag-
nosed with bowel cancer. In life one of fourteen men 
and one of eighteen women will eventually be diag-
nosed with bowel cancer but one of thirty-two men 
and one of thirty-nine women die of bowel cancer 
only.
Almost two thirds of tumours were located in the 
colon, some 30 % affected the shorter rectum, while 
the remainder were located at the junction between 
the colon and the rectum (rectosigmoid), respectively 
the anal canal. The rare cases of – for instance neuro-
endocrine – cancer in the longest part of the bowel 
the upper intestine (C17) are not included here, in 
line with international practice. Histologically, be-
sides squamous-cell carcinomas of the anus and rare 
neuroendrocrine tumours (approx. 1 %), almost all 
tumours are adenocarcinomas (approx. 85 %).
The risk of developing the disease increases 
steadily with advancing age up to very old age. Corre-
spondingly the median age at diagnosis is 72 years 
for men and 75 years for women. More than half of 
those affected were diagnosed after the age of 70 
years, with only about 10 % before 55 years of age, i. e. 
before qualifying for the colonoscopy offered in the 
early detection programme. The age-standardised 
incidence rates for women and men are decreasing 
since 2002, even the number of cases is on the de-
crease. The age-standardised mortality rates for men 
and women have declined by more than 20 % in the 
past 10 years. The relative survival rates are approxi-
mately 63 % for men and for women.
3.5 Colon and rectum
Table 3.5.1
Overview of key epidemiological parameters for Germany, ICD-10 C18 – C21
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 34,460 29,330 33,740 28,490 33,400 27,600
Crude incidence rate1 88.0 71.4 85.8 69.3 83.5 66.6
Standardised incidence rate1,2 59.5 37.9 57.1 36.8 52.7 33.9
Median age at diagnosis 71 75 72 75
Deaths 13,863 12,439 13,772 12,200
Crude mortality rate1 35.4 30.3 35.0 29.7
Standardised mortality rate1,2 23.2 13.7 22.4 13.3
5-year prevalence 117,700 98,800 116,200 97,200
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 52 (50 – 55) 52 (49 – 56) 38 (35 – 42) 40 (37 – 44)
Relative survival rate (2011 – 2012)3 63 (60 – 66) 63 (58 – 68) 58 (55 – 61) 61 (54 – 70)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.5.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C18 – C21, Germany 1999 – 2012
Figure 3.5.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C18 – C21, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.5.2











































40 Cancer in Germany Colon and rectum
Table 3.5.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C18 – C21, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 840) 7.0 % (1 in 14) <0.1 % (1 in 4,100) 3.1 % (1 in 32) 
45 years 0.4 % (1 in 250) 7.0 % (1 in 14) 0.1 % (1 in 890) 3.1 % (1 in 32)
55 years 1.2 % (1 in 80) 6.9 % (1 in 15) 0.4 % (1 in 260) 3.1 % (1 in 32)
65 years 2.4 % (1 in 41) 6.3 % (1 in 16) 0.9 % (1 in 110) 3.1 % (1 in 33)
75 years 3.3 % (1 in 31) 4.9 % (1 in 20) 1.6 % (1 in 62) 2.8 % (1 in 36)
Lifetime risk 6.9 % (1 in 14) 3.1 % (1 in 32)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 800) 5.7 % (1 in 18) <0.1 % (1 in 5,000) 2.6 % (1 in 39)
45 years 0.3 % (1 in 300) 5.6 % (1 in 18) 0.1 % (1 in 1,200) 2.6 % (1 in 39)
55 years 0.8 % (1 in 130) 5.4 % (1 in 19) 0.2 % (1 in 500) 2.5 % (1 in 39)
65 years 1.4 % (1 in 71) 4.9 % (1 in 20) 0.5 % (1 in 210) 2.5 % (1 in 40)
75 years 2.3 % (1 in 44) 4.0 % (1 in 25) 1.1 % (1 in 93) 2.3 % (1 in 44)
Lifetime risk 5.7 % (1 in 18) 2.6 % (1 in 39)
Figure 3.5.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C18 – C21, Germany 2011 – 2012
Figure 3.5.4b
Relative survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C18 – C21, Germany 2011 – 2012
Figure 3.5.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C18 – C21, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
14% 15% 54% 16%
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Figure 3.5.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C18 – C21, 2011 – 2012
per 100,000 (European standard)
Figure 3.5.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C18 – C21, 2011 – 2012 or latest available year (details and sources, see appendix)
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42 Cancer in Germany Liver
Epidemiology
Liver cancer is relatively uncommon, but in view of its 
poor prognosis it ranks among the ten most frequent 
causes of death due to cancer for both men and wom-
en. There are approximately 8,600 new cases in Ger-
many every year, and roughly the same number of 
deaths. The median age at diagnosis is 71 years for 
men and 74 years for women. Only about 4 % of cases 
are diagnosed before 45 years of age. One in 84 men 
and one in 200 women in Germany develop a malig-
nant liver tumour in the course of their life.
Some 66 % of malignant tumours develop from 
liver cells (hepatocellular carcinoma), and almost 21 % 
from cells in the intrahepatic bile ducts (cholangiocar-
cinoma). This proportion is significantly higher for 
women.
Since 1980, the mortality rate for men has risen 
steadily by a total of 52 %, even after age-standardisa-
tion, while it has remained more or less unchanged 
for women in the same period. The increased mortal-
ity rate in men was independent of the histology of the 
tumour. The age-standardised incidence rate for liver 
cancer in men has increased by about 20 % since 
1999.
Currently, incidence and mortality rates in the 
north-western federal states are somewhat lower than 
in the rest of Germany. In an international compari-
son, the highest incidence and mortality rates are to 
be observed in France and in The United States.
In Germany, the relative 5-year-survival rates for 
women and for men are around 15 %.
Risk factors and early detection
Cirrhosis of the liver is the most important risk factor 
for liver cancer. In Germany, the most common caus-
es for the development of cirrhosis of the liver are 
high alcohol consumption levels and/or chronic hep-
atitis C virus infection. Non-alcoholic fatty liver dis-
ease also increases the risk of liver cancer. These may, 
for example, occur as a consequence of diabetes mel-
litus and/or due to metabolic syndrome. In turn, the 
trigger for metabolic syndrome is very often obesity.
A chronic infection with the hepatitis B virus, 
even without cirrhosis of the liver, is also a risk factor 
for liver cancer. Tobacco consumption is associated 
with an increased risk, as well. Besides, contamina-
tion of food with Aflatoxin B1 (mould fungus poison-
ing) increases the risk of liver cancer. Finally, heredi-
tary metabolic diseases such as haemochromatosis 
can also increase this risk.
Early detection examinations for the general pop-
ulation are not included in the statutory health insur-
ance screening programmes. It is recommended that 
regular ultrasound check-ups be offered to all patients 
with cirrhosis of the liver, chronic hepatitis B or C 
infections, or with fatty liver disease. Blood tests (for 
alpha-fetoprotein) are only of minor relevance.
3.6 Liver
Table 3.6.1
Overview of key epidemiological parameters for Germany, ICD-10 C22
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 5,880 2,600 6,020 2,560 6,600 2,900
Crude incidence rate1 15.0 6.3 15.3 6.2 16.6 7.0
Standardised incidence rate1,2 10.1 3.4 10.2 3.4 10.5 3.6
Median age at diagnosis 71 74 71 74
Deaths 5,011 2,551 5,117 2,553
Crude mortality rate1 12.8 6.2 13.0 6.2
Standardised mortality rate1,2 8.4 3.1 8.5 3.0
5-year prevalence 7,800 2,800 7,900 2,900
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 13 (9 – 15) 13 (6 – 17) 7 (4 – 10) 8 (0 – 11)
Relative survival rate (2011 – 2012)3 15 (10 – 17) 14 (8 – 19) 10 (7 – 14) 11 (0 – 14)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.6.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C22, Germany 1999 – 2012
Figure 3.6.1a
Age-standardised incidence and mortality rates,  
by sex,  ICD-10 C22, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.6.2
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Table 3.6.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C22, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 7,900) 1.2 % (1 in 83) <0.1 % (1 in 11,800) 1.1 % (1 in 94)
45 years 0.1 % (1 in 1,600) 1.2 % (1 in 83) <0.1 % (1 in 2,300) 1.1 % (1 in 94)
55 years 0.2 % (1 in 430) 1.2 % (1 in 84) 0.2 % (1 in 550) 1.1 % (1 in 94)
65 years 0.5 % (1 in 210) 1.1 % (1 in 94) 0.4 % (1 in 260) 1.0 % (1 in 100)
75 years 0.5 % (1 in 190) 0.7 % (1 in 140) 0.5 % (1 in 190) 0.7 % (1 in 140)
Lifetime risk 1.2 % (1 in 84) 1.1 % (1 in 95)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 10,400) 0.5 % (1 in 200) <0.1 % (1 in 16,600) 0.5 % (1 in 190)
45 years <0.1 % (1 in 3,900) 0.5 % (1 in 200) <0.1 % (1 in 5,600) 0.5 % (1 in 200)
55 years 0.1 % (1 in 1,400) 0.5 % (1 in 210) 0.1 % (1 in 1,800) 0.5 % (1 in 200)
65 years 0.1 % (1 in 740) 0.4 % (1 in 230) 0.1 % (1 in 780) 0.5 % (1 in 210)
75 years 0.2 % (1 in 480) 0.3 % (1 in 300) 0.2 % (1 in 430) 0.4 % (1 in 250)
Lifetime risk 0.5 % (1 in 200) 0.5 % (1 in 190)
Figure 3.6.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C22, Germany 2011 –  2012
Figure 3.6.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C22, Germany 2011 – 2012
Figure 3.6.3
Distribution of T-stages at first diagnosis by sex
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Figure 3.6.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C22, 2011 – 2012
per 100,000 (European standard)
Figure 3.6.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C22, 2011 – 2012 or latest available year (details and sources, see appendix)
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46 Cancer in Germany Gall bladder and biliary tract
Risk factors and early detection
The triggers for carcinomas of the gall bladder and 
biliary tract are not absolutely clear. Overweight is 
considered to be a risk factor for both. The presence 
of gallstones can be a risk for gall bladder carcino-
mas. In the current scientific debate, chronic inflam-
matory diseases of the biliary tract, such as a primary 
sclerosing cholangitis (PSC), choledochal cysts, the 
inflammatory bowel disease ulcerative colitis, liver 
diseases as a result of the high consumption of alco-
hol, hepatitis-C virus infection, and HIV infection, 
Diabetes and smoking are all deemed to be possible 
risk factors. A further risk factor, especially in Asia, is 
an infection with the parasitic liver flukes Clonorchis 
sinensis or Opisthorchis viverrini.
Various markers are being tested for their suit-
ability for early detection among persons at risk, how-
ever, without any practical consequences. There is no 
screening programme on offer for the general popu-
lation. Often, however, early stage diagnosis is made 
upon removing the gall bladder for other reasons.
Epidemiology
In Germany, about 4,950 new cases of malignant tu-
mours of the gall bladder (approx. 37  %) and of the 
biliary tract outside the liver (63  %) were diagnosed 
in 2012. Women develop gall bladder carcinomas 
more frequently, whereas tumours in the extra hepat-
ic biliary tracts are diagnosed more frequently in men.
Histologically, the majority of these are adenocar-
cinomas. Other histological variants such as squa-
mous-cell carcinomas or hybrid forms are rare. As 
with liver cancer, the risk of developing this type in-
creases steadily with age. The lifetime risk is about 
0.6  % for women and 0.5  % for men.
Since 1999 the age-standardised incidence rate 
in Germany has declined for women (especially for 
gall bladder carcinomas) and remained largely un-
changed for men. However, because of demographic 
changes the absolute number of new cases has in-
creased slightly among men. The age-standardised 
mortality rates for the same period have decreased 
constantly in both genders.
The survival prospects with malignant tumours 
of the gall bladder and biliary tract are generally poor, 
yet better than for liver cancer. The relative 5-year sur-
vival rate for women is 15  % and 21  % for men. Details 
with regard to tumour stage at point of diagnosis exist 
for approximately 60  % of gall bladder cases regis-
tered, most of which were diagnosed in stage T2 and 
T3.
3.7 Gall bladder and biliary tract
Table 3.7.1
Overview of key epidemiological parameters for Germany, ICD-10 C23 – C24
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 2,350 3,050 2,170 2,780 2,400 2,600
Crude incidence rate1 6.0 7.4 5.5 6.8 5.9 6.2
Standardised incidence rate1,2 3.9 3.7 3.6 3.4 3.7 3.0
Median age at diagnosis 73 76 72 76
Deaths 1,421 2,149 1,415 2,122
Crude mortality rate1 3.6 5.2 3.6 5.2
Standardised mortality rate1,2 2.4 2.4 2.3 2.4
5-year prevalence 3,700 3,900 3,700 3,800
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 18 (9 – 41) 13 (7 – 19) 12 (5 – 17) 9 (2 – 15)
Relative survival rate (2011 – 2012)3 21 (10 – 48) 15 (9 – 23) 18 (8 – 26) 14 (3 – 26)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.7.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C23 – C24, Germany 1999 – 2012
Figure 3.7.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C23 – C24, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.7.2











































48 Cancer in Germany Gall bladder and biliary tract
Table 3.7.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C23 – C24, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 16,600) 0.5% (1 in 220) <0.1 % (1 in 42,800) 0.3 % (1 in 320)
45 years <0.1 % (1 in 4,200) 0.5% (1 in 220) <0.1 % (1 in 9,800) 0.3 % (1 in 320)
55 years 0.1 % (1 in 1,500) 0.5% (1 in 220) <0.1 % (1 in 2,900) 0.3 % (1 in 320)
65 years 0.2 % (1 in 660) 0.4% (1 in 230) 0.1 % (1 in 1,000) 0.3 % (1 in 320)
75 years 0.2 % (1 in 430) 0.4% (1 in 290) 0.2 % (1 in 590) 0.3 % (1 in 370)
Lifetime risk 0.5% (1 in 220) 0.3 % (1 in 320)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 24,200) 0.6 % (1 in 180) <0.1 % (1 in 75,000) 0.4 % (1 in 230)
45 years <0.1 % (1 in 4,900) 0.6 % (1 in 180) <0.1 % (1 in 8,900) 0.4 % (1 in 230)
55 years 0.1 % (1 in 1,400) 0.6 % (1 in 180) <0.1 % (1 in 2,100) 0.4 % (1 in 230)
65 years 0.1 % (1 in 710) 0.5 % (1 in 200) 0.1 % (1 in 1,000) 0.4 % (1 in 240)
75 years 0.2 % (1 in 400) 0.4 % (1 in 240) 0.2 % (1 in 520) 0.3 % (1 in 290)
Lifetime risk 0.6 % (1 in 180) 0.4 % (1 in 230)
Figure 3.7.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C23 – C24, Germany 2011 – 2012
Figure 3.7.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C23 – C24, Germany 2011 – 2012
Figure 3.7.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 only C23, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
11% 34% 46% 9%
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Figure 3.7.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C23 – C24, 2011 – 2012
per 100,000 (European standard)
Figure 3.7.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C23 – C24, 2011 – 2012 or latest available year (details and sources, see appendix)
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50 Cancer in Germany Pancreas
Risk factors
Smoking tobacco is a proven risk factor and passive 
smoking also plays a part. Obesity (adipositas) and 
type 2 diabetes mellitus also have a negative bearing. 
Further lifestyle-related factors have not been conclu-
sively proven. It is believed that high consumption of 
processed meat goods, eating smoked or grilled 
foods, as well as high alcohol consumption levels can 
increase the risk of pancreatic cancer. Patients with 
chronic inflammation of the pancreas (pancreatitis) 
also have an increased risk. First-degree relatives of 
patients with a pancreatic carcinoma have a statisti-
cally higher risk of developing the cancer themselves. 
It is not clear, whether this is due to a hereditary pre-
disposition or shared lifestyle. An inheritable risk 
does indeed appear to play a part for some patients at 
least. Research is being conducted to establish which 
genes are involved. The risk of developing this cancer 
is higher for people affected by certain, rare, genetic 
cancer syndromes. It is not yet fully clear what role is 
played by environmental factors or occupational ex-
posure to harmful substances. The contact with pes-
ticides, herbicides and fungicides may increase the 
risk of pancreatic carcinoma. Also an exposure to 
chlorinated hydrocarbons, chromium and chromium 
compounds, electromagnetic fields and fuel vapours 
may also increase the risk.
Epidemiology
The pancreas produces hormones (endocrinal func-
tion of islet cells) as well as digestive juices (exocrine 
function). The vast majority of malignant tumours in 
the pancreas originate in the exocrine portion of the 
pancreas. In 2012 more than 16,700 people were di-
agnosed with pancreatic cancer. In line with the un-
favourable prognosis, almost that many people also 
died of the disease. The age-standardised incidence 
and mortality rates among men have remained al-
most constant since the late 1990s, whereas the rates 
among women are slightly increasing. The absolute 
number of new cases and deaths has risen steadily 
among both, men and women. In the early stages, 
malignant neoplasms of the pancreas frequently 
cause no or only nonspecific symptoms, thus the 
 tumour is frequently only detected late. Accordingly, 
the relative 5-year survival rate is extremely unfavour-
able. In Germany it is 8 % for men and 9 % for wom-
en, although the rare malignant islet cell tumours 
have a significantly better prognosis. The pancreatic 
carcinoma thus has the lowest survival rate of all 
forms of cancer and is the fourth most frequent cause 
of death due to cancer.
The median age at diagnosis is 71 years for men 
and 75 years for women.
3.8 Pancreas
Table 3.8.1
Overview of key epidemiological parameters for Germany, ICD-10 C25
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 8,280 8,420 8,250 8,480 9,100 9,500
Crude incidence rate1 21.1 20.5 21.0 20.6 22.7 23.0
Standardised incidence rate1,2 14.2 10.5 14.0 10.6 14.3 11.3
Median age at diagnosis 71 75 71 75
Deaths 7,812 8,128 7,936 8,184
Crude mortality rate1 19.9 19.8 20.2 19.9
Standardised mortality rate1,2 13.2 9.6 13.1 9.6
5-year prevalence 7,700 7,900 7,800 8,100
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 7 (5 – 10) 8 (4 – 11) 5 (3 – 6) 6 (4 – 7)
Relative survival rate (2011 – 2012)3 8 (5 – 11) 9 (5 – 13) 6 (4 – 9) 8 (5 – 10)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.8.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C25, Germany 1999 – 2012
Figure 3.8.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C25, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.8.2
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Table 3.8.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C25, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 4,900) 1.7 % (1 in 59) <0.1 % (1 in 8,700) 1.7 % (1 in 60)
45 years 0.1 % (1 in 1,000) 1.7 % (1 in 59) 0.1 % (1 in 1,200) 1.7 % (1 in 59)
55 years 0.3 % (1 in 310) 1.7 % (1 in 60) 0.3 % (1 in 360) 1.7 % (1 in 60)
65 years 0.6 % (1 in 160) 1.5 % (1 in 68) 0.6 % (1 in 180) 1.5 % (1 in 65)
75 years 0.7 % (1 in 130) 1.1 % (1 in 91) 0.8 % (1 in 120) 1.2 % (1 in 82)
Lifetime risk 1.7 % (1 in 60) 1.7 % (1 in 61)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 5,600) 1.7 % (1 in 59) <0.1 % (1 in 12,200) 1.7 % (1 in 60)
45 years 0.1 % (1 in 1,500) 1.7 % (1 in 59) 0.1 % (1 in 1,900) 1.7 % (1 in 60)
55 years 0.2 % (1 in 470) 1.7 % (1 in 60) 0.2 % (1 in 550) 1.7 % (1 in 60)
65 years 0.5 % (1 in 210) 1.5 % (1 in 66) 0.4 % (1 in 230) 1.6 % (1 in 64)
75 years 0.7 % (1 in 140) 1.2 % (1 in 85) 0.7 % (1 in 140) 1.3 % (1 in 79)
Lifetime risk 1.7 % (1 in 59) 1,7 % (1 in 60)
Figure 3.8.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C25, Germany 2011 – 2012
Figure 3.8.4b
Relative survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C25, Germany 2011 – 2012
Figure 3.8.3
Distribution of T-stages at first diagnosis by sex

















53ICD-10 C25 Cancer in Germany
Figure 3.8.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C25, 2011 – 2012
per 100,000 (European standard)
Figure 3.8.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C25, 2011 – 2012 or latest available year (details and sources, see appendix)










































24 20 16 12 8 4 0 0 4 8 12 16 20 24

































54 Cancer in Germany Larynx
Risk factors
Smoking is the most important risk factor for the 
development of laryngeal cancer. Alcohol consump-
tion also increases the probability of developing this 
cancer, whereby the combination of both factors is 
particularly harmful. The influences of lifestyle, diet, 
or environmental factors are not yet completely clear, 
because in the majority of cases the influence of to-
bacco and alcohol consumption overshadows other 
effects. However, there are indications that increased 
consumption of red meat, as well as a vitamin-defi-
cient diet may increase risk. There is a known link 
between tumours of the larynx and occupational 
 exposure to asbestos, nickel or polycyclic aromatic 
hydrocarbons. The role of infections with human 
papillomaviruses (HPV) has not been completely 
clarified to date. There are indications that infections 
with Helicobacter pylori may also be of significance. 
First-degree relatives of patients have a higher risk of 
developing laryngeal cancer, but it is not clear in de-
tail, whether this is attributable to risk-genes which 
are directly involved in the development of the tu-
mour or to genes which determine the individual 
susceptibility to carcinogens.
Epidemiology
Laryngeal cancer is almost exclusively due to squa-
mous cell carcinoma. Men are affected by laryngeal 
cancer considerably more frequently than women 
due to higher consumption of tobacco and alcohol at 
all ages. Currently in Germany, one in every 170 men 
develops cancer of the larynx compared to only one 
in every 1,100 women (lifetime risk). The median age 
of diagnosis in women is 64 years and in men 66 
years and thus in each case four to five years earlier 
than for cancer in general.
Incidence and mortality rates among men have 
been declining since as early as the 1980s. After sig-
nificant increases in the 1980s and 1990s the rates 
among women have remained unchanged since the 
turn of the millennium. After the year 2000, this led 
to an increase in the number of mortalities and new 
cases among women, especially in older age groups 
– whilst numbers of new cases among men remained 
unchanged.
The relative 5-year-survival rates for men and 
women do not differ significantly with rates of 62 % 
and 65 % respectively. The percentage of earlier tu-
mour stages on diagnosis among men is somewhat 
more favourable at a figure of 42 % T1 compared to a 
figure for women of 38 %.
3.9 Larynx
Table 3.9.1
Overview of key epidemiological parameters for Germany, ICD-10 C32
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 3,160 510 3,110 490 3,200 600
Crude incidence rate1 8.1 1.2 7.9 1.2 8.0 1.4
Standardised incidence rate1,2 5.9 0.9 5.7 0.9 5.4 1.0
Median age at diagnosis 66 65 66 64
Deaths 1,333 212 1,265 178
Crude mortality rate1 3.4 0.5 3.2 0.4
Standardised mortality rate1,2 2.4 0.3 2.2 0.3
5-year prevalence 11,600 1,800 11,400 1,800
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 55 (51 – 63) 60 37 (29 – 43) 46
Relative survival rate (2011 – 2012)3 62 (58 – 73) 65 49 (38 – 58) 55
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.9.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C32, Germany 1999 – 2012
Figure 3.9.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C32, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.9.2











































56 Cancer in Germany Larynx
Table 3.9.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C32, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 9,200) 0.6 % (1 in 170) <0.1 % (1 in 52,800) 0.3 % (1 in 390)
45 years 0.1 % (1 in 1,500) 0.6 % (1 in 170) <0.1 % (1 in 5,400) 0.3 % (1 in 390)
55 years 0.2 % (1 in 570) 0.5 % (1 in 180) 0.1 % (1 in 1,700) 0.2 % (1 in 400)
65 years 0.2 % (1 in 440) 0.4 % (1 in 250) 0.1 % (1 in 1,100) 0.2 % (1 in 480)
75 years 0.2 % (1 in 590) 0.2 % (1 in 430) 0.1 % (1 in 950) 0.2 % (1 in 650)
Lifetime risk 0.6 % (1 in 170) 0.3 % (1 in 400)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 60,700) 0.1 % (1 in 1,100) <0.1 % (1 in 216,800) <0.1 % (1 in 2,800)
45 years <0.1 % (1 in 7,600) 0.1 % (1 in 1,100) <0.1 % (1 in 47,900) <0.1 % (1 in 2,800)
55 years <0.1 % (1 in 3,400) 0.1 % (1 in 1,300) <0.1 % (1 in 14,700) <0.1 % (1 in 3,000)
65 years <0.1 % (1 in 3,300) 0.1 % (1 in 1,900) <0.1 % (1 in 8,700) <0.1 % (1 in 3,500)
75 years <0.1 % (1 in 5,700) <0.1 % (1 in 4,100) <0.1 % (1 in 8,300) <0.1 % (1 in 5,200)
Lifetime risk 0.1 % (1 in 1,100) <0.1 % (1 in 2,900)
Figure 3.9.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C32, Germany 2011 – 2012
Figure 3.9.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C32, Germany 2011 – 2012
Figure 3.9.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C32, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
42% 21% 20% 17%
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Figure 3.9.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C32, 2011 – 2012
per 100,000 (European standard)
Figure 3.9.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C32, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  data with C10.1 (Anterior surface of epiglottis)
  
58 Cancer in Germany Lung
Risk factors and early detection
Exposure to tobacco smoke has long been recognised 
as the main risk factor for lung cancer. Up to nine out 
of ten cases of lung cancer in men, and at least six out 
of ten cases in women are attributable to active smok-
ing. Passive smoke inhalation also increases the risk 
of cancer and is a major contributor to indoor pollu-
tion.
Other risk factors play a comparatively minor 
role. About 9 to 15 out of 100 cases of lung cancer are 
attributable to exposure to various carcinogenic sub-
stances, including asbestos, polycyclic aromatic hy-
drocarbons and quartz and nickel dust. In areas with 
a high natural exposure to radon in buildings, the 
risk of lung cancer is higher for occupants, particu-
larly in lower storeys. This also applies for occupa-
tional exposure to radon or other sources of ionising 
radiation. Diesel exhaust fumes are the most import-
ant risk factor among air pollutants. An impact of 
other environmental pollutants (e. g. particulate mat-
ter) is presumed to exist, but the extent of this is still 
the subject of research. The same applies for the in-
fluence of genetic factors. There is also a relationship 
between infection with human papillomavirus (HPV) 
or Epstein-Barr virus (EBV) and the development of 
lung carcinomas.
To date there is no established means of screen-
ing for lung cancer. The role that examinations, such 
as a regular computed tomography, could have for 
risk groups is being explored in clinical trials.
Epidemiology
In 2012 about 18,000 women and 34,500 men were 
diagnosed with malignant lung tumours and about 
14,800 woman and 29,700 men died of the disease. 
Lung cancer therefore remains by far the commonest 
cause of death due to cancer among men in Germany, 
accounting for 25 % of deaths due to cancer, while it 
is the second most common among women (15 %).
The age-standardised incidence and mortality 
rates show opposing trends for men and for women. 
Among women they have risen continuously since 
the end of the 1990s, while for men the rates de-
creased over the same period. These differing trends 
for the two sexes can be attributed to a change in 
smoking habits dating back some time and will prob-
ably continue in future. In terms of prognosis, lung 
cancer is one of the more unfavourable cancers, with 
relatively low 5-year survival rates of about 21 % for 
women and 16 % for men. Histologically, three main 
types are distinguished. Adenocarcinomas account 
for a third of all cases, while squamous-cell and 
small-cell lung carcinomas each account for about a 
quarter of cases. Due to the tendency to metastasise 
early, small cell carcinomas have the worst prognosis. 
In comparison with international data, the highest 
incidence rates can be identified among women from 
Denmark and men from Poland.
3.10 Lung
Table 3.10.1
Overview of key epidemiological parameters for Germany, ICD-10 C33 – C34
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 35,270 17,710 34,490 18,030 35,000 20,300
Crude incidence rate1 90.0 43.1 87.8 43.9 87.5 49.1
Standardised incidence rate1,2 61.3 27.4 59.1 27.7 56.0 30.1
Median age at diagnosis 70 68 70 69
Deaths 29,653 14,291 29,713 14,752
Crude mortality rate1 75.7 34.8 75.6 35.9
Standardised mortality rate1,2 50.6 20.9 49.8 21.3
5-year prevalence 49,600 28,700 49,000 29,200
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 14 (12 – 16) 19 (14 – 24) 9 (7 – 11) 13 (9 – 17)
Relative survival rate (2011 – 2012)3 16 (14 – 19) 21 (16 – 26) 12 (10 – 15) 16 (11 – 22)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.10.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C33 – C34, Germany 1999 – 2012
Figure 3.10.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C33 – C34, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.10.2











































60 Cancer in Germany Lung
Table 3.10.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C33 – C34, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,600) 6.9 % (1 in 14) <0.1 % (1 in 2,600) 6.1 % (1 in 16)
45 years 0.4 % (1 in 220) 6.9 % (1 in 14) 0.3 % (1 in 310) 6.2 % (1 in 16)
55 years 1.5 % (1 in 66) 6.8 % (1 in 15) 1.1 % (1 in 87) 6.1 % (1 in 16)
65 years 2.6 % (1 in 38) 5.8 % (1 in 17) 2.2 % (1 in 45) 5.5 % (1 in 18)
75 years 3.0 % (1 in 34) 4.0 % (1 in 25) 2.8 % (1 in 35) 4.1 % (1 in 24)
Lifetime risk 6.8 % (1 in 15) 6.1 % (1 in 17)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,700) 3.4 % (1 in 29) <0.1 % (1 in 2,800) 2.9 % (1 in 35)
45 years 0.3 % (1 in 300) 3.4 % (1 in 30) 0.2 % (1 in 450) 2.8 % (1 in 35)
55 years 0.8 % (1 in 120) 3.1 % (1 in 32) 0.6 % (1 in 170) 2.7 % (1 in 37)
65 years 1.1 % (1 in 89) 2.4 % (1 in 42) 0.9 % (1 in 110) 2.2 % (1 in 46)
75 years 1.0 % (1 in 100) 1.5 % (1 in 69) 0.9 % (1 in 110) 1.5 % (1 in 68)
Lifetime risk 3.4 % (1 in 29) 2.8 % (1 in 35)
Figure 3.10.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C33 – C34, Germany 2011 – 2012
Figure 3.10.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C33 – C34, Germany 2011 – 2012
Figure 3.10.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C33 – C34, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
17% 29% 22% 32%
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Figure 3.10.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C33 – C34, 2011 – 2012
per 100,000 (European standard)
Figure 3.10.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C33 – C34, 2011 – 2012 or latest available year (details and sources, see appendix)
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1 Data for incidence for England only
62 Cancer in Germany Malignant melanoma of the skin
Risk factors and early detection
The most important endogenous risk factor for the 
development of a malignant melanoma is the num-
ber of pigmented moles a person has. These maligno-
ma occur in people with lighter skin types rather than 
in those with darker complexions. If family members 
are already suffering from this type of skin cancer (at 
least 2 first-degree relatives) it may indicate the pres-
ence of gene mutations. Depending on the mutation, 
the risk of developing a malignant melanoma can be 
increased to a varying extent. Even if you have ever 
had a melanoma, there is an increased risk of devel-
oping another.
The most important exogenous risk factor is ul-
traviolet (UV) radiation. This is true for natural sun-
light and artificial UV radiation for example from a 
solarium/sunbed. Exposure to the sun during child-
hood and adolescence and so-called intermittent sun 
exposure (as is typical during summer holidays) in-
crease the risk in particular. Being exposed to arti-
ficial UV radiation in the workplace, for example 
during welding work, could possibly also be a risk 
factor.
In mid-2008, new screening regulations were 
introduced in Germany for skin cancer within the 
framework of legislation on the early detection of 
cancer. Men and women above 35 years of age with 
statutory health insurance are entitled to a skin exam-
ination every two years by a suitably trained doctor 
(dermatologist, general practitioner, etc.).
Epidemiology
In 2012, about 20,800 people were newly diagnosed 
in Germany with malignant melanoma of the skin, 
which constitutes a share of 4 % of all new cases of 
cancer.
The median age of women at diagnosis is cur-
rently 59 years, which is comparatively low. The me-
dian age of men at diagnosis is eight years higher.
Since the 1980s, the age-standardized incidence 
rates of women and men have more than tripled. The 
jump since 2008 in both sexes is probably the result 
of skin cancer screening being introduced in July of 
that year in Germany. Overall, mortality rates re-
mained largely unchanged over the observed period.
From a histological point of view, it is possible to 
distinguish between different subtypes of malignant 
melanoma. The dominant type is the superficial 
spreading melanoma (SSM), which is associated with 
a favourable prognosis. Other forms, in particular the 
nodular and amelanotic melanoma, are to be seen as 
having considerably less favourable prognoses.
Currently, the relative 5-year survival rate in Ger-
many for women with malignant melanoma of the 
skin is 94 % and for men 91 %. The tumour stage at 
diagnosis also contributes to what have in the mean-
time become very favourable survival rates. Two-
thirds of all melanomas are discovered while still at 
an early tumour stage (T1).
3.11 Malignant melanoma of the skin
Table 3.11.1
Overview of key epidemiological parameters for Germany, ICD-10 C43
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 10,540 10,510 10,400 10,420 12,300 12,200
Crude incidence rate1 26.9 25.6 26.5 25.3 30.8 29.4
Standardised incidence rate1,2 19.9 19.5 19.2 19.2 21.4 22.2
Median age at diagnosis 66 59 67 59
Deaths 1,709 1,212 1,627 1,248
Crude mortality rate1 4.4 3.0 4.1 3.0
Standardised mortality rate1,2 3.0 1.7 2.8 1.7
5-year prevalence 42,800 45,400 45,000 47,100
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 79 (73 – 84) 86 (79 – 89) 67 (62 – 72) 75 (68 – 79)
Relative survival rate (2011 – 2012)3 91 (85 – 96) 94 (86 – 97) 90 (83 – 97) 92 (85 – 96)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.11.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C43, Germany 1999 – 2012
Figure 3.11.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C43, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.11.2











































64 Cancer in Germany Malignant melanoma of the skin
Table 3.11.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C43, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 720) 1.9 % (1 in 52) <0.1 % (1 in 9,900) 0.3 % (1 in 290)
45 years 0.2 % (1 in 430) 1.8 % (1 in 55) <0.1 % (1 in 4,100) 0.3 % (1 in 300)
55 years 0.4 % (1 in 270) 1.7 % (1 in 60) 0.1 % (1 in 2,000) 0.3 % (1 in 310)
65 years 0.7 % (1 in 150) 1.4 % (1 in 70) 0.1 % (1 in 1,000) 0.3 % (1 in 330)
75 years 0.7 % (1 in 140) 1.0 % (1 in 100) 0.2 % (1 in 650) 0.3 % (1 in 390)
Lifetime risk 2.0 % (1 in 50) 0.3 % (1 in 290)
Women aged in the next ten years ever in the next ten years ever
35 years 0.2 % (1 in 410) 1.7 % (1 in 58) <0.1 % (1 in 11,000) 0.2 % (1 in 410)
45 years 0.3 % (1 in 330) 1.5 % (1 in 67) <0.1 % (1 in 4,600) 0.2 % (1 in 420)
55 years 0.3 % (1 in 310) 1.2 % (1 in 82) <0.1 % (1 in 3,200) 0.2 % (1 in 450)
65 years 0.4 % (1 in 240) 0.9 % (1 in 110) <0.1 % (1 in 2,100) 0.2 % (1 in 500)
75 years 0.4 % (1 in 260) 0.6 % (1 in 160) 0.1 % (1 in 1,100) 0.2 % (1 in 580)
Lifetime risk 1.9 % (1 in 52) 0,2 % (1 in 400)
Figure 3.11.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C43, Germany 2011 – 2012
Figure 3.11.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C43, Germany 2011 – 2012
Figure 3.11.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C43, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
63% 16% 11% 10%
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Figure 3.11.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C43, 2011 – 2012
per 100,000 (European standard)
Figure 3.11.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C43, 2011 – 2012 or latest available year (details and sources, see appendix)
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66 Cancer in Germany Mesothelioma
Risk factors
Even today, asbestos and above all the inhalation of 
asbestos fibres are still responsible for the majority of 
newly diagnosed cases. Admittedly, the processing of 
asbestos in Germany was restricted in the early 1980s 
and completely banned since 1993. However, there is 
a latency period of on average 30 years between expo-
sure beginning and the manifestation of the illness. 
Approximately 900 newly diagnosed cases per year 
are being recognised by employersʼ liability insur-
ance associations. The occupational groups affected 
include metalworkers, welders, electricians, install-
ers, roofers, bricklayers, construction workers, auto-
motive engineers and tilers. Even if there is no known 
vocational exposure to asbestos, mesotheliomas are 
often asbestos-related. In autopsy studies high con-
centrations of asbestos fibres are often found in the 
lung tissue even without any corresponding vocation-
al history.
Loosely bound asbestos with high fibre content 
is particularly dangerous. In contrast, asbestos ce-
ment (commonly referred to as ›Eternit‹, after a man-
ufacturer), which is to be found even today both in 
and on buildings, is deemed to be largely safe, pro-
vided it remains intact and does not weather.
Further risk factors only play a minor role. These 
can be the exposition to other fibres as for example 
Erionit or a radiation therapy of breast or abdomen.
Epidemiology
Malignant mesothelioma refer to a rare soft tissue 
tumour (in the cells of the mesothelium), mainly oc-
curring in men of advanced age. The most frequently 
affected site is the pleura (pleural mesothelioma) – 
around 90 %.
Because of the long-term latency, no evidence of 
a reduction in age-standardised incidence and mor-
tality rates is to be noted even 20 years after the ban 
on asbestos processing (see right). Meanwhile, the 
incidence and mortality rates in men under the age 
of 65 years are falling, whereas they are still increas-
ing in men over the age of 75. In Germany, in 2012 
approximately 1,260 men and 300 women were diag-
nosed.
Clear regional differences with high incidence 
and mortality rates, especially in Hamburg and Bre-
men can be explained by high exposure to asbestos 
among former shipyard workers. Comparatively high 
rates in England and the Netherlands can be inter-
preted in a similar way.
With relative 5-year survival rates of 9 % in men 
and 17 % in women, mesothelomia belong to the 
types of cancer with very unfavourable prognosis, 
which to date has not been significantly affected by 




Overview of key epidemiological parameters for Germany, ICD-10 C45
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 1,310 360 1,260 300 1,400 400
Crude incidence rate1 3.3 0.9 3.2 0.7 3.4 0.9
Standardised incidence rate1,2 2.1 0.5 2.0 0.4 2.0 0.5
Median age at diagnosis 73 74 73 73
Deaths 1,147 287 1,085 275
Crude mortality rate1 2.9 0.7 2.8 0.7
Standardised mortality rate1,2 1.9 0.4 1.7 0.3
5-year prevalence 1,800 600 1,700 500
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 7 15 2 9
Relative survival rate (2011 – 2012)3 9 17 4 12
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.12.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C45, Germany 1999 – 2012
Figure 3.12.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C45, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.12.2











































68 Cancer in Germany Mesothelioma
Table 3.12.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C45, database 2012 
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 100,300) 0.3 % (1 in 380) <0.1 % (1 in 78,600) 0.2 % (1 in 430)
45 years <0.1 % (1 in 13,400) 0.3 % (1 in 380) <0.1 % (1 in 17,300) 0,2 % (1 in 420)
55 years <0.1 % (1 in 2,800) 0.3 % (1 in 380) <0.1 % (1 in 3,800) 0,2 % (1 in 420)
65 years 0.1 % (1 in 930) 0.3 % (1 in 390) 0.1 % (1 in 1,200) 0,2 % (1 in 420)
75 years 0.1 % (1 in 740) 0.2 % (1 in 540) 0.1 % (1 in 750) 0,2 % (1 in 520)
Lifetime risk 0.3 % (1 in 390) 0,2 % (1 in 430)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 72,600) 0.1 % (1 in 1,700) <0.1 % (1 in 358,200) 0,1 % (1 in 1,800)
45 years <0.1 % (1 in 35,500) 0.1 % (1 in 1,700) <0.1 % (1 in 45,400) 0,1 % (1 in 1,800)
55 years <0.1 % (1 in 13,000) 0.1 % (1 in 1,800) <0.1 % (1 in 18,000) 0,1 % (1 in 1,900)
65 years <0.1 % (1 in 5,000) 0.1 % (1 in 2,000) <0.1 % (1 in 6,100) 0,1 % (1 in 2,000)
75 years <0.1 % (1 in 4,400) <0.1 % (1 in 2,900) <0.1 % (1 in 3,700) <0,1 % (1 in 2,600)
Lifetime risk 0.1 % (1 in 1,700) 0,1 % (1 in 1,800)
Figure 3.12.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C45, Germany 2011 – 2012
Figure 3.12.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C45, Germany 2011 – 2012
Figure 3.12.3
Distribution of T-stages at first diagnosis by sex

















69ICD-10 C45 Cancer in Germany
Figure 3.12.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C45, 2011 – 2012
per 100,000 (European standard)
Figure 3.12.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C45, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  no comparable data   
²  no comparable data for mortality    
³  data incl. C38.4 (Malignant neoplasm of Pleura)   
70 Cancer in Germany Soft tissue without mesothelioma
Epidemiology
This disease group includes the rare Kaposi sarcoma, 
occurring mainly on the skin and malignant tumours 
of the peripheral nerves, connective and other soft 
tissue such as the peritoneum and retroperitoneal 
soft tissue behind it. In almost 90 % of cases these 
are sarcomas, which in contrast to carcinomas do not 
develop from epithelial or glandular tissue, but from 
connective tissue structures, which also include fatty 
tissue and muscles. Conversely, around 45 % of all 
sarcomas are, according to ICD-10, assigned to other 
organs, this relates, for example, to sarcomas of the 
gastro-intestinal tract, the female genitalia and the 
breast. About 800 of the approximate total of 3,500 
new cases of malignant soft tissue tumours are ac-
counted for in lower extremities. The two most prev-
alent forms of soft tissue sarcoma in adulthood are 
the leiomyosarcoma originating in smooth muscle 
and liposarcoma (fatty tissue tumour). The embryon-
ic rhabdomyosarcoma (RMS) and Ewing’s sarcomas 
occur almost exclusively in children and adolescents.
Age-standardised incidence and mortality rates 
for malignant soft tissue tumours have been almost 
constant since 1999 in Germany. The conspicuously 
high mortality in Berlin and Brandenburg is probably 
attributable to coding differences, since it only refers 
to tumours of the peritoneum or retro-peritoneum 
(C48).
Risk factors
In most cases, no cause can be found for the emer-
gence of a soft tissue sarcoma. Exposure to radiation 
can increase the risk of soft tissue sarcomas. This is 
evident, for example, in atom bomb survivors in Ja-
pan. Even after previous radiation therapy, a sarcoma 
in the irradiated body region can be observed in rare 
cases. Furthermore, sarcomas can occur in cases of 
rare congenital genetic mutations. An example is neu-
rofibromatosis, where malignant peripheral nerve 
sheath tumours are observed more frequently.
The human herpes virus type 8 (HHV8) is re-
garded as the clear cause of the Kaposi sarcoma. In 
patients with severe immune deficiency, the Ep-
stein-Barr virus (EBV) is possibly also involved in the 
development of soft tissue sarcomas. Beyond the 
above, there is no clear evidence to date that viruses 
play a significant role in the development of soft tis-
sue sarcomas.
Environmental toxins and chemicals may con-
tribute to the development of sarcomas. Being dis-
cussed here, among other things are phenoxyacetic 
acid herbicides, chlorinated phenolics and dioxins. 
Vinyl chloride increases the risk of angiosarcoma.
In addition, it is presumed that chronic inflam-
mation may promote the emergence of soft tissue 
sarcomas. After a mastectomy (breast removal), 
chronic lymphedema may result, in rare cases, in the 
emergence of an angiosarcoma (Stewart Treves Syn-
drome).
3.13 Soft tissue without mesothelioma
Table 3.13.1
Overview of key epidemiologic parameters for Germany, ICD-10 C46 – C49
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 1,900 1,860 1,800 1,710 2,100 1,900
Crude incidence rate1 4.9 4.5 4.6 4.2 5.0 4.5
Standardised incidence rate1,2 3.8 3.1 3.5 2.9 3.8 3.1
Median age at diagnosis 66 68 65 69
Deaths 750 871 747 794
Crude mortality rate1 1.9 2.1 1.9 1.9
Standardised mortality rate1,2 1.4 1.3 1.3 1.1
5-year prevalence 6,300 5,700 6,300 5,600
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 54 46 40 35
Relative survival rate (2011 – 2012)3 62 52 55 46
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.13.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C46 – C49, Germany 1999 – 2012
Figure 3.13.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C46 – C49, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.13.2











































72 Cancer in Germany Soft tissue without mesothelioma
Table 3.13.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C46 – C49, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 4,700) 0.3 % (1 in 310) <0.1 % (1 in 12,600) 0.2 % (1 in 650)
45 years <0.1 % (1 in 2,700) 0.3 % (1 in 330) <0.1 % (1 in 8,700) 0.1 % (1 in 680)
55 years 0.1 % (1 in 1,800) 0.3 % (1 in 360) <0.1 % (1 in 4,600) 0.1 % (1 in 710)
65 years 0.1 % (1 in 880) 0.2 % (1 in 400) <0.1 % (1 in 2,500) 0.1 % (1 in 756)
75 years 0.1 % (1 in 760) 0.2 % (1 in 510) 0.1 % (1 in 1,300) 0.1 % (1 in 860)
Lifetime risk 0.4 % (1 in 280) 0.2 % (1 in 630)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 5,800) 0.3 % (1 in 340) <0.1 % (1 in 16,400) 0.2 % (1 in 660)
45 years <0.1 % (1 in 3,300) 0.3 % (1 in 350) <0.1 % (1 in 8,900) 0.1 % (1 in 680)
55 years 0.1 % (1 in 1,900) 0.3 % (1 in 390) <0.1 % (1 in 5,100) 0.1 % (1 in 720)
65 years 0.1 % (1 in 1,200) 0.2 % (1 in 460) <0.1 % (1 in 2,600) 0.1 % (1 in 800)
75 years 0.1 % (1 in 1,000) 0.2 % (1 in 660) 0.1 % (1 in 1,700) 0.1 % (1 in 1,000)
Lifetime risk 0.3 % (1 in 300) 0.2 % (1 in 640)
Figure 3.13.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C46 – C49, Germany 2011 – 2012
Figure 3.13.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C46 – C49, Germany 2011 – 2012
Figure 3.13.3
Distribution of T-stages at first diagnosis by sex
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Figure 3.13.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C46 – C49, 2011 – 2012
per 100,000 (European standard)
Figure 3.13.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C46 – C49, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  data for C46.1 and C49 only  
²  no comparable data  
³  data incl. C38 (malignant neoplasm of heart, mediastinum and pleura)  
4  no comparable data for mortality  
74 Cancer in Germany Breast
Epidemiology
With some 70,000 new cases currently being diag-
nosed annually, breast cancer is by far the most com-
mon form of cancer among women. There are also an 
additional 5,500 in situ tumours annually. According 
to current incidence figures, about one woman in 
eight will develop breast cancer in the course of her 
life. Almost three in every ten women are younger 
than 55 years at diagnosis.
The incidence and mortality rates in eastern Ger-
many are still significantly lower than in the western 
part. Only the rates for women under 55 years have 
become more or less similar. Following the introduc-
tion of mammography screening in 2005, the inci-
dence rates in Germany initially spiked, although 
since 2009 they have started to fall again slightly. It is 
very likely that through the screening some tumours 
that have been diagnosed would otherwise have gone 
unrecognised for the entire life of the patient (over- 
diagnosis). Despite the increased incidence, fewer 
women die of breast cancer now than ten years ago. 
The prospects of survival have improved considerably 
due to advances in therapy. It will be some years until 
it is possible to tell if screening leads to a further re-
duction in breast cancer mortality. So far, it seems that 
incidence rates of advanced tumours have declined 
slightly in the screening age groups, indicating that a 
reduction in mortality might follow.
Risk factors and early detection
Early first menses and late last menses, childless-ness, 
and having a first child late are all associated with an 
increased risk of breast cancer. Conversely, numerous 
or early births and longer periods of breast-feeding 
reduce the risk of breast cancer. Hormone replace-
ment therapy during and after menopause increases 
the risk of breast cancer, especially if it involves a com-
bination of oestrogen and progestogen. Ovulation 
inhibitors containing hormones (»the pill«), on the 
other hand, have only a minor influence on the inci-
dence rate. Studies have shown an increased risk as-
sociated with being overweight and with lack of exer-
cise after menopause, and alcohol is also a proven risk 
factor. There are indications that active and passive 
smoking increase the risk slightly before menopause.
In addition, women with very dense breast tissue 
or with certain benign breast neoplasms (lobular neo-
plasias and atypical ductal hyperplasias) have an in-
creased risk. Having family clusters of breast or ovar-
ian cancer is also a risk factor. In approximately half 
of these cases (5–10 % of all cases of breast cancer) the 
high family incidence results from a mutation in the 
»classic« breast cancer genes BRCA1 and BRCA2.
The statutory early detection programme offers 
women above 30 years of age an annual palpation 
examination by a physician. Between 2005 and 2009 
the quality assured Mammography Screening Pro-
gramme was introduced in Germany, and women 
between 50 and 69 years of age are invited to an X-ray 
examination of the breasts every two years.
3.14 Breast
Table 3.14.1
Overview of key epidemiological parameters for Germany, ICD-10 C50
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 600 70,190 620 69,550 700 65,500
Crude incidence rate1 1.5 170.8 1.6 169.1 1.7 158.1
Standardised incidence rate1,2 1.0 119.0 1.1 117.4 1.1 106.6
Median age at diagnosis 71 64 71 64
Deaths 159 17,815 150 17,748
Crude mortality rate1 0.4 43.4 0.4 43.2
Standardised mortality rate1,2 0.3 24.6 0.3 23.9
5-year prevalence 2,200 316,800 2,300 317,200
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 64 80 (76 – 81) 43 66 (62 – 68)
Relative survival rate (2011 – 2012)3 78 88 (83 – 89) 65 82 (79 – 83)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.14.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C50, Germany 1999 – 2012
Figure 3.14.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C50, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.14.2











































76 Cancer in Germany Breast
Table 3.14.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C50, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 28,800) 0.1 % (1 in 790) <0.1 % (1 in 92,800) <0.1 % (1 in 3,100)
45 years <0.1 % (1 in 11,600) 0.1 % (1 in 800) <0.1 % (1 in 68,100) <0.1 % (1 in 3,200)
55 years <0.1 % (1 in 4,400) 0.1 % (1 in 820) <0.1 % (1 in 21,700) <0.1 % (1 in 3,200)
65 years <0.1 % (1 in 2,400) 0.1 % (1 in 920) <0.1 % (1 in 10,500) <0.1 % (1 in 3,400)
75 years 0.1 % (1 in 1,900) 0.1 % (1 in 1,200) <0.1 % (1 in 5,900) <0.1 % (1 in 3,900)
Lifetime risk 0.1 % (1 in 790) <0.1 % (1 in 3,100)
Women aged in the next ten years ever in the next ten years ever
35 years 0.9 % (1 in 110) 12.7 % (1 in 8) 0.1 % (1 in 990) 3.5 % (1 in 28)
45 years 2.1 % (1 in 48) 12.0 % (1 in 8) 0.3 % (1 in 380) 3.4 % (1 in 29)
55 years 3.0 % (1 in 33) 10.3 % (1 in 10) 0.5 % (1 in 190) 3.2 % (1 in 31)
65 years 3.5 % (1 in 28) 7.9 % (1 in 13) 0.9 % (1 in 120) 2.9 % (1 in 35)
75 years 3.3 % (1 in 31) 5.1 % (1 in 20) 1.2 % (1 in 81) 2.3 % (1 in 44)
Lifetime risk 12.8 % (1 in 8) 3.5 % (1 in 29)
Figure 3.14.4a
Absolute survival rates up to 10 years after first diagnosis,  
women, ICD-10 C50, Germany 2011 – 2012
Figure 3.14.4b
Relative survival rates up to 10 years after first diagnosis,  
women, ICD-10 C50, Germany 2011 – 2012
Figure 3.14.3
Distribution of T-stages at first diagnosis for all women and women between 50 and 69 years  

















0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
53% 36% 6% 6%







T1       T2       T3       T4       
77ICD-10 C50 Cancer in Germany
Figure 3.14.5
Registered age-standardised incidence and mortality rates in German federal states, women,   
ICD-10 C50, 2011 – 2012
per 100,000 (European standard)
Figure 3.14.6
International comparison of age-standardised incidence and mortality rates, women,  
ICD-10 C50, 2011 – 2012 or latest available year (details and sources, see appendix)
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78 Cancer in Germany Vulva
Epidemiology
A significant increase in the number of vulvar carci-
nomas has been observed in Germany in recent years. 
In 2012 some 3,200 women were diagnosed with this 
carcinoma. Just ten years ago there were fewer than 
half as many cases. The mortality rate has not de-
creased in recent years, in contrast to the mortality 
rates for most other gynaecological tumours. Latest 
data shows that about 830 women die of this disease 
every year.
The increase in the incidence rate is observed in 
young women in particular, although the majority of 
the burden of disease is still accounted for by women 
over 70 years of age. Median age at diagnosis is 72 
years. The relative 5-year survival rate after diagnosis 
of a malignant vulvar tumour is 70 %. The vast major-
ity of invasive carcinomas are diagnosed at an early 
tumour stage (T1), although lymph nodes are already 
affected in one of every five of these cases. There are 
significant regional differences in both the incidence 
and the mortality rates. The Saarland has by far the 
highest incidence and mortality rates among Ger-
many’s federal states. Germany has a broadly com-
parable mortality rate at a higher incidence rate than 
its neighbours, although data was not available for 
comparison in all neighbouring countries.
Risk factors and prevention
The majority of vulvar carcinomas are squamous-cell 
carcinomas (90 %). A distinction is made between 
two types of these carcinomas: non-keratinising and 
keratinising squamous-cell carcinomas. The former 
involve chronic infection with the human papilloma-
virus (HPV), while the keratinising carcinomas devel-
op independent of HPV.
HPV-dependent vulvar carcinomas and their 
pre-cancerous conditions (usual-type vulvar intraepi-
thelial neoplasia, uVIN) occur predominantly in 
younger women. In contrast, HPV-independent car-
cinomas usually occur in older women, and these are 
the commonest type of vulvar carcinoma (65 % to 
80 % of cases). Significant risk factors for this type of 
carcinoma and its precancerous conditions (differen-
tiated VIN, dVIN) are in particular degenerative and 
chronic inflammatory skin diseases such as Lichen 
sclerosus.
Further risk factors are smoking and alcohol 
abuse. Long-standing immunosuppression, e. g. fol-
lowing organ transplants or in case of HIV infection, 
can facilitate infection with HPV and thus increase 
the risk. The presence of other cancers or their pre-
cursors in the genital area, for example cervical can-
cer, also constitutes a risk factor for vulvar carcinoma. 
The incidence in particular of HPV-related precursors 
to vulvar carcinoma has increased in recent years. 
One possible means of preventing these precancerous 
conditions and carcinomas is HPV vaccination.
3.15 Vulva
Table 3.15.1
Overview of key epidemiological parameters for Germany, ICD-10 C51
2011 2012 Prediction for 2016
Women Women Women
Incident cases 3,160 3,190 4,400
Crude incidence rate1 7.7 7.7 10.6
Standardised incidence rate1,2 4.6 4.5 6.1
Median age at diagnosis 72 72
Deaths 860 827
Crude mortality rate1 2.1 2.0
Standardised mortality rate1,2 1.0 0.9
5-year prevalence 10,900 11,200
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 59 (47 – 70) 44 (32 – 53)
Relative survival rate (2011 – 2012)3 70 (58 – 81) 64 (50 – 89)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.15.1b
Absolute numbers of incident cases and deaths,  
ICD-10 C51, Germany 1999 – 2012
Figure 3.15.1a
Age-standardised incidence and mortality rates, 
ICD-10 C51, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.15.2











































80 Cancer in Germany Vulva
Table 3.15.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C51, database 2012
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 3,300) 0.6 % (1 in 160) <0.1 % (1 in 47,300) 0.2 % (1 in 570)
45 years 0.1 % (1 in 1,900) 0.6 % (1 in 170) <0.1 % (1 in 15,700) 0.2 % (1 in 580)
55 years 0.1 % (1 in 1,100) 0.5 %  (1 in 180) <0.1 % (1 in 8,900) 0.2 % (1 in 590)
65 years 0.1 % (1 in 690) 0.5 % (1 in 210) <0.1 % (1 in 3,200) 0.2 % (1 in 600)
75 years 0.2 % (1 in 440) 0.4 % (1 in 270) 0.1 % (1 in 1,300) 0.2 % (1 in 650)
Lifetime risk 0.6 % (1 in 160) 0.2 % (1 in 580)
Figure 3.15.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C51, Germany 2011 – 2012
Figure 3.15.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C51, Germany 2011 – 2012
Figure 3.15.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C51, Germany 2011 – 2012
no information
DCO
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Figure 3.15.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C51, 2011 – 2012
per 100,000 (European standard)
Figure 3.15.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C51, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  incl. C52, C57.7, C57.8 and C57.9  
2  no comparable data for mortality  
3  no comparable data  
  
82 Cancer in Germany Cervix
Epidemiology
In 2012 about 4,600 women were diagnosed with 
cervical carcinoma in Germany. About three quarters 
of cervical carcinomas are of squamous-cell origin. 
Adenocarcinomas (approx. 20 %) have a more proxi-
mate origin at the transition from uterus to cervix.
The incidence rates for invasive cervical carcino-
mas have remained largely stable since the late 1990s 
at a markedly lower level than in the 1980s. The high-
est incidence rates are currently found among women 
between 40 and 59 years of age. The median age at 
diagnosis for invasive cancer is 53 years. The median 
age at diagnosis for in situ carcinomas is just 34 years. 
These are diagnosed considerably more often than 
invasive carcinomas, a result of the cervical cancer 
early detection examinations, aimed at identifying 
and treating cancer precursors.
Currently, about 1,600 women in Germany die of 
cervical cancer every year. The relative 5-year survival 
rate after diagnosis of an invasive cervical tumour is 
68 %.
Incidence rates significantly differ between fed-
erals states within Germany as well as between coun-
tries. The federal state of Saarland has one of the high-
est cervical cancer incidence rates in Germany, 
comparable to incidence rates in Denmark. Denmark 
is one of the neighboring countries with the highest 
incidence rates at moderate mortality rates, whereas 
Switzerland and Finland have some of the lowest in-
cidence rates and low mortality rates.
Risk factors and early detection
The main cause of cervical cancer is infection with the 
human papillomavirus (HPV). The majority of wom-
en are infected with HPV at some point in their life. 
Usually the infection is transient and disappears with-
out further effect, but in some cases it persists and a 
cervical carcinoma can develop, especially with virus 
subtypes from the high risk group (e. g. HPV 16 or 18). 
Further risk factors are smoking, infections in the 
genital area with other sexually transmitted patho-
gens such as herpes simplex or chlamydia, becoming 
sexually active at a young age, numerous births, and 
a severely impaired immune system. Taking oral con-
traceptives (»the pill«) over a long period of time is 
also associated with a slightly higher risk of develop-
ing cervical cancer. However, the risk falls again when 
oral contraceptives are discontinued, and after ap-
proximately ten years these women seem no more 
at-risk than women who never took oral contracep-
tives.
Women in Germany aged 20 years and above are 
entitled to an annual cervical smear test (PAP smear). 
In March 2007, the German Standing Committee on 
Vaccination Recommendations (STIKO) proposed 
vaccinating girls between 9 and 14 years of age against 
HPV 16 and 18, which are responsible for about 70 % 
of all cervical carcinomas. It has been proved that the 
vaccination can prevent the development of prelimi-
nary stages of cervical cancer. However, the vaccina-
tion does not supersede the PAP smear, as it only 




Overview of key epidemiological parameters for Germany, ICD-10 C53
2011 2012 Prediction for 2016
Women Women Women
Incident cases 4,720 4,640 4,300
Crude incidence rate1 11.5 11.3 10.4
Standardised incidence rate1,2 9.4 9.3 8.5
Median age at diagnosis 54 53
Deaths 1,626 1,617
Crude mortality rate1 4.0 3.9
Standardised mortality rate1,2 2.6 2.6
5-year prevalence 18,200 17,900
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 65 (60 – 71) 58 (55 – 65)
Relative survival rate (2011 – 2012)3 68 (62 – 74) 65 (60 – 71)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.16.1b
Absolute numbers of incident cases and deaths,  
ICD-10 C53, Germany 1999 – 2012
Figure 3.16.1a
Age-standardised incidence and mortality rates,  
ICD-10 C53, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.16.2











































84 Cancer in Germany Cervix
Table 3.16.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C53, database 2012
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
15 years <0.1 % (1 in 9,100) 0.8 % (1 in 120) <0.1 % (1 in 353,400) 0.3 % (1 in 330)
25 years 0.1 % (1 in 1,100) 0.8 % (1 in 120) <0.1 % (1 in 12,700) 0.3 % (1 in 330)
35 years 0.2 % (1 in 620) 0.8 % (1 in 130) <0.1 % (1 in 4,800) 0.3 % (1 in 340)
45 years 0.2 % (1 in 620) 0.6 % (1 in 170) <0.1 % (1 in 2,200) 0.3 % (1 in 360)
55 years 0.2 % (1 in 650) 0.4 % (1 in 230) 0.1 % (1 in 1,600) 0.2 % (1 in 420)
65 years 0.1 % (1 in 750) 0.3 % (1 in 330) 0.1 % (1 in 1,600) 0.2 % (1 in 530)
75 years 0.1 % (1 in 820) 0.2 % (1 in 520) 0.1 % (1 in 1,300) 0.1 % (1 in 710)
Lifetime risk 0.8 % (1 in 120) 0.3 % (1 in 330)
Figure 3.16.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C53, Germany 2011 – 2012
Figure 3.16.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C53, Germany 2011 – 2012
Figure 3.16.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C53, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
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Figure 3.16.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C53, 2011 – 2012
per 100,000 (European standard)
Figure 3.16.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C53, 2011 – 2012 or latest available year (details and sources, see appendix)
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86 Cancer in Germany Uterus
Epidemiology
With approximately 10,930 newly diagnosed cases ev-
ery year, accounting for 4.8 % of all malignant neo-
plasms, uterine cancer is the fourth most common 
form of cancer among women and the most common 
cancer of the female genital organs. Due to the good 
prognosis, the proportion of all deaths the cancer ac-
counts for is markedly lower, at just 2.5 %.
One in 49 women develops cancer of the uterus 
in the course of her life, and one in 200 dies of it. The 
incidence rate for cancer of the uterus has fallen 
slightly, while the age-standardised mortality rate has 
recently remained almost constant. The median age 
at diagnosis is 69 years. Histologically, cancers of the 
uterus are mostly endometrial (i. e. originating from 
the lining of the uterus) adenocarcinomas. Approxi-
mately 80 % of the carcinomas are diagnosed at an 
early stage (T1).
Uterine carcinomas are one of the types of cancer 
with a favourable prognosis. The relative 5-year sur-
vival rate in Germany is approximately 80 %.
Regional differences within Germany are rela-
tively small. Internationally, higher incidence rates 
have been observed in Eastern Europe, Scandinavia 
and also in the US.
Risk factors
About 80 % of endometrial carcinomas are hor-
mone-dependent, and the long-term influence of 
 oestrogen is a risk factor. Thus early first menses 
(menarche), late onset of menopause (climacterium), 
childlessness, and diseases of the ovaries, such as 
polycystic ovary syndrome (PCOS), all have the effect 
of increasing the risk. Oestrogen as monotherapy 
during menopause also increases the risk, although 
when combined with progesterone it does not. Oral 
contraceptives (»the pill«), in particular oestro-
gen-progesterone combinations, reduce the risk. For 
hormone-dependent tumours, lifestyle risk factors 
also play a role, particularly overweight and lack of 
exercise. Women with type 2 diabetes mellitus are 
more frequently affected. Women with breast cancer 
who have been treated with tamoxifen often develop 
endometrial hyperplasia and thus have a higher risk 
of developing a uterine carcinoma.
Gene mutations that can lead to hereditary non-
polyposis colorectal carcinoma (HNPPC) also contrib-
ute to an increased risk of uterine cancer.
For the rarer oestrogen-independent types of this 
tumour (15 % of endometrial carcinoma), advanced 
age is a risk-factor. Exposure of the uterus to radiation 
can also increase the risk. Study results do not permit 
conclusive interpretation of the roles played by life-




Overview of key epidemiological parameters for Germany, ICD-10 C54 – C55
2011 2012 Prediction for 2016
Women Women Women
Incident cases 11,140 10,930 10,800
Crude incidence rate1 27.1 26.6 26.2
Standardised incidence rate1,2 16.9 16.6 15.8
Median age at diagnosis 69 69
Deaths 2,442 2,515
Crude mortality rate1 5.9 6.1
Standardised mortality rate1,2 3.0 3.0
5-year prevalence 45,900 45,600
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 71 (66 – 73) 58 (55 – 61)
Relative survival rate (2011 – 2012)3 80 (75 – 82) 76 (73 – 78)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
87ICD-10 C54 – C55 Cancer in Germany
Figure 3.17.1b
Absolute numbers of incident cases and deaths,  
ICD-10 C54 – C55, Germany 1999 – 2012
Figure 3.17.1a
Age-standardised incidence and mortality rates,  
ICD-10 C54 – C55, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.17.2











































88 Cancer in Germany Uterus
Table 3.17.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C54 – C55, database 2012
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 2,100) 2.1 % (1 in 49) <0.1 % (1 in 22,900) 0.5 % (1 in 200)
45 years 0.2 % (1 in 500) 2.0 % (1 in 49) <0.1 % (1 in 5,400) 0.5 % (1 in 200)
55 years 0.5 % (1 in 210) 1.9 % (1 in 53) 0.1 % (1 in 1,700) 0.5 % (1 in 200)
65 years 0.6 % (1 in 150) 1.5 % (1 in 68) 0.1 % (1 in 730) 0.5 % (1 in 220)
75 years 0.6 % (1 in 160) 0.9 % (1 in 110) 0.2 % (1 in 490) 0.4 % (1 in 270)
Lifetime risk 2.1 % (1 in 49) 0.5 % (1 in 200)
Figure 3.17.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C54 – C55, Germany 2011 – 2012
Figure 3.17.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C54 – C55, Germany 2011 – 2012
Figure 3.17.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C54 – C55, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
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Figure 3.17.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C54 – C55, 2011 – 2012
per 100,000 (European standard)
Figure 3.17.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C54 – C55, 2011 – 2012 or latest available year (details and sources, see appendix)
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90 Cancer in Germany Ovaries
Epidemiology
Ovarian cancer accounts for 3.3 % of all malignant 
neoplasms among women and 5.6 % of all female 
deaths due to cancer. The incidence rates increase 
continually up to the age of 85 years, while the median 
age at diagnosis is 69 years. Histologically, malignant 
tumours of the ovaries are predominantly adenocar-
cinomas. The rare germ cell tumours of the ovaries 
occur in younger women. One in approximately 72 
women develops ovarian cancer in the course of her 
lifetime.
Since the millennium, incidence and mortality 
rates in Germany have continued to fall significantly, 
also absolute numbers of incident cases decrease. Dif-
ferences in the age-standardised incidence rates be-
tween German federal states exist, whereas regional 
mortality rates do not differ.
Since diagnosis often only occurs at a late tumour 
stage, the survival prospects for patients with ovarian 
cancer are relatively unfavourable. The relative 5-year 
survival rate is currently around 41 %.
Risk factors
The risk of developing ovarian cancer increases with 
age. Among the lifestyle-related risk factors, obesity 
(adipositas) plays a part. There are important associa-
tions with hormonal factors: childlessness and infer-
tility increase the risk of developing ovarian cancer, 
while numerous births and longer periods of 
breast-feeding reduce the risk. It has not been conclu-
sively proved whether early first menses (menarche) 
or late onset of menopause (climacterium) also lead 
to an increased risk. Hormonal factors probably also 
increase the risk for women with polycystic ovaries. 
Hormone replacement therapy (particularly with oes-
trogen monotherapy) for women after menopause is 
also a risk factor. In contrast, hormonal ovulation in-
hibitors (»the pill«) protect against ovarian cancer. 
Sterilisation by means of tubal ligation also reduces 
the risk of developing this cancer.
The risk of ovarian cancer is higher for women 
with first-degree relatives diagnosed with breast or 
ovarian cancer and for women who themselves have 
been diagnosed with breast, uterine or colorectal can-
cer. Underlying genetic mutations, above all of BRCA1 
and BRCA2, considerably increase the risk, but they 
only play a part in one out of ten diseased women.
3.18 Ovaries
Table 3.18.1
Overview of key epidemiological parameters for Germany, ICD-10 C56
2011 2012 Prediction for 2016
Women Women Women
Incident cases 7,750 7,380 7,200
Crude incidence rate1 18.9 18.0 17.3
Standardised incidence rate1,2 12.1 11.4 10.7
Median age at diagnosis 69 69
Deaths 5,837 5,646
Crude mortality rate1 14.2 13.7
Standardised mortality rate1,2 7.9 7.5
5-year prevalence 21,800 21,300
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 38 (33 – 41) 27 (23 – 29)
Relative survival rate (2011 – 2012)3 41 (36 – 45) 32 (27 – 36)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
91ICD-10 C56 Cancer in Germany
Figure 3.18.1b
Absolute numbers of incident cases and deaths,  
ICD-10 C56, Germany 1999 – 2012
Figure 3.18.1a
Age-standardised incidence and mortality rates,  
ICD-10 C56, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.18.2











































92 Cancer in Germany Ovaries
Table 3.18.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C56, database 2012
Risk of developing cancer Mortality risk
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in1,500) 1.4 % (1 in 73) <0.1 % (1 in 5,300) 1.1 % (1 in 91)
45 years 0.2 % (1 in 660) 1.3 % (1 in 76) 0.1 % (1 in 1,400) 1.1 % (1 in 92)
55 years 0.3 % (1 in 380) 1.2 % (1 in 84) 0.2 % (1 in 630) 1.0 % (1 in 96)
65 years 0.4 % (1 in 260) 1.0 % (1 in 103) 0.3 % (1 in 320) 0.9 % (1 in 110)
75 years 0.4 % (1 in 230) 0.7 % (1 in 150) 0.4 % (1 in 220) 0.7 % (1 in 140)
Lifetime risk 1.4 % (1 in 72) 1.1 % (1 in 91)
Figure 3.18.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C56, Germany 2011 – 2012
Figure 3.18.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C56, Germany 2011 – 2012
Figure 3.18.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C56, Germany 2011 – 2012
no information
DCO
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Figure 3.18.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C56, 2011 – 2012
per 100,000 (European standard)
Figure 3.18.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C56, 2011 – 2012 or latest available year (details and sources, see appendix)
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94 Cancer in Germany Prostate
Epidemiology
Prostate cancer is the most common cancer and the 
third most common cause of death due to cancer 
among men in Germany. The number of new cases 
has risen steadily for a long time, but decreases since 
2010 (67,300 cases) and was about 63,700 cases in 
2012. After increasing for almost two decades, the 
age-standardised incidence rate has remained largely 
constant since 2003 and actually decreases slightly 
since 2008. Similar trends can also be observed in 
most other Western industrialised nations and may 
be attributable to the introduction of the prostate spe-
cific antigen test (PSA test) in the late 1980s as an 
(unorganised) screening method. In contrast to the 
incidence rate, the age-standardised mortality rate re-
duced continuously until 2007 and is leveling off 
since then. Internationally, Germany is one of the 
countries with a comparatively low incidence.
Prostate cancer occurs seldom in people under 
50 years of age. For a 35-year old man, the risk of being 
diagnosed with prostate cancer within the next ten 
years is less than 0.1 %, while for a 75-year old man it 
is approximately 6 %.
The relative 5-year survival rate for prostate can-
cer is currently 93 %. Deaths may, however, still occur 
after a longer course of the disease, e. g. through re-
currence. Three out of four tumours were diagnosed 
at an early stage (T1 or T2).
Risk factors and early detection
Little is known about the causes of prostate carcinoma 
development and the factors influencing its course. 
Age is an important risk factor. Moreover, the disease 
more often occurs among men with black African 
origin than among European or white North Ameri-
can men and relatively seldom among Asian men. 
The presence of clustered cases among close relatives 
has now been adequately proved as a risk factor, al-
though there is no understanding of the hereditary 
gene mutations involved. The male sex hormone (tes-
tosterone) also clearly plays a part.
Despite extensive research, there are few reliable 
findings relating to lifestyle, diet, or the environment. 
However, it is thought that diet, body weight and 
physical activity may have an influence on the devel-
opment of the prostate carcinoma. A large-scale can-
cer prevention study has shown that taking vitamin E 
as a dietary supplement increases the risk of develop-
ing prostate cancer.
For men above 45 years of age, the cancer early 
detection directive in Germany currently recom-
mends an annual interview focusing on complaints 
and other health-related changes, an examination of 
the external sexual organs, as well as a palpation ex-
amination of the prostate and the lymph nodes. The 
test for PSA in the blood is not covered by the statuto-
ry health insurance, as to date the benefit of the PSA 
test has not been irrefutably proven.
3.19 Prostate
Table 3.19.1
Overview of key epidemiological parameters for Germany, ICD-10 C61
2011 2012 Prediction for 2016
Men Men Men
Incident cases 66,660 63,710 66,900
Crude incidence rate1 170.2 162.1 167.1
Standardised incidence rate1,2 113.4 106.7 106.7
Median age at diagnosis 71 71
Deaths 13,324 12,957
Crude mortality rate1 34.0 33.0
Standardised mortality rate1,2 21.2 20.1
5-year prevalence 291,000 287,100
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 78 (75 – 81) 60 (55 – 64)
Relative survival rate (2011 – 2012)3 93 (90 – 95) 91 (87 – 94)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
95ICD-10 C61 Cancer in Germany
Figure 3.19.1b
Absolute numbers of incident cases and deaths,  
ICD-10 C61, Germany 1999 – 2012
Figure 3.19.1a
Age-standardised incidence and mortality rates,  
ICD-10 C61, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.19.2











































96 Cancer in Germany Prostate
Table 3.19.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C61, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 3,900) 13.0 % (1 in 8) <0.1 % (1 in 59,100) 3.3 % (1 in 30)
45 years 0.4 % (1 in 220) 13.1 % (1 in 8) <0.1 % (1 in 4,500) 3.4 % (1 in 30)
55 years 2.5 % (1 in 39) 13.3 % (1 in 8) 0.2 % (1 in 580) 3.5 % (1 in 29)
65 years 5.9 % (1 in 17) 12.2 % (1 in 8) 0.7 % (1 in 140) 3.7 % (1 in 27)
75 years 5.9 % (1 in 17) 8.3 % (1 in 12) 1.9 % (1 in 54) 3.8 % (1 in 27)
Lifetime risk 12.8 % (1 in 8) 3.3 % (1 in 30)
Figure 3.19.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C61, Germany 2011 – 2012
Figure 3.19.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C61, Germany 2011 – 2012
Figure 3.19.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C61, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       




















97ICD-10 C61 Cancer in Germany
Figure 3.19.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C61, 2011 – 2012
per 100,000 (European standard)
Figure 3.19.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C61, 2011 – 2012 or latest available year (details and sources, see appendix)








































98 Cancer in Germany Testicle
Epidemiology
In 2012 about 4,020 men in Germany were diagnosed 
with testicular cancer. It accounts for 1.6 % of all cases 
of cancer in men, making it a relatively rare tumour.
In contrast to almost all other types of cancer, 
most cases are diagnosed at a comparatively young 
age, namely between 25 and 45 years of age. In this 
age group, testicular cancer is the most common ma-
lignant tumour in men. Correspondingly, the median 
age at diagnosis is 38 years.
The age-standardised incidence rate has re-
mained almost constant recently, levelling off after 
decades during which a steady increase was observed 
in Germany and other European countries. Over 
90 % of testicular tumours are diagnosed in the early 
stages T1 or T2. Histologically, testicular cancers are 
predominantly germ cell tumours, of which approxi-
mately two thirds are seminomas. Approximately one 
case in six is a malignant teratoma or a combination 
of the latter types.
Since the introduction of cis-platinum in chemo-
therapy for testicular cancer over 30 years ago, this 
disease has become one of the malignant neoplasms 
with more favourable prognoses (5-year survival rate 
most recently 96 %) and a low mortality (179 deaths 
in 2012).
Risk factors and early detection
A proven risk factor for testicular cancer is cryptorchi-
dism (undescended testis), even after this has been 
properly treated. Men who have already had cancer or 
a preliminary stage of cancer in one testicle have an 
increased risk of developing a tumour in the other 
testicle. In a small proportion of cases there may be a 
genetic predisposition. Sons and brothers (especially 
twin brothers) of patients with testicular cancer have 
a significantly higher risk of developing the disease. 
A hypothesis is that the predisposition for the most 
frequently occurring germ cell tumours in the testes 
may have its origin in cells which are scattered during 
the embryonic stage, and which then undergo a ma-
lignant development in puberty. A birth weight below 
2500 g or above 4500 g as well as tall stature are also 
being discussed as possible risk factors. The causes of 
the increase in incidence observed in former decades 
are not clearly understood. The current view is that 
lifestyle and environmental factors play no part in the 
development of testicular cancer. Rather an early di-
agnosis is correlated with the stage and a better prog-
nosis. Thus, adolescents and men are advised to carry 
out regular self-examination by palpation of the testes. 
The statutory early detection program offers men 




Overview of key epidemiological parameters for Germany, ICD-10 C62
2011 2012 Prediction for 2016
Men Men Men
Incident cases 4,010 4,020 4,200
Crude incidence rate1 10.2 10.2 10.5
Standardised incidence rate1,2 10.2 10.2 10.5
Median age at diagnosis 38 38
Deaths 170 179
Crude mortality rate1 0.4 0.5
Standardised mortality rate1,2 0.4 0.4
5-year prevalence 19,700 19,500
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 94 (90 – 96) 92 (87 – 94)
Relative survival rate (2011 – 2012)3 96 (92 – 98) 95 (90 – 98)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
99ICD-10 C62 Cancer in Germany
Figure 3.20.1b
Absolute numbers of incident cases and deaths, 
ICD-10 C62, Germany 1999 – 2012
Figure 3.20.1a
Age-standardised incidence and mortality rates,  
ICD-10 C62, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.20.2











































100 Cancer in Germany Testicle
Table 3.20.2
Cancer incidence and mortality risks in Germany by age, ICD-10 C62, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years 0.1 % (1 in 990) 0.7 % (1 in 140) <0.1 % (1 in 78,400) <0.1 % (1 in 2,800)
25 years 0.2 % (1 in 440) 0.6 % (1 in 160) <0.1 % (1 in 22,300) <0.1 % (1 in 2,900)
35 years 0.2 % (1 in 470) 0.4 % (1 in 240) <0.1 % (1 in 15,300) <0.1 % (1 in 3,300)
45 years 0.1 % (1 in 830) 0.2 % (1 in 480) <0.1 % (1 in 17,200) <0.1 % (1 in 4,200)
55 years 0.1 % (1 in 1,900) 0.1 % (1 in 1,100) <0.1 % (1 in 19,400) <0.1 % (1 in 5,300)
65 years <0.1 % (1 in 4,900) <0.1 % (1 in 2,400) <0.1 % (1 in 30,100) <0.1 % (1 in 6,600)
75 years <0.1 % (1 in 6,600) <0.1 % (1 in 3,700) <0.1 % (1 in 14,600) <0.1 % (1 in 6,700)
Lifetime risk 0.8 % (1 in 130) <0,1 % (1 in 2,800)
Figure 3.20.4a
Absolute survival rates up to 10 years after first diagnosis, 
ICD-10 C62, Germany 2011 – 2012
Figure 3.20.4b
Relative survival rates up to 10 years after first diagnosis, 
ICD-10 C62, Germany 2011 – 2012
Figure 3.20.3
Distribution of T-stages at first diagnosis (top: all cases; bottom: only valid reports) 
ICD-10 C62, Germany 2011 – 2012
no information
DCO
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101ICD-10 C62 Cancer in Germany
Figure 3.20.5
Registered age-standardised incidence and mortality rates in German federal states,  
ICD-10 C62, 2011 – 2012
per 100,000 (European standard)
Figure 3.20.6
International comparison of age-standardised incidence and mortality rates, 
ICD-10 C62, 2011 – 2012 or latest available year (details and sources, see appendix)
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102 Cancer in Germany Kidney
Epidemiology
Malignant neoplasms of the kidney can develop from 
various tissues. Among all types of kidney tumours in 
adults, renal cell carcinomas (hypernephromas) occur 
most frequently, account for 90 % of all cases. In con-
trast, nephroblastomas (Wilms’ tumours), lympho-
mas or sarcomas of the kidney are more frequent in 
children.
The absolute number of incident cases has been 
rising continuously since the end of the 1990s for 
men, while a decrease can be observed for women 
since the year 2009. In contrast, the age-standardised 
incidence rates have remained at a fairly constant lev-
el for men and women over the whole period, al-
though the incidence rate for men is twice as high as 
in women. As far as the age-standardised mortality 
rates are concerned, a slightly downward trend is ob-
served for both sexes.
The median age at diagnosis is 68 years for men 
and 72 years for women.
The prognosis for kidney carcinoma is compara-
tively favourable, the relative 5-year survival rate for 
kidney tumours is approx. 76 % in men and 78 % in 
women. Around three-quarters of all tumours are di-
agnosed at a relatively early stage (T1 and T2). In re-
gional and/or international comparison, relatively 
high incidence and mortality rates are apparent in the 
eastern federal states, as well as in the neighbouring 
Czech Republic.
Risk factors
Smoking and passive smoking, as well as hyperten-
sion and obesity are the most important risk factors. 
Furthermore, a lack of physical activity seems to in-
crease the risk of developing kidney cancer.
On the whole, chronic renal insufficiency, regard-
less of cause, may promote carcinogenesis in the kid-
ney. It can be caused for example by nephrotoxic med-
ications or repeated inflammations of the urinary 
tract. Also following a kidney transplant, the immu-
no-suppressed patient has an increased risk of devel-
oping a renal cell carcinoma.
Familial predisposition probably only plays a role 
in relatively few cases. Approximately three per cent 
of renal cell carcinomas occur in patients with com-
plex hereditary diseases such as those affected by Hip-
pel-Lindau syndrome. These genetic renal cell carci-
nomas are often multifocal and occur more often at a 
younger age than kidney cancers in patients without 
a genetic disposition.
Table 3.21.1
Overview of key epidemiological parameters for Germany, ICD-10 C64
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 9,320 5,600 9,500 5,530 10,400 6,100
Crude incidence rate1 23.8 13.6 24.2 13.5 26.1 14.8
Standardised incidence rate1,2 16.9 8.1 16.9 8.0 17.4 8.2
Median age at diagnosis 68 72 68 72
Deaths 3,223 2,104 3,125 2,131
Crude mortality rate1 8.2 5.1 8.0 5.2
Standardised mortality rate1,2 5.4 2.4 5.1 2.4
5-year prevalence 35,200 22,000 35,800 21,900
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 66 (61 – 69) 69 (58 – 75) 50 (43 – 54) 54 (46 – 59)
Relative survival rate (2011 – 2012)3 76 (71 – 79) 78 (66 – 84) 68 (60 – 73) 71 (62 – 78)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentage (lowest and highest value of the included German federal states)
3.21 Kidney
103ICD-10 C64 Cancer in Germany
Abbildung 3.21.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C64, Germany 1999 – 2012
Figure 3.21.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C64, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.21.2











































104 Cancer in Germany Kidney
Table 3.21.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C64, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,700) 1.8 % (1 in 55) <0.1 % (1 in 18,000) 0.7 % (1 in 150)
45 years 0.2 % (1 in 570) 1.8 % (1 in 56) <0.1 % (1 in 3,200) 0.7 % (1 in 150)
55 years 0.4 % (1 in 240) 1.7 % (1 in 59) 0.1 % (1 in 1,000) 0.7 % (1 in 150)
65 years 0.7 % (1 in 150) 1.4 % (1 in 71) 0.2 % (1 in 510) 0.7 % (1 in 150)
75 years 0.7 % (1 in 140) 0.9 % (1 in 110) 0.4 % (1 in 270) 0.6 % (1 in 170)
Lifetime risk 1.8 % (1 in 55) 0.7 % (1 in 150)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 3,900) 1.0 % (1 in 96) <0.1 % (1 in 28,200) 0.4 % (1 in 230)
45 years 0.1 % (1 in 1,400) 1.0 % (1 in 97) <0.1 % (1 in 8,800) 0.4 % (1 in 230)
55 years 0.2 % (1 in 560) 1.0 % (1 in 100) <0.1 % (1 in 2,900) 0.4 % (1 in 230)
65 years 0.3 % (1 in 300) 0.8 % (1 in 120) 0.1 % (1 in 1,000) 0.4 % (1 in 240)
75 years 0.4 % (1 in 250) 0.6 % (1 in 170) 0.2 % (1 in 480) 0.4 % (1 in 270)
Lifetime risk 1.1 % (1 in 94) 0.4 % (1 in 230)
Figure 3.21.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C64, Germany 2011 – 2012
Figure 3.21.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C64, Germany 2011 – 2012
Figure 3.21.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C64, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
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105ICD-10 C64 Cancer in Germany
Figure 3.21.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C64, 2011 – 2012
per 100,000 (European standard)
Figure 3.21.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C64, 2011 – 2012 or latest available year (details and sources, see appendix)
per 100,000 (European standard)
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106 Cancer in Germany Bladder
Epidemiology
Some 15,400 people, one quarter of them women, 
were newly diagnosed with an invasive bladder carci-
noma in Germany in 2012. In addition, about 13,500 
were diagnosed with non-invasive papillary carcino-
ma or in situ tumours of the bladder. The latter in 
particular, exhibit a high tendency of progression and 
recurrence and are thus of particular clinical rele-
vance, despite the fact that they currently do not rank 
among malignant tumours according to ICD-10. The 
majority of bladder cancer cases are carcinomas of the 
urothelium, which frequently occur simultaneously 
at various places in the bladder and urinary tract.
Incidence rates increase steadily with age. For 
men, the age-standardised incidence and mortality 
rates show a clear downward trend since the 1990s, 
probably due to a decline in tobacco consumption, but 
possibly also because of a reduction in occupational 
exposure to carcinogens (see right). For women, both 
rates have remained relatively stable over the years, 
whereby they are much lower compared to men. The 
mortality rate for bladder cancer is higher in the east-
ern federal states than in the western parts of Germa-
ny, above all among men. The higher relative 5-year 
survival rates for men (58 %) compared with women 
(48 %) relate to the more favourable distribution of 
tumour stages at diagnosis (47 % vs. 37 % T1 tumours).
Risk factors
Tobacco consumption is a key risk factor for the de-
velopment of cancer of the bladder. Passive smoking 
also contributes to an increase in risk. The risk is fur-
ther increased by exposure to some chemical sub-
stances such as aromatic amines, which play a role 
especially for certain occupational groups. The known 
hazardous substances have largely been eliminated 
from industrial processes and workplaces in Europe. 
However, there is a long latency period between expo-
sure and the development of cancer, so that bladder 
carcinomas caused by occupational exposure will con-
tinue to be registered. Cytostatic drugs used in che-
motherapy and local radiation therapy can increase 
the risk. The risk potential for some other pharmaceu-
ticals is currently being debated. In 2013 the Interna-
tional Agency for Research on Cancer (IARC) classi-
fied pioglitazone hydrochloride, an anti-diabetic 
agent, as probably carcinogenic to humans (Class 2A) 
with regard to cancer of the bladder. According to the 
IARC, air pollution is also associated with a higher 
risk of bladder cancer. 
Furthermore, arsenic and chrome in drinking 
water increase the risk for developing a carcinoma of 
the bladder. Chronic inflammatory damage to the 
 mucosa of the bladder also increases the risk of blad-
der cancer.
Family clusters have been observed. Further-
more, there are indications that genetic factors play a 
direct role in the occurrence of bladder cancer, by in-
creasing the susceptibility to carcinogens.
3.22 Bladder
Table 3.22.1
Overview of key epidemiological parameters for Germany, ICD-10 C67
2011 2012 Prediction for 2016
Men Women Men Women Men Women









Crude incidence rate1 29.3 (57.3)4 10.5 (17.9)4 28.7 (55.5)4 10.1 (17.3)4 29.8 10.7
Standardised incidence rate1,2 19.2 (37.8)4 5.2 (9.6)4 18.4 (36.0)4 4.9 (9.1)4 17.7 5.1
Median age at diagnosis 73 (73)4 76 (74)4 74 (73)4 76 (75)4
Deaths 4,046 1,891 3,791 1,826
Crude mortality rate1 10.3 4.6 9.6 4.4
Standardised mortality rate1,2 6.6 1.9 6.0 1.9








after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 46 (44 – 53) 39 (33 – 52) 32 (27 – 36) 28 (22 – 37)
Relative survival rate (2011 – 2012)3 58 (54 – 66) 48 (41 – 64) 52 (48 – 58) 44 (36 – 57)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states) 
4 in parentheses: including in situ tumours and neoplasms of uncertain or unknown behavior (D09,0, D41,4)
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Figure 3.22.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C67, Germany 1999 – 2012
Figure 3.22.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C67, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.22.2
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Table 3.22.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C67, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 6,700) 2.5 % (1 in 40) <0.1 % (1 in 41,100) 1.0 % (1 in 100)
45 years 0.1 % (1 in 1,000) 2.5 % (1 in 40) <0.1 % (1 in 6,000) 1.0 % (1 in 100)
55 years 0.3 % (1 in 300) 2.5 % (1 in 40) 0.1 % (1 in 1,500) 1.0 % (1 in 100)
65 years 0.8 % (1 in 130) 2.4 % (1 in 41) 0.2 % (1 in 550) 1.0 % (1 in 97)
75 years 1.3 % (1 in 78) 2.1 % (1 in 48) 0.5 % (1 in 190) 1.0 % (1 in 93)
Lifetime risk 2.5 % (1 in 41) 1.0 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 11,500) 0.8 % (1 in 120) <0.1 % (1 in 34,700) 0.4 % (1 in 250)
45 years <0.1 % (1 in 2,900) 0.8 % (1 in 120) <0.1 % (1 in 13,700) 0.4 % (1 in 250)
55 years 0.1 % (1 in 1,100) 0.8 % (1 in 120) <0.1 % (1 in 4,100) 0.4 % (1 in 250)
65 years 0.2 % (1 in 500) 0.8 % (1 in 130) 0.1 % (1 in 1,600) 0.4 % (1 in 260)
75 years 0.4 % (1 in 280) 0.6 % (1 in 160) 0.2 % (1 in 600) 0.4 % (1 in 270)
Lifetime risk 0.8 % (1 in 120) 0.4 % (1 in 260)
Figure 3.22.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C67, Germany 2011 – 2012
Figure 3.22.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C67, Germany 2011 – 2012
Figure 3.22.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C67, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
47% 34% 13% 7%
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Figure 3.22.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C67, 2011 – 2012
per 100,000 (European standard)
Figure 3.22.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C67, 2011 – 2012 or latest available year (details and sources, see appendix)
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110 Cancer in Germany Central nervous system
Risk factors
The causes of the various brain tumours are still 
largely unclear. The only exceptions are the rare he-
reditary tumour syndromes, which are associated 
with a significantly higher risk of brain tumours. Fol-
lowing therapeutic radiation of the scalp in childhood 
(from 1910–late 1950s due to tinea capitis) there is a 
slightly higher risk of developing a brain tumour af-
ter a long period of latency. Computed tomography 
during childhood may also marginally increase the 
risk of a brain tumour. In contrast, there is no indica-
tion from available data that either the use of ionising 
radiation in diagnostic imaging procedures as for 
x-ray of the teeth causes any discernible risk.
Further, current thinking is that neither environ-
mental factors nor electromagnetic radiation (mobile 
telephones) contribute to an increased risk. There is 
similarly no evidence that viruses or toxic substances 
cause brain tumours in humans. First-degree rela-
tives of patients with brain tumours have a slightly 
higher risk to develope a brain tumour themselves. 
Genetic mutations are presumably also involved in 
this marginal familial increased risk.
Epidemiology
Cancers of the central nervous system (CNS) pre-
dominantly affect the brain, including the brain 
stem. The remaining 5 % are cancers of the menin-
ges, cranial nerves, and the spinal nerves in the cauda 
equina. Malignant neoplasms of the central nervous 
system originate from glial cells, nerve sheaths and 
meninges. Histologically, approximately two thirds 
are accounted for by glioblastomas, as well as astro-
cytomas in particular (15 %) and other gliomatous 
tumours.
In 2012 nearly 7,200 people developed cancer of 
the central nervous system in Germany, of whom 
around 3,200 were women and 4,000 men. Men 
show higher incidence and mortality rates in all age 
groups than women and have a median age at diag-
nosis of 63 years, 3 years younger than for women 
with 66 years, though CNS tumours eventually occur 
at earlier age – even during their first years – in both 
sexes as well.
Following increases in mortality rates through 
the 1980s to the mid-1990s, especially among the 
more advanced age groups, no major changes of the 
rates are seen since the millennium in Germany. 
However, with the demographic change, the absolute 
number of malignant neoplasms occurring in men 
has continued to rise, significantly steeper than in 
women.
The relative 5-year survival rates for patients with 
cancer of the central nervous system have improved 
slightly and are currently at 21 % and 22 % respective-
ly, although for example survival with glioblastomas 
of the brain is at 8 % considerably worse.
3.23 Central nervous system
Table 3.23.1
Overview of key epidemiological parameters for Germany, ICD-10 C70 – C72
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 3,900 3,180 3,960 3,220 4,200 3,400
Crude incidence rate1 10.0 7.7 10.1 7.8 10.5 8.2
Standardised incidence rate1,2 8.0 5.6 7.9 5.6 8.0 5.6
Median age at diagnosis 62 66 63 66
Deaths 3,124 2,623 3,293 2,591
Crude mortality rate1 8.0 6.4 8.4 6.3
Standardised mortality rate1,2 6.0 4.1 6.1 4.0
5-year prevalence 6,900 5,400 6,900 5,300
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 19 (14 – 25) 21 (16 – 26) 13 (3 – 21) 17 (12 – 21)
Relative survival rate (2011 – 2012)3 21 (14 – 27) 22 (17 – 28) 15 (4 – 24) 19 (13 – 23)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.23.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C70 – C72, Germany 1999 – 2012
Figure 3.23.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C70 – C72, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.23.2
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Table 3.23.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C70 – C72, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,800) 0.7 % (1 in 150) <0.1 % (1 in 3,100) 0.6 % (1 in 160)
45 years 0.1 % (1 in 1,100) 0.6 % (1 in 160) 0.1 % (1 in 1,500) 0.6 % (1 in 170)
55 years 0.1 % (1 in 690) 0.6 % (1 in 180) 0.1 % (1 in 760) 0.5 % (1 in 190)
65 years 0.2 % (1 in 450) 0.5 % (1 in 220) 0.2 % (1 in 500) 0.5 % (1 in 220)
75 years 0.2 % (1 in 460) 0.3 % (1 in 340) 0.2 % (1 in 440) 0.3 % (1 in 320)
Lifetime risk 0.8 % (1 in 130) 0.6 % (1 in 160)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 2,700) 0.5 % (1 in 180) <0.1 % (1 in 4,800) 0.5 % (1 in 210)
45 years 0.1 % (1 in 1,500) 0.5 % (1 in 190) <0.1 % (1 in 2,300) 0.5 % (1 in 220)
55 years 0.1 % (1 in 920) 0.5 % (1 in 220) 0.1 % (1 in 1,100) 0.4 % (1 in 230)
65 years 0.2 % (1 in 660) 0.4 % (1 in 270) 0.1 % (1 in 690) 0.4 % (1 in 280)
75 years 0.2 % (1 in 590) 0.2 % (1 in 410) 0.2 % (1 in 620) 0.2 % (1 in 420)
Lifetime risk 0.6 % (1 in 160) 0.5 % (1 in 200)
Figure 3.23.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C70 – C72, Germany 2011 – 2012
Figure 3.23.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C70 – C72, Germany 2011 – 2012
Figure 3.23.3
Distribution of T-stages at first diagnosis by sex
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Figure 3.23.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C70 – C72, 2011 – 2012
per 100,000 (European standard)
Figure 3.23.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C70 – C72, 2011 – 2012 or latest available year (details and sources, see appendix)
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Risk factors
By now it is confirmed that environmental ionizing 
radiation increases the risk for thyroid cancer. Espe-
cially in childhood, the thyroid gland is radiation-sen-
sitive. Thus, the risk for thyroid cancer increases, if 
the thyroid gland is in the radiation field during ra-
diotherapy. The intake of radioactive iodine, e. g. after 
the nuclear accident in Chernobyl, also increases the 
risk of thyroid cancer.
There is no clear proof of other environmental, 
dietary or lifestyle factors. It is also unclear why wom-
en are more frequently affected than men. Many pa-
tients have a history of iodine deficiency or benign 
thyroid complaints such as struma (goitre) and ade-
noma, which increase the risk of developing thyroid 
carcinomas. About a quarter of patients with a rare 
medullary thyroid carcinoma have hereditary genetic 
mutations with autosomal dominant inheritance. 
Medullary thyroid carcinomas can also occur togeth-
er with other endocrine tumours – as part of a so-
called type 2 multiple endocrine neoplasia (MEN 2). 
A genetic component is also suspected for papillary 
thyroid carcinomas.
Epidemiology
Annually in Germany approximately 4,390 women 
and 1,820 men are diagnosed with thyroid cancer. 
The median age at diagnosis is 51 years for women 
and 56 for men, though the cancer does also occur at 
a younger age, especially in women.
In the period from 1999 to 2012, the mortality 
rates in both men and women in Germany have de-
creased slightly, whilst the age-standardised inci-
dence rates for both sexes have increased consider-
ably. Papillary carcinomas – very favourable from the 
point of view of prognosis – were exclusively respon-
sible for this increase, predominantly in younger 
adults. This trend is observed in other countries to a 
similar extent and is most likely attributable to im-
proved examination methods (e. g. ultrasound) which 
are used in the course of clarifying other thyroid dis-
orders or other internal illnesses. Within Germany, 
the highest incidence rates by far in both men and 
women are to be observed in Bavaria, Berlin and 
North Rhine-Westphalia, which corresponds with 
similarly high rates in Austria and France, and for 
women also in Czech Republic.
The majorities of cancers of the thyroid gland are 
diagnosed at an early stage (T1), especially among 
women (63 % of all thyroid cancers) and have a fa-
vourable prognosis with relative 5-year survival rates 
of 94 % among women and 85 % among men. Ana-




Overview of key epidemiological parameters for Germany, ICD-10 C73
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 1,830 4,540 1,820 4,390 2,100 5,200
Crude incidence rate1 4.7 11.1 4.6 10.7 5.2 12.4
Standardised incidence rate1,2 3.9 9.5 3.8 9.3 4.3 11.1
Median age at diagnosis 55 51 56 51
Deaths 336 388 330 419
Crude mortality rate1 0.9 0.9 0.8 1.0
Standardised mortality rate1,2 0.6 0.5 0.6 0.5
5-year prevalence 7,600 20,300 7,700 20,700
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 79 (66 – 89) 91 (82 – 95) 71 (59 – 82) 85 (79 – 91)
Relative survival rate (2011 – 2012)3 85 (72 – 95) 94 (86 – 99) 84 (68 – 94) 94 (89 – 99)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.24.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C73, Germany 1999 – 2012
Figure 3.24.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C73, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.24.2
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Table 3.24.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C73, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
25 years <0.1 % (1 in 4,000) 0.3 % (1 in 320) <0.1 % (1 in 262,800) 0.1 % (1 in 1,400)
35 years <0.1 % (1 in 2,200) 0.3 % (1 in 340) <0.1 % (1 in 72,600) 0.1 % (1 in 1,400)
45 years 0.1 % (1 in 1,600) 0.3 % (1 in 400) <0.1 % (1 in 25,300) 0.1 % (1 in 1,400)
55 years 0.1 % (1 in 1,300) 0.2 % (1 in 510) <0.1 % (1 in 8,800) 0.1 % (1 in 1,400)
65 years 0.1 % (1 in 1,300) 0.1 % (1 in 740) <0.1 % (1 in 5,100) 0.1 % (1 in 1,600)
75 years 0.1 % (1 in 1,800) 0.1 % (1 in 1,300) <0.1 % (1 in 2,700) 0.1 % (1 in 1,800)
Lifetime risk 0.3 % (1 in 300) 0.1 % (1 in 1,400)
Women aged in the next ten years ever in the next ten years ever
25 years 0.1 % (1 in 1,000) 0.8 % (1 in 130) <0.1 % (1 in 554,800) 0.1 % (1 in 1,200)
35 years 0.1 % (1 in 700) 0.7 % (1 in 150) <0.1 % (1 in 261,600) 0.1 % (1 in 1,200)
45 years 0.2 % (1 in 630) 0.5 % (1 in 190) <0.1 % (1 in 66,900) 0.1 % (1 in 1,200)
55 years 0.2 % (1 in 660) 0.4 % (1 in 270) <0.1 % (1 in 10,900) 0.1 % (1 in 1,200)
65 years 0.1 % (1 in 790) 0.2 % (1 in 430) <0.1 % (1 in 5,100) 0.1 % (1 in 1,200)
75 years 0.1 % (1 in 1,200) 0.1 % (1 in 840) <0.1 % (1 in 2,500) 0.1 % (1 in 1,400)
Lifetime risk 0.8 % (1 in 120) 0.1 % (1 in 1,200)
Figure 3.24.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C73, Germany 2011 – 2012
Figure 3.24.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C73, Germany 2011 – 2012
Figure 3.24.3
Distribution of T-stages at first diagnosis by sex (top: all cases; bottom: only valid reports) 
ICD-10 C73, Germany 2011 – 2012
no information
DCO
T1       T2       T3       T4       
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
51% 16% 26% 7%
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Figure 3.24.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C73, 2011 – 2012
per 100,000 (European standard)
Figure 3.24.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C73, 2011 – 2012 or latest available year (details and sources, see appendix)
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Risk factors
The risk factors for Hodgkin’s lymphoma are not 
completely understood. It remains unclear whether 
lifestyle-related risk factors or environmental risks 
are responsible for the development of Hodgkin’s 
lymphoma. The associations are complex. It is possi-
ble that the risk is increased by a long-term cigarette 
smoking habit.
As with non-Hodgkin lymphomas, congenital 
and acquired characteristics of the immune system 
and viral infections are topics of debate, although 
their influence cannot be quantified and it is not pos-
sible to ascribe a definite cause for any individual 
patient.
It has long been suspected that the Epstein-Barr 
virus (EBV), the cause of glandular fever (infectious 
mononucleosis), and retroviruses (e. g. HTLV and 
HIV) are involved. The results of recent studies con-
firm that EBV infection plays an important part in the 
development of Hodgkin’s lymphoma. Other viruses, 
such as the hepatitis B virus, may also be involved in 
the development of Hodgkin’s lymphoma.
The children and siblings of patients with 
 Hodgkin’s lymphoma have a much higher risk of 
developing the disease themselves. Researchers are 
therefore paying increasing attention to hereditary 
factors. However, research has not yet identified any 
risk-enhancing and inheritable gene mutations.
Epidemiology
Hodgkin’s lymphoma is histologically distinguished 
from non-Hodgkin lymphomas by the presence 
of Reed-Sternberg giant cells in the bone marrow. 
Hodgkin’s lymphoma is a rare disease, and in Ger-
many some 1,240 men and 990 women were diag-
nosed with it in 2012. It can occur at any age, and 
about one patient in ten was under 20 years of age at 
diagnosis. The risk of developing Hodgkin’s lympho-
ma at any stage in life is 0.2 % for both men and 
women.
In recent years the incidence rates, and the abso-
lute number of new cases annually, have shown no 
discernible trends, while ever fewer people are dying 
of Hodgkin’s lymphoma. The mortality rate in Ger-
many in 2012 was just over 300, almost 200 fewer 
than ten years previously. The prognosis is corre-
spondingly favourable, with about 83 % of women 
and 80 % of men still alive 5 years after diagnosis. 
Due to the chronic relapsing nature of the disease, 
the long-term prognosis is also determined by side 
effects of therapy (including secondary tumours).
3.25 Hodgkin’s lymphoma
Table 3.25.1
Overview of key epidemiological parameters for Germany, ICD-10 C81
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 1,260 970 1,240 990 1,300 1,100
Crude incidence rate1 3.2 2.4 3.2 2.4 3.2 2.5
Standardised incidence rate1,2 3.0 2.2 2.9 2.3 2.9 2.4
Median age at diagnosis 45 44 46 41
Deaths 194 141 219 158
Crude mortality rate1 0.5 0.3 0.6 0.4
Standardised mortality rate1,2 0.3 0.2 0.4 0.2
5-year prevalence 5,200 4,000 5,200 4,100
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 80 (60 – 87) 83 (68 – 93) 73 76
Relative survival rate (2011 – 2012)3 84 (63 – 91) 86 (72 – 97) 80 81
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.25.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C81, Germany 1999 –  2012
Figure 3.25.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C81, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.25.2
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Table 3.25.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C81, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
15 years <0.1 % (1 in 2,700) 0.2 % (1 in 430) <0.1 % (1 in 330,300) <0.1 % (1 in 2,200)
25 years <0.1 % (1 in 2,800) 0.2 % (1 in 520) <0.1 % (1 in 63,600) <0.1 % (1 in 2,200)
35 years <0.1 % (1 in 3,200) 0.2 % (1 in 630) <0.1 % (1 in 42,100) <0.1 % (1 in 2,200)
45 years <0.1 % (1 in 3,500) 0.1 % (1 in 770) <0.1 % (1 in 40,300) <0.1 % (1 in 2,300)
55 years <0.1 % (1 in 3,700) 0.1 % (1 in 940) <0.1 % (1 in 14,600) <0.1 % (1 in 2,400)
Lifetime risk 0.2 % (1 in 400) <0.1 % (1 in 2,200)
Women aged in the next ten years ever in the next ten years ever
15 years <0.1 % (1 in 2,300) 0.2 % (1 in 530) <0.1 % (1 in 345,900) <0.1 % (1 in 3,100)
25 years <0.1 % (1 in 2,900) 0.1 % (1 in 690) <0.1 % (1 in 88,200) <0.1 % (1 in 3,200)
35 years <0.1 % (1 in 4,300) 0.1 % (1 in 910) <0.1 % (1 in 127,100) <0.1 % (1 in 3,300)
45 years <0.1 % (1 in 5,600) 0.1 % (1 in 1,100) <0.1 % (1 in 64,200) <0.1 % (1 in 3,300)
55 years <0.1 % (1 in 5,800) 0.1 % (1 in 1,400) <0.1 % (1 in 34,200) <0.1 % (1 in 3,400)
Lifetime risk 0.2 % (1 in 490) <0.1 % (1 in 3,200)
Figure 3.25.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C81, Germany 2011 – 2012
Figure 3.25.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C81, Germany 2011 – 2012
Figure 3.25.3
Distribution of T-stages at first diagnosis by sex
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Figure 3.25.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C81, 2011 – 2012
per 100,000 (European standard)
Figure 3.25.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C81, 2011 – 2012 or latest available year (details and sources, see appendix)
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122 Cancer in Germany Non-Hodgkin lymphomas
Risk factors
Risk factors for non-Hodgkin lymphoma can only 
rarely be conclusively identified. Immunodeficiency 
(hereditary, because of HIV infection, or due to im-
munosuppressive treatment) is associated with an 
increased risk, as are a number of rare autoimmune 
diseases. Nuclear radiation or chemotherapy can also 
cause malign lymphomas. Viruses and other patho-
gens also contribute to the development of some lym-
phomas. For example, the link between infection 
with the Epstein-Barr virus (EBV, glandular fever) 
and Burkitt’s lymphoma, which occurs predominant-
ly in Africa, has been proven. Chronic infection of the 
stomach with the Helicobacter pylori bacterium can 
lead to a lymphoma of the gastric mucosa (MALT 
lymphoma). Certain T-cell lymphomas that are rare 
in Europe are found clustered in carriers of the hu-
man T-cell leukaemia virus (HTLV-1). Studies suggest 
that certain types of lymphoma are more likely to 
develop in people chronically infected with hepatitis 
viruses (type B or C). Environmental pollutants such 
as heavy metals, organic solvents as well as some 
herbicides, insecticides and fungicides are being dis-
cussed as causes of malign lymphomas. Smoking 
and being overweight appear to play a role, particu-
larly for aggressive lymphomas. Regular exercise may 
reduce the risk. New studies suggest that hereditary 
genetic variations could affect the risk of developing 
the disease, without being a direct cause of the lym-
phomas.
Epidemiology
Non-Hodgkin lymphomas originate from cells of the 
lymphatic system, mostly from B-lymphocytes. A dis-
tinction is made between high-grade and low-grade 
malignancy forms. In 2012, some 16,000 people 
were diagnosed with non-Hodgkin lymphoma in 
Germany. The disease occurs as early as in childhood 
and the risk of developing it rises almost steadily with 
increasing age. The median age at diagnosis for men 
was 70 years and for women 72 years.
The significant increases in the age-standardised 
incidence rates should be seen within the context of 
falling rates for leukaemias, since chronic lymphatic 
leukaemias are now classified clinically under the 
low-grade malignancy non-Hodgkin lymphomas. 
The majority of cases are non-follicular lymphomas 
(49 % among men, 44 % among women). The 
age-standardised mortality rates are decreasing in 
both men and women since the turn of the millenni-
um and reached a constant level by now, though they 
are lower among women compared to men. Approx-
imately 6,000 people in Germany die of this disease 
annually.
With a relative 5-year survival rate of 66 % 
among men and 69 % among women, the prognosis 
for non-Hodgkin lymphomas is generally favourable, 
although in individual cases it depends on age, as 
well as on type and distribution of the disease. Some 
forms, even highly malignant ones, can now be treat-
ed with the prospect of a permanent cure.
3.26 Non-Hodgkin lymphomas
Table 3.26.1
Overview of key epidemiological parameters for Germany, ICD-10 C82 – C88
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 8,690 7,510 8,580 7,570 9,800 8,200
Crude incidence rate1 22.2 18.3 21.8 18.4 24.5 19.9
Standardised incidence rate1,2 15.9 10.9 15.4 11.0 16.7 11.2
Median age at diagnosis 69 72 70 72
Deaths 3,232 3,027 3,407 2,955
Crude mortality rate1 8.3 7.4 8.7 7.2
Standardised mortality rate1,2 5.4 3.4 5.5 3.3
5-year prevalence 29,200 25,600 29,500 25,900
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 57 (52 – 61) 61 (53 – 66) 42 (38 – 44) 47 (41 – 52)
Relative survival rate (2011 – 2012)3 66 (61 – 69) 69 (62 – 74) 57 (51 – 61) 62 (57 – 66)
1 per 100.000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
123ICD-10 C82 – C88 Cancer in Germany
Figure 3.26.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C82 – C88, Germany 1999 – 2012
Figure 3.26.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C82 – C88, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.26.2
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Table 3.26.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C82 – C88, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,500) 1.7 % (1 in 60) <0.1 % (1 in 13,000) 0.8 % (1 in 130)
45 years 0.1 % (1 in 700) 1.6 % (1 in 62) <0.1 % (1 in 3,600) 0.8 % (1 in 130)
55 years 0.3 % (1 in 350) 1.5 % (1 in 65) 0.1 % (1 in 1,300) 0.8 % (1 in 130)
65 years 0.6 % (1 in 180) 1.4 % (1 in 72) 0.2 % (1 in 490) 0.8 % (1 in 130)
75 years 0.7 % (1 in 140) 1.1 % (1 in 94) 0.4 % (1 in 230) 0.7 % (1 in 140)
Lifetime risk 1.7 % (1 in 58) 0.8 % (1 in 130)
Women aged in the next ten years ever in the next ten years ever
35 years 0.1 % (1 in 1,900) 1.4 % (1 in 70) <0.1 % (1 in 20,300) 0.6 % (1 in 170)
45 years 0.1 % (1 in 900) 1.4 % (1 in 72) <0.1 % (1 in 7,500) 0.6 % (1 in 170)
55 years 0.2 % (1 in 420) 1.3 % (1 in 77) <0.1 % (1 in 2,200) 0.6 % (1 in 170)
65 years 0.4 % (1 in 240) 1.1 % (1 in 89) 0.1 % (1 in 710) 0.6 % (1 in 170)
75 years 0.5 % (1 in 190) 0.8 % (1 in 120) 0.3 % (1 in 350) 0.5 % (1 in 200)
Lifetime risk 1.5 % (1 in 68) 0.6 % (1 in 170)
Figure 3.26.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C82 – C88, Germany 2011 – 2012
Figure 3.26.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C82 – C88, Germany 2011 – 2012
Figure 3.26.3
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for non-Hodgkin lymphomas.
Table 3.26.3
Proportion of the various non-Hodgkin lymphomas for all new diagnoses C82 – C88,  
by sex, Germany 2011 – 2012
C821 C832 C843 C854 C865 C886
Men 15 % 49 % 8 % 19 % 2 % 6 %



















3 Mature T/NK-cell lymphomas
4 Other and unspecified types  
of non-Hodgkin lymphoma
5 Other specified types of T/NK-cell lymphoma
6 Malignant immunoproliferative diseases
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Figure 3.26.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C82 – C88, 2011 – 2012
per 100,000 (European standard)
Figure 3.26.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C82 – C88, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  data for mortality for C81–C85  
2  data for incidence for C82–C85 and C96  
3  data for C82–C85  
   
4  no comparable data  
5  no comparable data for mortality
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Risk factors
The causes of the development of plasmacytomas 
(multiple myeloma) are largely still not yet under-
stood. A monoclonal gammopathy of undetermined 
significance (MGUS) is considered to be the prelim-
inary stage of the multiple myeloma. Recognised risk 
factors for multiple myeloma are advanced age and 
the male sex. Chronic infections such as HIV-infec-
tion or infection with the hepatitis C virus are associ-
ated with an increased risk of developing a multiple 
myeloma. There are currently conflicting opinions as 
to whether certain lifestyle habits or exposure to en-
vironmental toxins or radiation significantly increase 
the risk of developing a myeloma. According to more 
recent study data, being very overweight is linked 
with increased risk. Familial clustering has been ob-
served though there is no definite evidence of hered-
ity to date. However, variations in incidence within 
different population groups also point to genetic fac-
tors. People of black African origin are probably more 
frequently affected than white North Americans, 
 Europeans or Asians.
Epidemiology
Multiple myeloma (Plasmacytoma) is a malignant 
proliferation of anti-body-producing plasma cells. 
The disease mostly occurs initially in the bone mar-
row where it forms multiple myeloma with corre-
sponding complications such as bone fractures and 
bone pain or blood count changes. In approximately 
1 % of cases involvement of other organs not asso-
ciated with bone marrow leads to diagnosis (extra-
medullary plasmacytoma).
In Germany, in 2012 approximately 3,490 men 
and 2,850 women were newly diagnosed with the 
illness. The risk of developing the disease increases 
significantly in advanced years with cases being ex-
tremely rare before the age of 45 years (approximate-
ly 2 % of all cases). Following age-standardisation the 
incidence rates for women and men were almost 
constant with the mortality rates in contrast for both 
genders declining slightly.
Given a relative 5-year survival rate of approxi-
mately 45 % in women and 48 % in men, the progno-
sis is relatively unfavourable. Even after maximum 
therapy, e. g. autologous stem cell transplant, a per-
manent cure is not to be expected. However, the 
course of the illness may in some cases be asymp-
tomatic for a relatively long period, and during ther-
apy temporary remissions may be possible.
3.27 Multiple myeloma
Table 3.27.1
Overview of key epidemiological parameters for Germany, ICD-10 C90
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 3,560 2,940 3,490 2,850 3,800 3,000
Crude incidence rate1 9.1 7.2 8.9 6.9 9.4 7.4
Standardised incidence rate1,2 6.1 3.9 5.8 3.7 5.8 3.9
Median age at diagnosis 71 73 72 74
Deaths 1,992 1,916 1,956 1,870
Crude mortality rate1 5.1 4.7 5.0 4.6
Standardised mortality rate1,2 3.3 2.2 3.1 2.1
5-year prevalence 10,200 8,400 10,500 8,400
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 41 (23 – 48) 40 (36 – 48) 22 (7 – 26) 22 (18 – 27)
Relative survival rate (2011 – 2012)3 48 (27 – 56) 45 (41 – 55) 31 (11 – 37) 30 (23 – 35)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.27.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C90, Germany 1999 – 2012
Figure 3.27.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C90, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.27.2
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Table 3.27.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C90, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 7,900) 0.7 % (1 in 140) <0.1 % (1 in 36,100) 0.4 % (1 in 230)
45 years <0.1 % (1 in 2,300) 0.7 % (1 in 140) <0.1 % (1 in 6,900) 0.4 % (1 in 230)
55 years 0.1 % (1 in 840) 0.7 % (1 in 140) 0.1 % (1 in 2,000) 0.4 % (1 in 230)
65 years 0.2 % (1 in 410) 0.6 % (1 in 160) 0.1 % (1 in 750) 0.4 % (1 in 240)
75 years 0.3 % (1 in 290) 0.5 % (1 in 200) 0.2 % (1 in 410) 0.4 % (1 in 270)
Lifetime risk 0.7 % (1 in 140) 0.4 % (1 in 240)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 11,200) 0.6 % (1 in 180) <0.1 % (1 in 64,100) 0.4 % (1 in 260)
45 years <0.1 % (1 in 3,300) 0.6 % (1 in 180) <0.1 % (1 in 11,000) 0.4 % (1 in 260)
55 years 0.1 % (1 in 1,200) 0.5 % (1 in 190) <0.1 % (1 in 3,000) 0.4 % (1 in 260)
65 years 0.2 % (1 in 600) 0.5 % (1 in 210) 0.1 % (1 in 1,000) 0.4 % (1 in 270)
75 years 0.2 % (1 in 420) 0.4 % (1 in 290) 0.2 % (1 in 530) 0.3 % (1 in 330)
Lifetime risk 0.6 % (1 in 180) 0.4 % (1 in 260)
Figure 3.27.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C90, Germany 2011 – 2012
Figure 3.27.4b
Relative survival rates up to 10 years after first diagnosis,  
by sex, ICD-10 C90, Germany 2011 – 2012
Figure 3.27.3
Distribution of T-stages at first diagnosis by sex
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Figure 3.27.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C90, 2011 – 2012
per 100,000 (European standard)
Figure 3.27.6
International comparison of age-standardised incidence and mortality rates, by sex,   
ICD-10 C90, 2011 – 2012 or latest available year (details and sources, see appendix)
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1  incl. C88  
2  data for mortality incl. C96  
3  no comparable data for mortality  
  
4  data for mortality incl. C88, C96  
5  no comparable data  
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Risk factors
The risk factors known to cause acute leukaemia in-
clude ionising radiation in radiotherapy, cytostatic 
drugs in chemotherapy for cancer, and probably also 
various chemicals (e. g. at the workplace). If, for ex-
ample, occupational contact with benzene is a causal 
factor, then leukaemia can be recognised as an occu-
pational disease. However, none of these risk factors 
is found in the medical history of most patients. In 
particular the causes of chronic leukaemias are un-
clear.
The possible influence of dietary habits and life-
style is under discussion, particularly for chronic 
lymphatic leukaemias. So far, however, there is no 
proof of such influences for this or for other chronic 
and acute forms of leukaemia. The influence of virus-
es has not been conclusively proved and is also the 
subject of research. Besides, there is a debate as to 
whether insufficient training of the immune system 
in childhood contributes towards increased risk, with 
no conclusion having yet been reached. No link to 
exposure to electromagnetic fields of any origin has 
been proved.
A number of comparatively rare genetic muta-
tions can increase the incidence risk for leukaemia, 
including trisomy of chromosome 21. It is likely that 
some hereditary gene variations play a role in the risk 
of disease without causing leukaemia directly. Sever-
al factors presumably need to interact in order for 
leukaemia to develop.
Epidemiology
In 2012, some 12,640 people in Germany were diag-
nosed with leukaemia, 5 % of whom were under 15 
years of age. The risk for leukaemia falls with increas-
ing age among children and young adults indepen-
dent of gender. Above the age of 30 the risk increases 
again continuously, with a higher incidence among 
men than women. One in 67 men and one in 91 
women develop a leukaemia during their lifetime.
More than a third of the diagnosed cases were 
chronic lymphatic leukaemia (CLL) and over a quar-
ter of the cases were acute myeloid leukaemia (AML).
The age-standardised incidence rates have been 
relatively stable since 1999 to 2012 among both sexes. 
However, the age-standardised mortality rates have 
declined continuously. Within Germany, the highest 
incidence rates are observed in Hamburg, whereas 
the highest mortality rates are in Saarland.
The prognosis for leukaemia depends on its 
form and the age of the subject at diagnosis. It is most 
favourable by far for the leukaemia forms in child-
hood, whereas in adults the acute forms still have a 
poorer prognosis.
Overall, about a third of adult patients are still 
alive ten years after diagnosis. However, a permanent 




Overview of key epidemiological parameters for Germany, ICD-10 C91 – C95
2011 2012 Prediction for 2016
Men Women Men Women Men Women
Incident cases 7,520 5,840 7,180 5,460 7,800 5,900
Crude incidence rate1 19.2 14.2 18.3 13.3 19.4 14.1
Standardised incidence rate1,2 14.1 8.9 13.3 8.2 13.3 8.6
Median age at diagnosis 70 72 71 73
Deaths 4,083 3,535 4,155 3,445
Crude mortality rate1 10.4 8.6 10.6 8.4
Standardised mortality rate1,2 6.9 4.2 6.8 4.0
5-year prevalence 22,700 16,500 22,700 16,400
after 5 years after 10 years
Absolute survival rate (2011 – 2012)3 50 (34 – 58) 49 (31 – 58) 34 (20 – 39) 36 (23 – 45)
Relative survival rate (2011 – 2012)3 58 (40 – 67) 55 (35 – 64) 46 (28 – 54) 46 (28 – 55)
1 per 100,000 persons  2 age-standardised (European standard)  3 in percentages (lowest and highest value of the included German federal states)
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Figure 3.28.1b
Absolute numbers of incident cases and deaths,  
by sex, ICD-10 C91 – C95, Germany 1999 – 2012
Figure 3.28.1a
Age-standardised incidence and mortality rates,  
by sex, ICD-10 C91 – C95, Germany 1999 – 2012
per 100,000 (European standard)
Figure 3.28.2
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Table 3.28.2
Cancer incidence and mortality risks in Germany by age and sex, ICD-10 C91 – C95, database 2012
Risk of developing cancer Mortality risk
Men aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 2,100) 1.4 % (1 in 72) <0.1 % (1 in 6,700) 0.9 % (1 in 110)
45 years 0.1 % (1 in 1,000) 1.4 % (1 in 73) <0.1 % (1 in 3,800) 0.9 % (1 in 110)
55 years 0.2 % (1 in 440) 1.3 % (1 in 76) 0.1 % (1 in 1,100) 0.9 % (1 in 110)
65 years 0.4 % (1 in 230) 1.2 % (1 in 82) 0.2 % (1 in 410) 0.9 % (1 in 110)
75 years 0.6 % (1 in 160) 1.0 % (1 in 100) 0.5 % (1 in 190) 0.9 % (1 in 120)
Lifetime risk 1.5 % (1 in 67) 0.9 % (1 in 110)
Women aged in the next ten years ever in the next ten years ever
35 years <0.1 % (1 in 2,600) 1.0 % (1 in 99) <0.1 % (1 in 9,400) 0.7 % (1 in 140)
45 years 0.1 % (1 in 1,600) 1.0 % (1 in 100) <0.1 % (1 in 4,600) 0.7 % (1 in 140)
55 years 0.1 % (1 in 730) 0.9 % (1 in 110) 0.1 % (1 in 1,800) 0.7 % (1 in 150)
65 years 0.3 % (1 in 380) 0.8 % (1 in 120) 0.2 % (1 in 660) 0.7 % (1 in 150)
75 years 0.4 % (1 in 260) 0.7 % (1 in 150) 0.3 % (1 in 320) 0.6 % (1 in 170)
Lifetime risk 1.1 % (1 in 91) 0.7 % (1 in 140)
Figure 3.28.4a
Absolute survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C91 – C95, Germany 2011 – 2012
Figure 3.28.4b
Relative survival rates up to 10 years after first diagnosis, 
by sex, ICD-10 C91 – C95, Germany 2011 – 2012
Figure 3.28.3 
Distribution of T-stages at first diagnosis by sex
T-stages are not defined for leukaemias.
Table 3.28.3
Proportion of the various leukaemia forms for all new diagnoses C91 – C95, by sex, Germany 2011 – 2012
ALL1 CLL2 AML3 CML4 others5
Men 7 % 40 % 20 % 8 % 24 %
Women 8 % 36 % 23 % 9 % 24 %
1 Acute lymphatic leukaemia (C91.0)
2 Chronic lymphatic leukaemia (C91.1)
3 Acute myeloid leukaemia (C92.0)
4 Chronic myeloid leukaemia (C92.1)
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Figure 3.28.5
Registered age-standardised incidence and mortality rates in German federal states, by sex,   
ICD-10 C91 – C95, 2011 – 2012
per 100,000 (European standard)
Figure 3.28.6
International comparison of age-standardised incidence and mortality rates, by sex,  
ICD-10 C91 – C95, 2011 – 2012 or latest available year (details and sources, see appendix)
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be explained by the fact that suspicious skin changes 
especially in old age are more likely to heal complete-
ly in otherwise healthy people.
In the case of squamous-cell carcinoma, metas-
tases occur somewhat more frequently, the prognosis 
is however generally good. An acquired immune de-
ficiency and/or suppression through medication, for 
example following transplant surgery, can encourage 
the occurrence of this tumour.
Rare forms of skin cancer include, amongst oth-
ers, Merkel-cell tumours, fibrosarcoma and carcino-
ma of the sebaceous and sweat glands. In cause of 
death statistics, no differentiation can be made be-
tween the various forms of non-melanoma skin can-
cer.
Non-melanoma skin cancer
Non-melanoma skin cancers can mainly be divided 
into basal cell carcinomas (basaliomas) and squa-
mous-cell carcinomas, both of which occur particu-
larly in advanced age (Table 3.29.2). The most im-
portant risk factor for both forms is the long-term 
impact of the ultraviolet part of sunshine, which is 
why they are particularly located on the face or on the 
head and neck.
The basalioma metastasises only in very rare ex-
ceptional circumstances and therefore is not usually 
life-threatening. It can however grow destructively in 
the surrounding tissue and can considerably affect 
quality of life given an unfavourable site. The relative 
survival rate of over 100 % for basalioma can probably 
fined sites (C26, C76). The remainders are presented 
in Table 3.29.1. Detailed results regarding estimated 
nationwide incidence and mortality, for instance ac-
cording to age group and year of diagnosis can be 
found at www.krebsdaten.de.
Rare malignant tumours
A good 5 % of all malignant neoplasms excluding 
non-melanoma skin cancer affect sites which have 
not been covered in the preceding chapters. Of 
these, approximately half again are malignant tu-
mours of unspecified site (C80) or other and ill-de-
3.29 Rare cancer sites and non-melanoma skin cancer
Table 3.29.1
Frequency, median age at diagnosis and survival rates for rare malignant tumours in Germany 2012
Cancer site ICD-10 Incident cases Deaths Ø age at diagnosis rel. 5-Y-SR1
 Men Women Men Women Men Women total
Small intestine C17 1,170 1,010 281 258 69 70 60
Nasal cavity, nasal sinuses and middle ear C30, C31 560 350 125 65 63 66 58
Mediastinum and other intrathoracic organs C37 – C39 290 210 157 136 67 70 44
Bone and articular cartilage C40, C41 360 330 250 215 53 55 60
Vagina and other female genital organs C52, C57, C58 1,110 453 71 49
Penis and other male genital organs C60, C63 900 198 70 74
Urinary tract excl. kidney and bladder C65, C66, C68 1,530 1,000 2,270 1,042 74 76 46
Eye C69 340 330 127 136 66 68 66
Adrenal gland and other endocrine glands C74, C75 260 240 375 293 57 61 49
Other and unspecified malignant neoplasms 



























Frequency, median age at diagnosis and survival rates for types of non-melanoma skin cancer in Germany 2012
Cancer site ICD-O-3 Incident cases Deaths Ø age at diagnosis rel. 5-Y-SR1
 Men Women Men Women Men Women total
Basaliomas 809 – 811 80,800 78,400 72 71 104
Squamous cell carcinomas 805 – 808 26,400 17,900 76 79 95
Unspecific histology 800 – 804 500 500 75 77 91
Other types 1,100 900 75 76 80
Total 108,800 97,700 363 325 73 72 102
¹ relative 5-year survival rate in percentage, men and women, period 2011 – 2012
¹ relative 5-year survival rate in percentage, men and women, period 2011 – 2012
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The current data pool consists of over 55,000 
cancer cases.
Incidence of childhood cancers
About 1,800 cases of childhood (under the age of 15 
years) cancer are newly diagnosed every year in Ger-
many. With an overall population of approx. 11 million 
children under the age of 15 years, this means an an-
nual incidence of about 16.6 per 100,000 children in 
this age group. The likelihood that a newborn child 
will develop a malignant disease within the first 15 
years of his/her life is 0.2 %. In other words, a malig-
nant cancer is diagnosed in approx. one in 420 chil-
dren up to their 15th birthday. Since 2009, the begin-
ning of registration of all children and adolescents up 
to age 18, on average an additional 300 cases aged 
between 15 and 17 years were registered annually. 
Within the first 25 years since diagnosis, another can-
cer (subsequent cancer) was registered for 1,061 pa-
tients, which applies to 4.4 % of patients (cumulative 
incidence).
Range of diagnoses
The pattern of cancer diagnoses in children is com-
pletely different from that of adults. For example, 
children are mostly affected by embryonal tumours 
(neuroblastomas, retinoblastomas, nephroblasto-
mas, medulloblastomas, embryonic rhabdomyosar-
comas or germ-cell tumours); carcinomas, by con-
trast, are very rare in childhood (making up about 2 % 
of all malignant diseases). The largest diagnostic 
groups are leukaemias (33.4 %), CNS tumours 
(24.4  %) and lymphomas (10.9 %). Overall cancer 
incidence among children under the age of five is 
about twice as high as in the 5- to 14-year-old age 
group. The median age at onset among the under-15-
year-olds is five years, ten months. Boys are diag-
nosed with cancer 1.2 times more frequently than 
girls.
The German Childhood Cancer Registry (GCCR) has 
been based at the Institute of Medical Biostatistics, 
Epidemiology and Informatics at the University Med-
ical Centre of the Johannes Gutenberg University 
Mainz, since beginning its work in 1980. Close coop-
eration with the Society for Paediatric Oncology and 
Haematology (GPOH) and its associated hospitals 
was part of the GCCR›s original conception. This is 
a characteristic feature of the registry which cannot 
be easily applied to adult oncology. This nationwide, 
population based childhood cancer registry with a 
high level of data quality and a degree of complete-
ness of over 95 % (since about 1987) has been built up 
covering the whole of Germany. The GCCR thus 
meets international standards for population based 
cancer registries. A further characteristic of the 
GCCR is that it has implemented an active, open-end, 
long-term follow-up observation system which con-
tinues long into adulthood. In this way, the registry 
also provides the basis for research into long-term 
effects and secondary tumours and for studies with 
long-term survivors in general. The registry popula-
tion comprises children who are diagnosed with a 
malignant disease or a histologically benign brain 
tumour before their 15th birthday and are part of the 
resident population of the Federal Republic of Ger-
many when diagnosed. Cancer cases in eastern Ger-
many have also been registered since 1991. Since 1 
January 2009, the GCCR has been registering all 
children and adolescents up to the age of 18 years (i. e. 
who are diagnosed before their 18th birthday) on the 
basis of the »Agreement of the Joint Federal Commit-
tee on Quality-Assurance Measures for the In-Patient 
Care of Children and Adolescents with Haemato-On-
cological Diseases«. This will make it possible to bet-
ter consider the needs of the collaborating hospitals 
which have been combining paediatric and adoles-
cent medicine for several years now and thus also 
treat cancer patients aged 15 years and over.
4 Cancer in children
Figure 4.1 
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Leukaemias
Leukaemias make up more than a third of all cancers 
among the under-15-year-olds. The most common sin-
gle diagnosis overall (26.5 %) is lymphatic leukaemia 
(LL). It occurs more than twice as frequently among 
children under the age of five as in the other age 
groups. 4.4 % of all childhood malignancies are acute 
myeloid leukaemias (AML). AML is most common 
among children under the age of two. The survival 
prospects for AML are markedly lower than for LL. 
About 13 % of all subsequent cancers are AML.
The causes of leukaemias in childhood remain 
largely uncertain, even today. For a long time, envi-
ronmental influences were suspected of causing 
childhood leukaemias. Since then it has been shown 
that the number of cases caused by most environmen-
tal factors (low-dose ionising radiation, non-ionising 
radiation and pesticides) is quite small after all, even 
if a weak association with leukaemias in childhood 
cannot be ruled out. A number of clues have mean-
while strengthened hypotheses that assign a key role 
to infectious pathogens and the immune system in 
the development of childhood leukaemias. Genetic 
causes are still researched and discussed for all neo-
plasia in childhood.
CNS tumours
The most common single diagnoses among CNS tu-
mours are astrocytomas (total: 11.7 %), intracranial and 
intraspinal embryonal tumours (4.6 %) and ependy-
momas (1.9 %). Twenty-two percent of all subsequent 
cancers are CNS tumours. The increase in the inci-
dence of CNS tumours observed in a number of west-
ern countries over the past decades may be connected 
Figure 4.2
Incident cases by age and sex, all childhood malignancies
Number of cases per 100,000 by age group, determined for the period 2004 – 2013
Figure 4.3
Incident cases by age and sex, childhood acute lymphatic leukaemia (ALL)
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Figure 4.4
Trends of incidence of selected diagnostic groups and for all childhood malignancies
Number of cases per 100,000 (age standardised), including eastern Germany since 1991
Figure 4.5
Trends of incidence of childhood leukaemias, myeloproliferative and myelodysplastic disorders
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with a better registration and also with general chang-
es in environmental factors and related exposures. 
For example, a number of epidemiological studies is 
looking into the possible influence of ionising radia-
tion, electromagnetic fields, pesticides, the motherʼs 
diet and genetic aspects.
Lymphomas
The most common lymphomas are non-Hodgkin 
lymphomas (NHL), including Burkittʼs lymphoma 
(total: 6.5 %) and Hodgkin’s lymphoma (4.7 %). The 
chances of survival with Hodgkin’s lymphoma are 
among the best in paediatric oncology. Unfortunately, 
with more than 8 % the frequency of subsequent can-
cer (within 25 years after diagnosis) after Hodgkin’s 
lymphoma is particularly high. Children with congen-
ital or acquired immunodeficiency and those who 
have had immunosuppressive therapy are at in-
creased risk of developing NHL. An association is 
suspected between lymphomas and ionising radia-
tion; this has not, however, been substantiated.
Other common malignant diseases
Other common malignant diseases in childhood in-
clude neuroblastomas (nerve-cell tumours), nephro-
blastomas (kidney tumours), germ-cell tumours, 
bone tumours and rhabdomyosarcomas (tumours of 
the skeletal musculature). Among these malignan-
cies, the prognosis for children with nephroblastoma 
or a germ-cell tumour is much more favourable than 
for the other tumours. Skin tumours and thyroid can-
cer are other frequent subsequent cancers.
Survival
Children under 15 years of age with cancer make up 
less than 1 % of all cancer patients. However, malig-
nant neoplasms are the second most common cause 
of death among children. Fortunately, the survival 
rates have improved dramatically over the last 30 
years thanks to significantly more differentiated diag-
nostics and the use of multimodal therapy concepts. 
In the early 1980s the chances of children with cancer 
being still alive five years after diagnosis were 67 %; 
this figure has risen to 84 % since then. Looking at all 
patients of the registry population who were diag-
nosed between 2002 and 2011 and followed up, the 
overall chance of survival is 84 % after five years, 82 % 
after ten years, and 81 % after 15 years. The encourag-
ing increase in the number of long-term survivors is 
increasingly focusing attention on the long-term ob-
servation of former paediatric cancer patients. The 
GCCR provides an ideal data basis for carrying out 
studies with long-term survivors. As the above figures 
show, it is already possible to provide information on 
long-term survival (for example after 15 years) and to 
estimate the risk of developing a second neoplasia 
after cancer in childhood. Examples of further re-
search possibilities include the incidence of other 
long-term effects, such as the possible effects of ther-
apy on fertility, and studies examining the health risks 
of the descendants of fathers and mothers who had 
childhood cancer. About 32,000 of the more than 
42,000 patients currently known to be alive have 
been under observation by the registry for at least five 
years. The majority of these patients are at least 18 
years old.
Table 4.1
Incidence and survival rates for the most common diagnoses, determined for the period 2002 – 2011
Cancer sites Incidence* Survival rate in %**
after 5 years after 10 years after 15 years
Hodgkin’s lymphomas 0.6 99 98 97
Retinoblastomas 0.4 97 97 97
Germ-cell tumours 0.5 95 94 94
Nephroblastomas 1.0 93 92 92
Lymphoid leukaemias 4.4 92 90 89
Non-Hodgkin lymphomas 0.6 89 87 86
Astrocytomas 1.8 81 79 77
Neuroblastomas and ganglioneuroblastomas 1.4 79 77 76
Rhabdomyosarcomas 0.5 74 72 71
Acute myeloid leukaemias 0.7 73 72 71
Osteosarcomas 0.3 75 71 70
Intracranial and intraspinale embryonal tumours 0.8 67 59 56
All malignancies 16.6 84 82 81
* Related to 100,000 children under the age of 15, age standardised (standard: Segi world population), children diagnosed 2004 – 2013
** Brenner H, Spix C. Combining cohort and period methods for retrospective time trend analyses of long-term cancer patient survival rates.  
Br J Cancer 89, 1260 – 1265, 2003
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After the Federal Cancer Registry Data Act (Bundes-
krebsregisterdatengesetz – BKRG) came into force in 
August 2009, the German Centre for Cancer Registry 
Data was set up at the beginning of 2010 as an inde-
pendent division within the Robert Koch Institute’s 
Department of Epidemiology and Health Reporting to 
perform the tasks laid down in the Act:
▶ to check the completeness of case finding and of 
the variables included in the anonymised data 
submitted by the epidemiological (popula-
tion-based) state cancer registries
▶ to conduct a nationwide record linkage with the 
data from the different state cancer registries to 
discover any duplicate notifications and to inform 
the cancer registries accordingly
▶ to compile, update and extrapolate a dataset from 
the reviewed data from the state cancer registries
▶ to regularly estimate and analyse survival rates, 
stage distribution at diagnosis of the respective 
cancer, and other indicators, particularly on prev-
alence, the risk of developing and dying of the 
disease, and how these indicators develop over 
time
▶ to examine data from various states to determine 
any regional differences in selected cancer sites
▶ to provide a dataset for evaluating health-policy 
measures of cancer prevention, cancer screening, 
cancer treatment and healthcare
▶ to conduct analyses and studies on all aspects of 
cancer and to publish the results in national and 
international journals
▶ to publish the findings on incidence in Germany 
and its development over time in consultation 
with the state cancer registries every two years 
(booklet »Cancer in Germany«)
▶ to write a comprehensive report on cancer in Ger-
many every five years, first edition will be pub-
lished at the end of 2016
▶ to complement classic print-products through fa-
cilities of interactive analyses annually updated 
data and an extended offer of information on the 
Internet
▶ to further enhance methods and standardization 
rules on data collection and data transfer, and to 
analyse the data together with the state cancer reg-
istries
▶ to use further data sources to describe all aspects 
of cancer in Germany
▶ international cooperation
▶ to collaborate in scientific bodies as well as Euro-
pean and international organisations on cancer 
registration and cancer epidemiology (e. g. active 
collaboration in working groups of the German 
National Cancer Plan, in the Association of Popu-
lation-based Cancer Registries in Germany 
(GEKID), International Agency of Cancer Regis-
tries (IACR) membership)
The work of the German Centre for Cancer Reg-
istry Data is supported by a scientific advisory board 
with an office at the RKI. This advisory board can also 
give permission for the dataset at the Centre for Can-
cer Registry Data to be made available to third parties 
on application – i. e. in addition to the state cancer 
registries – if a justified and, in particular, scientific 
interest can be substantiated. Further information on 
the German Centre for Cancer Registry Data is avail-
able on the Internet at www.krebsdaten.de.
Staff of the German Centre for Cancer Registry Data:
Dr Klaus Kraywinkel (section head)













5.1  The German Centre for Cancer Registry Data at the Robert Koch Institute  
(Zentrum für Krebsregisterdaten, ZfKD)
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The Association of Population-based Cancer Regis-
tries in Germany (GEKID) was formed in 2004 as a 
registered, non-profit-making association. GEKID’s 
members include not only all Germany’s popula-
tion-based cancer registries, but also a tumour centre 
and interested scientists working in the field of cancer 
epidemiology. In the field of cancer control, GEKID 
cooperates closely with the Federal Ministry of Health, 
particularly in the context of the National Cancer Plan, 
and the German Centre for Cancer Registry Data 
based at the Robert Koch Institute (RKI). GEKID also 
participates actively in a wide range of scientific com-
mittees especially in working groups preparing the 
uniform data set for clinical and epidemiological can-
cer registration.
The association’s primary task is to standardise 
as far as possible the content and methodology of can-
cer registration, despite the differences in legislation 
between the federal states. The comparability of re-
sults from the cancer registries can only be assured by 
nationwide cooperation. To promote such coopera-
tion, GEKID published »The Manual of Popula-
tion-based Cancer Registration«. Furthermore, 
GEKID is a joint point of contact for the popula-
tion-based cancer registries on all issues of common 
interest and represents the registries at the European 
level. GEKID is a member of the European Network 
of Cancer Registries (ENCR) and the International 
Association of Cancer Registries.
In its charter, GEKID has set itself the following tasks:
▶ to be the point of contact both for national and 
international cooperation partners and for the in-
terested public
▶ to provide information on the status of cancer 
 registration in Germany and explain the aims of 
population-based cancer registration
▶ to engage in joint information activities and thus 
help the individual cancer registries achieve and 
maintain complete registration
▶ to define standards on content as a basis for the 
comparability of population-based cancer regis-
tries
▶ to coordinate tasks involving all the registries and 
foster contacts with clinical tumour documenta-
tion
▶ to initiate joint research activities
▶ to promote the scientific use of the popula-
tion-based cancer registries
▶ to use the data to advance quality assurance in 
oncological care
Essential results of the GEKID activities in the past 
years:
▶ Enhancement of the interactive GEKID-Atlas re-
garding actual cancer incidence, mortality and 
survival in the federal states; the GEKID-Atlas 
made significant contributions to the scientific 
usage of cancer registry data and is available via 
the GEKID-Homepage
▶ Enhancement of the uniform minimum data for-
mat for the report to a registry as well as an inter-
change format for the forwarding of data accord-
ing to the place of residence and for the data 
exchange with the Centre for Cancer Registry 
Data at the RKI
▶ Evaluation and publication of results of survival 
analyses in Germany together with German Can-
cer Research Centre, supported by German Can-
cer Aid
Information on GEKID can be obtained on the Inter-
net at www.gekid.de or from the respective regional 
member registries (see address section, appendix 5.4).
Contacts for the Association of Population-based 
 Cancer Registries in Germany (Gesellschaft der epi-
demiologischen Krebsregister in Deutschland e.V., 
GEKID) (see address section, appendix 5.4):
Prof Dr Alexander Katalinic
 (Chair of GEKID, Schleswig-Holstein Cancer Re-
gistry)
Dr Stefan Hentschel
 (1st Vice-chair, Hamburg Cancer Registry)
Roland Stabenow
 (2nd Vice-chair, Joint Cancer Registry)
5.2 Association of Population-based Cancer Registries in Germany
142 Cancer in Germany Appendix
The cancer Information service »KID« was set up in 
1986 to provide personal telephone contacts for pa-
tients and their relatives with questions regarding 
cancer. Nowadays, medical staff provides up-to-the 
minute, scientifically sound answers to around 
34,000 questions every year by phone, by e-mail and 
in consultation surgeries in both Heidelberg and 
Dresden. This encompasses not only patients, rela-
tives and interested citizens – even representatives 
from occupational groups concerned with the care of 
cancer patients turn to the Cancer Information Ser-
vice. The information on offer is individually tailored 
to the needs of the various target groups:
▶ Patients, their relatives and friends are provided 
with answers to their questions relating to diagno-
sis and cancer treatment options, on living with 
the disease and links to additional points of con-
tact within the healthcare system. However, inter-
ested citizens with questions on risk factors, can-
cer prevention and early detection or on cancer 
research can also obtain comprehensive informa-
tion by contacting the Cancer Information Ser-
vice. This strengthens the health literacy of indi-
viduals and creates the basis for active interaction 
and joint decision-making between patients or 
beneficiaries and the attending physicians.
▶ Specialists professionally concerned with the sub-
ject of cancer receive quick and reliable pertinent 
information on the basis of the best available 
 scientific evidence. Through clearly structured 
preparation, research results are made transpar-
ent and directly usable for patient care. Source 
references, individually compiled for experts in 
the written e-mail replies, enable more in-depth 
study of relevant literature.
Via its website www.krebsinformationsdienst.de the 
Cancer Information Service conveys the latest knowl-
edge about cancer, useful addresses and tips on 
 further links and information material. Between 
260,000 and 500,000 individual visitors per month 
use this facility in 2014. For specialist groups, the 
website offers an introduction into a wealth of can-
cer-related topics and provides references to further 
scientific sources. On the social networking site Face-
book and Google+, the service posts breaking news 
and invites discussion. The Cancer Information Ser-
vice is provided by the German Cancer research Cen-
tre in Heidelberg, the largest bio-medical research 
establishment in Germany. The service is financed by 
funds from the Federal Ministry of Education and 
Research (BMBF), the State of Baden-Württemberg’s 
Ministry of Science, Research and Art (MWK) and the 
Federal Ministry of Health. As a result, the service can 
provide information independently, free from con-
flicts of interest and free of charge. In its capacity as 
national reference centre for cancer information, the 
Cancer Information Service is committed to provid-
ing the highest possible standard of information. 
Through its accompanying research the Cancer Infor-
mation Service also provides feedback on how the 
care situation in Germany is directly experienced by 
cancer patients and their relatives.
Further information on the remit and workings 
of the Cancer Information Service can be found (in 
German) by following the link: www.krebsinforma-
tionsdienst.de/wirueberuns.php
Cancer Information Service (KID)
Telephone: + 49 (0) 800 – 420 30 40, (Free inside 
Germany) Daily from 08.00 to 20.00 hrs.
E-Mail: krebsinformationsdienst@dkfz.de,
Answers usually within 2 working days 
Internet: www.krebsinformationsdienst.de and 
www.facebook.com/krebsinformationsdienst
Contact partners at the Cancer Information Service 
– KID (also see address section, appendix 5.4):
Dr. Susanne Weg-Remers
 Head of the Cancer Information Service (KID)
Dr. Regine Hagmann
 Head of Working Group »Knowledge Manage-
ment« at KID
5.3  KID – The Cancer Information Service provided by the German Cancer  
Research Centre
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Krebsregister Baden-Württemberg (Baden-Württemberg Cancer Registry)
Epidemiologisches Krebsregister (Population-based Cancer Registry)
Deutsches Krebsforschungszentrum Heidelberg (German Cancer Research Centre)
Im Neuenheimer Feld 581
69120 Heidelberg Telephone: 06221/42 42 20
 E-Mail: ekr-bw@dkfz.de
 Internet: www.krebsregister-bw.de
Krebsregister Baden-Württemberg (Baden-Württemberg Cancer Registry)
Vertrauensstelle (Baden-Württemberg Confidentiality Unit)
bei der Deutschen Rentenversicherung (German Pension Insurance) Baden-Württemberg
Gartenstraße 105
76135 Karlsruhe Telephone: 0721/82 57 90 00 Telefax: 0721/82 59 97 90 99
 E-Mail: vs@drv-bw.de
Klinische Landesregisterstelle des Krebsregisters Baden-Württemberg (Clinical State Registration Unit)
bei der Baden-Württembergischen Krankenhausgesellschaft e.V. (Baden-Württemberg Hospital Association)
Birkenwaldstraße 145
70191 Stuttgart Telephone: 0711/2 57 77 70 Telefax: 0711/2 57 77 79
 E-Mail: info@klr-krbw.de
Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (Bavarian Health and Food Safety Authority)
Zentrum für Krebsfrüherkennung und Krebsregistrierung (Registration Unit)
Schweinauer Hauptstraße 80
90441 Nürnberg Telephone: 09131/68 08 29 20 Telefax: 09131/68 08 29 05
 E-Mail: zkfr@lgl.bayern.de
 Internet: www.krebsregister-bayern.de
Bevölkerungsbezogenes Krebsregister Bayern (Bavaria Population-based Cancer Registry)
Vertrauensstelle (Confidentiality Unit), Klinikum Nürnberg-Nord
Professor-Ernst-Nathan-Straße 1
90419 Nürnberg Telephone: 0911/3 78 67 38 Telefax: 0911/3 78 76 19
 E-Mail: vertrauensstelle@klinikum-nuernberg.de
 Internet: www.krebsregister-bayern.de
Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und 
der Freistaaten Sachsen und Thüringen (GKR) 
(Joint Cancer Registry of Berlin, Brandenburg, Mecklenburg-West Pomerania, Saxony-Anhalt, Saxony)
Brodauer Straße 16–22
12621 Berlin Telephone: 030/56 58 14 01 (R) Telefax: 030/56 58 14 44 (R)




Epidemiologisches Krebsregister Bremen (Bremen Cancer Registry)
Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH 
(Leibniz Institute for Prevention Research and Epidemiology)
Achterstraße 30
28359 Bremen Telephone: 0421/21 85 69 61 (R) Telefax: 0421/21 85 69 41 (R)
  0421/21 85 69 99 (V)
 E-Mail: krebsregister@bips.uni-bremen.de (R)
  vbkr.kvhb@t-online.de (V)
 Internet: www.krebsregister.bremen.de
R = Registerstelle (Registry Unit)   V = Vertrauensstelle (Confidentiality Unit)
5.4 Addresses
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Hamburgisches Krebsregister (Hamburg Cancer Registry)
Behörde für Gesundheit und Verbraucherschutz (State Ministry of Health and Consumer Protection)
Billstraße 80
20539 Hamburg Telephone: 040/4 28 37 22 11 Telefax: 040/4 27 31 00 94
 E-Mail: HamburgischesKrebsregister@bgv.hamburg.de
 Internet: www.hamburg.de/krebsregister
Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen
Landesauswertungsstelle des Hessischen Krebsregisters
Walter-Möller-Platz 1
60439 Frankfurt am Main Telephone: 069/1 56 77 12 Telefax: 069/1 56 77 16
 E-Mail: Ernst-Alfred.Burkhardt@hlpug.hessen.de 
 Internet: www.hlpug.de
Vertrauensstelle des Hessischen Krebsregisters (Confidentiality Unit of Hesse Cancer Registry)
bei der Landesärztekammer Hessen (at Hesse State Medical Council)
Im Vogelsgesang 3
60488 Frankfurt/Main Telephone: 069/7 89 04 50 Telefax: 069/78 90 45 29
 E-Mail: vertrauensstelle@laekh.de
 Internet: www.laekh.de
Epidemiologisches Krebsregister Niedersachsen (Lower Saxony Population-based Cancer Registry)
OFFIS CARE GmbH
Industriestraße 9
26121 Oldenburg Telephone: 0441/36 10 56 12 Telefax: 0441/36 10 56 10
 E-Mail: registerstelle@krebsregister-niedersachsen.de
 Internet: www.krebsregister-niedersachsen.de
Niedersächsisches Landesgesundheitsamt (Lower Saxony Local Health Authority)
Vertrauensstelle Epidemiologisches Krebsregister Niedersachsen 
(Confidentiality Unit of Lower Saxony Population-based Cancer Registry)
Andreaestraße 7
30159 Hannover Telephone: 0511/4 50 53 56 Telefax: 0511/4 50 51 32
 E-Mail: vertrauensstelle.ekn@nlga.niedersachsen.de
 Internet: www.krebsregister-niedersachsen.de
Epidemiologisches Krebsregister Nordrhein-Westfalen gGmbH
(North Rhine-Westphalia Population-based Cancer Registry)
Robert-Koch-Straße 40
48149 Münster Telephone: 0251/8 35 85 71 Telefax: 0251/8 35 85 77
 E-Mail: info@krebsregister.nrw.de
 Internet: www.krebsregister.nrw.de
Krebsregister Rheinland-Pfalz, Registerstelle (Registry Unit of Rhineland-Palatinate Cancer Registry)
Institut für Med. Biometrie, Epidemiologie und Informatik, IMBEI
(Institute for Medical Biostatistics, Epidemiology and Informatics)
55131 Mainz Telephone: 06131/17 67 13 Telefax: 06131/17 47 51 86
 E-Mail: krebsregister@uni-mainz.de
 Internet: www.krebsregister-rheinland-pfalz.de
Krebsregister Rheinland-Pfalz gGmbH, Vertrauensstelle 
(Confidentiality Unit of Rhineland-Palatinate Cancer Registry)
Am Pulverturm 13
55131 Mainz Telephone: 06131/17 30 02 Telefax: 06131/17 32 49
 E-Mail: krebsregister@mail.uni-mainz.de
 Internet: www.krebsregister-rheinland-pfalz.de
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Epidemiologisches Krebsregister Saarland (Saarland Population-based Cancer Registry)
Ministerium für Soziales, Gesundheit, Frauen und Familie
(Ministry of Social Affairs, Health, Women and Family)
Präsident-Baltz-Straße 5
66119 Saarbrücken Telephone: 0681/5 01 59 82 (R) Telefax: 0681/5 01 59 98 (R)
  0681/5 01 58 05 (V)
 E-Mail: krebsregister@gbe-ekr.saarland.de
 Internet: www.krebsregister.saarland.de
Krebsregister Schleswig-Holstein (Schleswig-Holstein Cancer Registry)
Registerstelle (Registry Unit)
Institut für Krebsepidemiologie e. V. (Institute for Cancer Epidemiology)
Ratzeburger Allee 160, Haus 50
23562 Lübeck Telephone: 0451/5 00 54 40 Telefax: 0451/5 00 54 55
 E-Mail: info@krebsregister-sh.de
 Internet: www.krebsregister-sh.de
Vertrauensstelle des Krebsregisters (Confidentiality Unit of Schleswig-Holstein Cancer Registry)
bei der Ärztekammer Schleswig-Holstein (at Schleswig-Holstein Medical Council)
Bismarckallee 8–12
23795 Bad Segeberg Telephone: 04551/80 31 04
 E-Mail: krebsregister-sh@aeksh.de
Deutsches Kinderkrebsregister (German Childhood Cancer Registry)
Institut für Medizinische Biometrie, Epidemiologie und Informatik
(Institute of Medical Biostatistics, Epidemiology and Informatics), IMBEI
Obere Zahlbacher Str. 69
55131 Mainz Telephone: 06131/17 31 11 Telefax: 06131/17 44 62
 E-Mail: kinderkrebsregister@imbei.uni-mainz.de
 Internet: www.kinderkrebsregister.de
Krebsinformationsdienst (KID) (Cancer Information Service)
Deutsches Krebsforschungszentrum (German Cancer Research Centre)
Im Neuenheimer Feld 280




Zentrum für Krebsregisterdaten im Robert Koch-Institut
(German Centre for Cancer Registry Data at the Robert Koch Institute)
General-Pape-Straße 62–66
12101 Berlin Telephone: 030/1 87 54 33 81 Telefax: 030/1 87 54 33 54
 E-Mail: krebsdaten@rki.de
 Internet: www.krebsdaten.de
Bundesministerium für Gesundheit (Federal Ministry of Health)
53107 Bonn
Referat 311 Telephone: 0228/9 94 41 15 10 Telefax: 0228/9 94 41 49 62
Referat 315 Telephone: 0228/9 94 41 31 08 Telefax: 0228/9 94 41 49 38
 E-Mail: poststelle@bmg.bund.de
 Internet: www.bmg.bund.de
146 Cancer in Germany Appendix
5.5 Sources for international comparison of cancer incidence and mortality rates 
 (for the years 2011–2012, if not otherwise stated. Access date: July to October 2015)
Netherlands: Netherlands Cancer Registry
 http://www.cijfersoverkanker.nl/?language=en
 
Sweden, Finland, Association of the Nordic Cancer Registries (ANCR)
Denmark: http://www-dep.iarc.fr/nordcan/English/frame.asp
 
Poland: Incidence for 2012 only, Mortality for C23–C24 and C62 for 2012 only:
 EUCAN, European Cancer Observatory ECO
 http://eco.iarc.fr/EUCAN/Country.aspx?ISOCountryCd=616
 Mortality: Eurostat, Statistical office of European Union
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
 
Czech Republic: SVOD Web Portal (http://www.svod.cz/?sec=aktuality&lang=en)
 Data for all cancer sites (C00–C97 w/o. C44) and for Leukaemias (C95) for 2011 only:
 Institute of Health Information and Statistics of the Czech Republic (UZIS)
 Cancer Incidence 2011 in the Czech Republic (http://www.uzis.cz/)
 
Switzerland: Incidence for 2012 only, Mortality for C23–C24 and C62 for 2012 only:
 EUCAN, European Cancer Observatory ECO
 http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=756
 Mortality: Eurostat, Statistical office of European Union
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
 
Belgium: Incidence: Belgian Cancer Registry
 http://www.kankerregister.org/
 Mortality: Eurostat, Statistical office of European Union
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
 
France: Data for 2012 only
 Incidence: EUCAN, European Cancer Observatory ECO
 http://eco.iarc.fr/EUCAN/Country.aspx?ISOCountryCd=250
 Mortality: Eurostat, Statistical office of European Union
 http://ec.europa.eu/eurostat/web/health/causes-death/data/database
 




Great Britain: Incidence for 2011 only
 Cancer Research UK
 http://www.cancerresearchuk.org/cancer-info/cancerstats/types/
 Incidence for C33–C34 for England and for 2011 only
 Office for National Statistics
 http://www.ons.gov.uk/ons/datasets-and-tables/index.html?newquery=cancer+england& 
 newoffset=50&pageSize=50&content-type=Reference+table&content-type=Dataset& 
 content-type-orig= %22Dataset %22+OR+content-type_original %3A %22Reference+table 
 %22&sortBy=none&sortDirection=none&applyFilters=true
 
Austria: Data for 2011 only
  STATISTIK AUSTRIA, Austrian Cancer Registry (Access date: 16th December 2014) and 
Official cause of death statistics. 
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5.7 Further Literature
The “Cancer in Germany” report is published every two years by the Associa- 
tion of Population-based Cancer Registries in Germany (GEKID) and the 
German Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institute. 
The results contained in this, the tenth edition, are based on data up to 2012.  
As of 2009, Germany has achieved nationwide coverage of population-based 
cancer registration. However, because reliable data are not yet available from 
all federal states, it is still necessary for the ZfKD to estimate figures in some 
areas. Altogether, this report presents the most important epidemiological 
statistics and current trends for 27 different types of cancer. It contains details 
regarding disease incidence and mortality, along with regional and internatio-
nal comparisons, as well as illustrations of the distribution of tumour stages 
and of survival prospects.
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